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cDNA - complementary DNA
CNS - Central Nervous System
C-terminus - Carboxy-terminus
dbcAMP - 2'-0-dibutyryladenosine 3', 5'-cyclic monophosphate
DNA - Deoxyribonucleic acid
E12.5 - Embryonic day 12.5
ECACC - European Collection of Cell Cultures
EGL - External granule layer
EMBL - European Molecular Biology Laboratory
ENU -N-ethyl N-nitrosourea
GITC - Guanidine isothiocyanate
HD - Homeodomain
1Z- Intermediate zone
mRNA - messenger RNA
N-terminus - Amino-terminus
OBLS - Olfactory bulb-like structure
ORF - Open reading frame
PD - Paired domain
RNA - Ribonucleic acid
RPA - RNase protection assay
SCO - Sub-commissural organ
ssRNA - Single stranded RNA
TAD - Transactivation domain
TCA - Thalamocortical axon
TPOC - Tract of the post-optic commissure
VZ - Ventricular zone
YAC - Yeast artificial chromosome
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Mouse Strains
All strain accession numbers are from Mouse Genome Informatics,
www.informatics.jax.org
WT - Wild type (in this study, WT mice were outbred CD-I strain, Harlan Scientific,
UK)
Sey - Pax6Sey (MGI: 1856155)
Se/e" - Pax6Sey~Ne" (MGI:1856158)
Pax6LacZ - Pax6tmlPgr (MGI: 1934347)
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Abstract
During murine development, organogenesis of the central nervous system is a tightly
controlled process. Complex regulatory gene networks exist, at the head of which are
transcription factors that affect the expression of downstream genes. One such
transcription factor, Pax6, is crucial for the correct development of a number of
organs, including the brain, eyes and spinal cord.
A number of Pax6 isoforms have been described, many of which involve alterations
to the two DNA-binding domains, the paired domain and the homeodomain. In the
best characterised of these isoforms, Pax6+5a, the insertion of a 42bp cassette exon
by alternative splicing leads to the disruption of a helix-turn-helix motif within the
paired domain. The DNA-binding specificity of the Pax6 protein is changed, thereby
altering the target genes on which Pax6 can act. Other isoforms exist in which the
entire paired domain is absent, and DNA-binding can only occur via the
homeodomain.
In this way, numerous transcription factors are derived from the Pax6 locus, all of
which are predicted to have the same transactivation properties, but which act on
different subsets of downstream genes.
The aims of this study were i) to characterise differences in the spatial and temporal
expression of Pax6 isoforms during murine embryonic development ii) to analyse the
expression of Pax6 isoforms in various Pax6 mutant mice during neurogenesis, and
iii) to examine the effects of over-expression of the best understood isoforms, in a cell
culture system. The overall aim was to elucidate the independent roles of Pax6
isoforms in organogenesis of the central nervous system.
RNase protection assay was used to determine the ratio between Pax6 and Pax6+5a
transcripts in a number of tissues of the central nervous system during neurogenesis.
In most tissues studied, Pax6 is much more prevalent than Pax6+5a at embryonic day
12.5, but the ratio has fallen by embryonic day 18.5. This may be indicative of a
change in the role of Pax6, from controlling proliferation to controlling neuronal
differentiation.
Pax6 protein expression was analysed in mice with 0, I, 2, 8 and 14 functional copies
of Pax6, in order to compare the levels of Pax6 expression between genotypes, and to
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determine if differential expression of one or more isoforms could be responsible for
the mutant phenotypes. Most isoforms are down-regulated in the Pax6Sey/+ eye,
whilst their relative expression is more varied in the Pax6ey/+ brain. Most isoforms
are significantly up-regulated in the brain and eye of mice with 8 or 14 copies of
Pax6, but there are no differences between expression levels in the brain of the two
genotypes, indicating that Pax6 is subject to autoregulation. Some Pax6 isoforms are
observed in the brain of mice thought to lack functional Pax6.
Expression constructs containing Pax6, Pax6+5a and "paired-less" Pax6 were
introduced into immortalised cell lines. Again, Pax6 autoregulation was
demonstrated; the over-expression of Pax6 leads to the up-regulation of Pax6+5a, and
vice versa. Pax6 over-expression also promotes neuronal differentiation in a
neuroblastoma-derived cell line.
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Chapter 1 : Introduction
Pax6 is a transcription factor, belonging to the paired box (Pax) gene family (Walther
and Gruss, 1991). The Pax genes are expressed in discrete domains during
development, and are important for the correct control of organogenesis, particularly
in the brain (reviewed in Mansouri et al, 1999; see Figure 1.1). Pax6 is expressed
throughout neurogenesis in the developing eye, brain, nasal epithelia, spinal cord and
pancreas, and is known to be important for the development of all these tissues (Hill
et al., 1991; Hogan et al., 1986; St-Onge et al., 1997; Stoykova and Gruss, 1994; Ton
et al., 1991).
Within the developing mouse brain, Pax6 is expressed in the dorsal telencephalon
(presumptive cortex), specifically within the ventricular zone (VZ), and in the
olfactory bulbs and olfactory epithelia. It is also found in distinct areas of the
diencephalon including the ventral thalamus and the epithalamus, and in the
cerebellum and the dorsal portion of the hindbrain (Stoykova and Gruss, 1994;
Walther and Gruss, 1994; see Figure 1.1 for a brief outline of the Pax6 expression
pattern in the brain during neurogenesis).
1.1: Pax6 Protein Domains
Pax6 is a 422 amino acid transcription factor, which binds to target DNA sequences
via one or both of two DNA-binding domains; the paired domain (PD), and the
homeodomain (HD). Transcriptional regulation of Pax6 target genes is mediated by a
C-terminal transactivation domain (TAD; see Figure 1.2 for an outline of the main
Pax6 protein domains).
1.1.1: The Pax6 Paired Domain
The Pax6 PD is situated at the N-terminus of the protein, and the crystal structure of
the Pax6 PD - DNA complex has been elucidated (Xu et al., 1999). Within the PD
are two separate DNA-binding subdomains, designated PAI and RED, both of which
are helix-turn-helix motifs, and can bind target DNA.
The two Pax6 PD subdomains are thought to interact with one another, as the
presence of PAI reduces the activity of the RED subdomain on its consensus binding
14
Figure 1.1 Pax6 expression in the E13.5 mouse brain
(taken from Stoykova and Gruss, 1994). In the
telencephalon, Pax6 expression (in pink) is seen in the
olfactory epithelium (OE), the olfactory bulbs (OB), and
the ventricular zone of the dorsal telencephalon (CFr, for
frontal cortex). In the diencephalon, Pax6 is expressed in
the ventral thalamus (VT), the epithalamus (ET), and a
thin strip along the dorsal surface of the dorsal thalamus
(DT). Pax6 is also expressed in the dorsal hindbrain
(pons, Pn and myelencephalon, My), the dorsal spinal
cord (Sc) and the external granular layer (egl) of the
cerebellum (Cb). GE, ganglionic eminence; LV, lateral
ventricle; Ms, mesencephalon; ORE, optic recess; PC
posterior commissure; POA, Pre-optic area; PT,
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Figure 1.2 Molecular structure Pax6. All known Pax6 coding exons
are shown as red and blue bars. Sections encoding DNA-binding
domains are indicated as bars below the coding exons. Canonical
translation begins at the 3' end of exon 4, and terminates within exon
13. Immediately at the N-terminus of the protein is a paired domain,
a DNA-binding domain characteristic of all Pax genes. In the centre
of the protein is a second DNA-binding domain, the paired-type
homeodomain. Between these two DNA-binding domains, the
protein is rich in glutamine and glycine residues. The C-terminal
portion of the gene is the transactivation domain, which dictates the
action of Pax6 once it is bound to target DNA.
16
sequence, and vice versa (Yamaguchi et al., 1997). Also, a naturally-occurring
mutation in the RED domain abolishes Pax6-DNA binding via the PAI domain
(Singh et al., 2000).
The best characterised Pax6 alternative splicing event involves the insertion of a 42bp
exon, designated exon 5a, into the PD (Walther and Gruss, 1991). As a result of this
alternative splicing, two major Pax6 isoforms are produced, Pax6 lacking exon 5a
(hereafter designated Pax6-5a), and Pax6 containing exon 5a (hereafter designated
Pax6+5a). The insertion of exon 5a is known to alter the DNA-binding properties of
the Pax6 PD. The PAI subdomain of Pax6-5a appears to preferentially bind a
consensus sequence known as P6CON (Epstein et al., 1994a). When exon 5a is
present, it disrupts the PAI subdomain (see Figure 1.2), acting as a "molecular
toggle", and allowing the RED subdomain to bind its consensus sequence, 5aCON
(Epstein et al., 1994b). Although these two consensus sequences were isolated in
vitro and have not yet been described in vivo, they provide evidence that the insertion
of exon 5a does alter the sequences on which Pax6 can act.
The alternative splicing of exon 5a, and other alternative splicing events within the
Pax6 gene, will be described in greater detail in Section 1.4.
1.1.2: The Pax6 Homeodomain
Pax6 contains a paired-type HD, distinguished from other HDs by a serine rather than
a glutamine or a lysine at position 50 (Wilson et al., 1993).
The Pax6 HD is known to bind to a number of target genes, including Retinoblastoma
(Cvekl et al., 1999), Engrailed-1 (Plaza et al., 1997) and Rax (Mikkola et al., 2001),
and is thought to be involved in the transcriptional regulation of a number of other
developmentally important genes (reviewed in Simpson and Price, 2002).
The Pax6 PD and HD are known to interact with one another, and affect
transactivation via consensus binding sequences. As expected of a HD-containing
transcription factor, both Pax6+5a and Pax6-5a can activate transcription when bound
to consensus HD-binding sequences (Czerny and Busslinger, 1995; Plaza et al., 1994;
Singh et al., 2000). Perhaps surprisingly, Pax6-5a has a stronger effect than Pax6+5a,
implying that the PD is involved in this interaction (Mishra et al., 2002). An
interaction between the PD and the HD was also shown by Singh et al. (2000), as a
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naturally-occurring mutation in the PAI subdomain of the PD leads to increased
transactivation via a HD-binding site. A Pax6 protein lacking the entire HD was
created (Mikkola et ah, 2001), and this was shown to bind to a Pax6 HD in vitro,
presumably through the PD.
Evidence from the Drosophila gene Paired, a member of the Pax family, suggests
that although both the PD and the HD need to be present for Pax gene activity, they
can act in trans, and need not be present as part of the same molecule (Miskiewicz et
ah, 1996). This implies that interactions can occur between protein domains of
different Pax6 molecules.
1.1.3: The Pax6 Transactivation Domain
After binding DNA through the PD and/or HD, Pax6 exerts its transcriptional control
over target genes via the C-terminal portion of the protein, the TAD (Singh et ah,
2000; Tang et ah, 1998). Various cDNA array-based studies have indicated that Pax6
can act as both an activator and a repressor of transcription (Chauhan et ah, 2002a;
Chauhan et ah, 2002b; Chauhan et ah, 2002c). This was also shown with a microarray
used to detect Pax3 target genes, and may be a general feature of the Pax gene family
(Mayanil et ah, 2001).
The Pax6 TAD is a complex molecular domain, and deletion studies have shown that
a whole, intact TAD is necessary for optimal transcriptional activity (Singh et ah,
2000; Tang et ah, 1998).
1.2: Pax6 mutant mice used in this study
For a diagrammatical representation of the Pax6 mutations in Sey, Sey'"'" and
Pax6LacZ, see Figure 1.3.
1.2.1: Small eye (Sey)
Sey is a spontaneous mutation in the Pax6 gene, first characterised at the molecular
level by Hill et al. (1991). A single base pair GGA —> TGA substitution results in a
glycine —» STOP mutation in exon 8 of the murine Pax6 locus. Pax6 mRNA is highly
expressed in Sey/Sey mice (Collinson et ah, 2003; Warren and Price, 1997), but the
18
Figure 1.3 The Pax6 mutations in Sey, SeyNeu and
Pax6LacZ. A, full-length Pax6. Red and blue bars represent
Pax6 exons. Orange bar: paired domain, Green bar:
homeodomain, Black bars: internal ATG codons. B, Sey
cDNA, the mutation introducing a STOP codon is
indicated with an arrow. Pale blue bar: translated Pax6
transcript. Dark green bar: untranslated mRNA C, SeyNeu
cDNA, the mutation introducing an abnormal splice donor
site, and the STOP codon within intron 10 are indicated
with arrows. Blue and pink hatched bar: translated region
of intron 10. Pink bar: untranslated region of intron 10. D,
Pax6-LacZ cDNA. Yellow bar represents LacZ cDNA,
which replaces Pax6 exons 4-6, including the canonical
start ATG. Translation stop site is unknown.
3'-truncated protein has only been detected at very low levels (Engelkamp et al.,
1999). Therefore, Sey/Sey mice are generally considered to be completely null for
Pax6 protein. Sey/+ mice have a milder phenotype than that seen in the Sey/Sey
mouse.
Sey/+ mice display micropthalmia, whilst Sey/Sey mice do not develop eyes.
Homozygous mice can be distinguished from heterozygotes from embryonic day 10.5
(El0.5), when the nasal placodes and lens are entirely absent, and die shortly after
birth (Grindley et al., 1995; Hill et al., 1991; Hogan et al., 1986).
The development of the brain is also severely affected in Sey/Sey mice (reviewed in
Callaerts et al, 1997; Simpson and Price, 2002); the forebrain is reduced in size
(Warren and Price, 1997), and shows profound morphological defects (Stoykova et
al., 1996). The cerebellum, hindbrain and spinal cord, areas where Pax6 is known to
be expressed (Stoykova and Gruss, 1994), are also abnormal in Sey/Sey mice
(Engelkamp et al., 1999; Ericson et al., 1997; Osumi et al., 1997; Sun et al., 1998).
Sey/+ mice have a mild brain phenotype, with defective development of the
subcommissural organ (SCO) (Estivill-Torrus et al., 2001) and the tract of the
postoptic commissure (TPOC) (Mastick et al., 1997).
1.2.2: Small eyeNeu (Sey"eu)
The SeyNe" allele was created in an ENU-induced mutation screen (Favor et al., 1988).
A G^T point mutation at the +l position of a Pcix6 splice donor site causes a
splicing error. A 116bp sequence from intron 10 fails to be spliced out, introducing a
premature STOP codon and resulting in a C-terminally truncated transcript (Hill et
al., 1991). The phenotype of the SeyNc'" mutation is generally considered to be the
same as that of the Sey mutation (Grindley et al., 1997; Hill et al., 1991; Mastick et
al., 1997), although there may be subtle differences between the two in the
diencephalon (Stoykova et al., 1996).
1.2.3: Pax6LacZ
Pax6lc"*z mice (St-Onge et al., 1997) contain a copy of the fi-galactosidase gene
inserted in the genomic Pax6 locus, replacing exons 4 to 6 of the endogenous Pax6
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gene. This has a two-fold effect, ablating Pax6 expression and replacing it with
expression of the p-galactosidase transgene under the control of the Pax6
promoter(s). The phenotype of the Pax6'"cZ mutation is generally considered to be the
same as that of the Sey mutation.
1.2.4: PAX77
PAX77 mice (Schedl et al., 1996) are an addition transgenic line containing
approximately 6 copies of a YAC spanning the 420kb human PAX6 locus. This YAC
contains not only the Pax6 coding sequence, but also all the known regulatory
elements (Fantes et al., 1995). Although it is an addition transgenic, the inclusion of
the human PAX6 regulatory elements in the YAC should abolish any position effect,
and lead to PAX6 over-expression in all tissues in which the endogenous Pax6 gene
is expressed.
Like Sey/+ mice, PAX77 hemizygotes and homozygotes show a decrease in eye size,
although this effect is highly variable (Schedl et al., 1996). Surprisingly, no brain
phenotype has been detected in PAX77 mice (Schedl et al., 1996; M. Manuel, pers.
comm.), although the expression domain of a Neurogenin2 enhancer, El, is altered in
the developing cortex (Scardigli et al., 2003), implying that there may be a mild, as
yet undetermined effect of Pax6 over-expression in the brain.
1.3: The role of Pax6 in embryonic development
Pax6 functions as a transcription factor, altering the expression of downstream genes.
The transcription of a number of genes is either directly or indirectly affected by
Pax6.
The role of Pax6 varies between tissues, and through embryonic development. Most
of our knowledge of its function comes from studies of Pax6 mutant mice, and from
experiments involving the expression of Pax6 in cell culture systems. This section
will describe what is known about the actions of Pax6 in the tissues used in this study,
followed by a discussion of the three main roles that Pax6 is thought to play
throughout all tissues; controlling proliferation, neuronal differentiation and cellular
adhesion.
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1.3.1: Pax6 in the olfactory bulb
Pax6 is known to be crucial for the development of the olfactory bulb. This structure
was thought to be absent from Sey/Sey mice (Hogan et al., 1986), but subsequent
studies have shown that a rudimentary olfactory bulb like structure (OBLS) does
develop (Jimenez et al., 2000; Lopez-Mascaraque et al., 1998; Stoykova et al., 1997;
Vitalis et al., 2000). A reduction in olfactory bulb size has also been demonstrated in
the Sey/+ mouse (Dellovade et al., 1998).
In the WT mouse, Pax6 is expressed in the olfactory bulb throughout embryonic
development (Stoykova and Gruss, 1994), and expression continues in some cell
types into adulthood (reviewed in Callaerts et al., 1997). The exact role of Pax6 in the
development of the olfactory bulb is unclear, but it is thought to be an important
regulator of cellular adhesion. It is co-expressed with the cellular adhesion molecule
R-cadherin throughout neurogenesis (Stoykova et al., 1997). These two proteins are
thought to interact in the telencephalon (Andrews and Mastick, 2003), and it is likely
that this interaction also occurs in the olfactory bulb. Mice lacking NCAM, a cellular
adhesion molecule which is directly regulated by Pax6 (Edelman and Jones, 1995;
Hoist et al., 1997), have a reduced olfactory bulb (Cremer et al., 1994).
Studies of the rat rSey2/rSey2 brain have shown that abnormalities in olfactory bulb
development are in part caused by the abnormal migration of progenitor cells from
the telencephalon (Nomura and Osumi, 2004). These cells travel along the rostral
migratory stream caudally and away from the OBLS, rather than rostrally and into it,
as seen in the WT. This migration occurs between E12.5 and E14.5 in the rat, which
roughly corresponds to El 1.5 to El3.5 in the mouse. At this age, cells are also created
by proliferation of neural precursors within the ventricular zone of the olfactory bulb
(reviewed in Lopez-Mascaraque and de Castro, 2002).
1.3.2: Pax6 in the telencephalon
Pax6 expression is first detected in the forebrain at E8.5 (Walther and Gruss, 1991).
At El3, it is found in the VZ and the intermediate zone (IZ) of the telencephalon
(Stoykova and Gruss, 1994), in a high rostrolateral to low mediocaudal gradient.
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In the telencephalon, Pax6 appears to be vital in controlling both cellular proliferation
and neuronal differentiation.
The role of Pax6 in controlling cellular proliferation is complex, and may vary
dependent on the expression of co-factors. It inhibits proliferation in the cortex at
E10.5 and E12.5, as demonstrated by a rise in the percentage of cells in S-phase in the
Sey/Sey VZ (Warren et al., 1999). Consistent with this, Estivill-Torrus et al. (2002)
described a shortening of the entire cell cycle in the Sey/Sey cortex at El 2.5, which is
reversed by El 5.5 as the proportion of cells undergoing asymmetrical division rises.
This is in direct contradiction with the role of Pax6 as an oncogene which promotes
proliferation in other tissues, as described by Maulbecker and Gruss (1993) and
Yamaoka et al (2000); it is possible that Pax6 acts to repress proliferation in the
developing cortex, but can have the opposite effect in different tissues and at different
ages.
A rise in the proportion of differentiating cells in the El5.5 Sey/Sey cortex is an
indication that Pax6 may act to inhibit differentiation at this age (Estivill-Torrus et al.,
2002). Another study suggests that the timing of neuronal differentiation is dependent
on Pax6 expression, as differentiation occurs abnormally early in Sey^L'"/SeyNc" mice,
at El6.5 (Schmahl et al., 1993). One hypothesis is that Pax6 acts in early
neurogenesis to hold neural precursor cells in the cell cycle, whilst later in
neurogenesis it acts to promote neuronal differentiation. The mechanism behind this
proposed change in Pax6 activity is unclear.
1.3.3: Pax6 in the diencephaion
In the developing diencephaion, Pax6 is important in controlling arealisation and the
formation of boundaries, as well as in cellular proliferation and differentiation.
Pax6 expression is high in the presumptive ventral thalamus at El 1.5, lower in the
dorsal thalamus, and absent in the mesencephalon (Stoykova and Gruss, 1994;
Walther and Gruss, 1991). Before E15.5, Pax6 expression acts as a clear marker of
the diencephalon-mesencephalon boundary (Grindley et al., 1997; Stoykova and
Gruss, 1994). The boundary between dorsal thalamus and mesencephalon is blurred
in Sey/Sey and SeyNc"/SeyNa' mice (Mastick et al., 1997), as is that between the
diencephaion and telencephalon (Grindley et al., 1997). Mis-expression of Pax6 in
the mesencephalon causes a shift in the diencephalon-mesencephalon boundary
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(Matsunaga et al., 2000), suggesting that Pax6 expression is vital for the correct
arealisation of the diencephalon.
In addition to its role in boundary formation, Pax6 is also thought to control
proliferation and differentiation in the diencephalon.
In contrast to the results observed in the Sey/Sey cortex, proliferation is reduced in the
Sey/Sey diencephalon at E10.5, and total cell number is reduced by E14.5 (Warren
and Price, 1997). This is further indication that there may be cell-type specific
differences in the effects of Pax6 on proliferation. The zona incerta of the
diencephalon is reduced in size (Grindley et al., 1997; Mastick and Andrews, 2001),
perhaps as a result of a reduction in cellular proliferation.
Both Sey/+ and Sey/Sey mice display defects in the differentiation of regions of the
diencephalon. In particular, the SCO, posterior commissure and pineal gland do not
form in Sey/Sey mice, and the differentiation of neurons within the SCO is defective
in Sey/+ mice (Estivill-Torrus et al., 2001).
The proliferative defects in the Sey/Sey diencephalon are seen as early as E10.5
(Warren and Price, 1997), whilst the defects in differentiation become more apparent
later in development (Estivill-Torrus et al., 2001; Grindley et al., 1997; Warren and
Price, 1997), indicating that the role of Pax6 in the diencephalon might change from
controlling proliferation early on in neurogenesis, to controlling differentiation at
later stages.
1.3.4: Pax6 in the eye
The role of Pax6 in the developing eye is varied and complex. Experiments involving
the expression of human PAX6 in the Drosophila melcinogaster leg imaginal disc
(Haider et al., 1995) and a reciprocal experiment over-expressing the D.
melanogaster Pax6 homologue ey in Xenopus laevis (Onuma et al., 2002) (see
Section 1.5.1 for a detailed description of the D. melanogaster Pax6 homologues)
have demonstrated that Pax6 is necessary and sufficient for eye formation. This role
as a "master regulator" is consistent across the metazoa, and encompasses both
compound and single-lens eyes.
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The tissues in which Pax6 is expressed in the eye are diverse in origin. For example,
the retina, which is derived from the neurectoderm, and the lens, which is formed
from head surface ectoderm, both express high levels of Pax6 (Collinson et ah, 2003;
Davis and Reed, 1996; Walther and Gruss, 1991). The eye is also the only Pax6-
expressing structure in which there is a strong heterozygous phenotype (Hill et ah,
1991). The eye seems more sensitive than the brain to Pax6 gene dosage, which is
also evidenced by the presence of an eye phenotype, but no strong brain phenotype in
PAX77 mice (Schedl et ah, 1996). As homozygous Sey/Sey, SeyNL'"/SeyNc" and
Pax6L"cZLc"z mice do not develop eyes, it is the heterozygous phenotype which will be
discussed here.
In the retina, the Pax genes Pax2 and Pax6 have opposing roles, and each represses
the other's transcription (Baumer et ah, 2002; Schwarz et ah, 2000). These two genes
are co-expressed early in eye development, and the action of either is required for the
correct differentiation of retinal pigmented epithelium (Baumer et ah, 2003). Pax6
alone is crucial for the formation of a boundary between optic cup and optic stalk
(Schwarz et ah, 2000). Consistent with a role for Pax6 in promoting cellular
differentiation, conditional inactivation of the Pax6 gene in retinal progenitor cells
leads to a restriction of potential cell fates, via the transcriptional control of proneural
genes (Marquardt et ah, 2001).
In the lens, Pax6 is thought to act on a different set of target genes (Chauhan et ah,
2002a; Chauhan et ah, 2002b; Chauhan et ah, 2002c). For example, Pax6 is a direct
transcriptional activator of 57x3, and vice versa (Goudreau et ah, 2002). Both of these
genes are thought to be crucial in promoting cellular proliferation in the lens, and
Pax6 is also necessary for the correct differentiation of lens fibre cells (Dimanlig et
ah, 2001; Goudreau et ah, 2002). A specific role for Pax6+5a has also been
demonstrated in the lens, where over-expression of this isoform leads to the formation
of cataracts and up-regulation of the cellular adhesion molecules a5pi integrin,
paxillin and pl20ctn (Duncan et ah, 2000).
An action of Pax6 which appears to be unique to the lens is in regulating the
expression of structural genes, the crystallins (Cvekl et ah, 1995b; Duncan et ah,
1998; Kralova et ah, 2002; Richardson et ah, 1995; Sharon-Friling et ah, 1998).
Although the effects of Pax6 seem to vary between the retina and the lens, the
behaviour of Pax6" cells in Pax6 <-> Pax6" chimeras is similar in both tissues.
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Pax6" cells are excluded during development, suggesting that Pax6 may in fact be
playing a similar role in each, perhaps in the control of cellular adhesion (Collinson et
al., 2000; Collinson et ah, 2003).
The ratio of Pax6-5a : Pax6+5a has been best described in the eye (see Section
2.2.1), and a number tissue-specific and developmental stage-specific variations have
been seen. The differential expression of these two Pax6 isoforms could play an
important role in correct eye development.
1.3.5; Pax6 in the spinal cord
Early in neurogenesis, at El0.5 to El2.5, Pax6 expression is highest in the dorsal
portion of the spinal cord, where, as in the cortex, it is found in the proliferative VZ
(Ericson et ah, 1997; Stoykova and Gruss, 1994). Its expression is developmentally
regulated, and becomes progressively restricted through neurogenesis (Goulding et
ah, 1993). This regulation is thought to be controlled by sonic hedgehog signalling,
and is key to establishing progenitor domains from which different neuronal subtypes
emerge (Briscoe and Ericson, 1999; Ericson et ah, 1997).
Direct regulation of the cellular adhesion molecule NCAM and the proneural gene
Neurogenin2 by Pax6 have been demonstrated in the spinal cord (Hoist et ah, 1997;
Scardigli et ah, 2003), but little else is known about direct targets of Pax6 in this
tissue.
Pax6 expressing cells in the VZ of the ventral spinal cord can generate either
motorneurons or oligodendrocytes, and the determination of both of these fates is
affected in Sey/Sey mice (Sun et ah, 1998). Sey/Sey mice also display deficiencies in
the formation of spinal cord intemeurons (Burrill et ah, 1997). Studies of the
developing Sey/Sey spinal cord show decreased numbers of somatic motorneurons
and VI interneurons, but normal formation of other neuronal subtypes (Takahashi
and Osumi, 2002). Again, Pax6 in the spinal cord is crucial in controlling cellular
differentiation.
After injury, the Pax6 expressing cell population in the adult rat spinal cord increases,
suggesting an involvement of Pax6 in regeneration and renewal (Yamamoto et ah,
2001), an involvement that has also been seen in the cornea (Collinson et ah. 2004).
This is further evidence for a global role of Pax6 in controlling cellular proliferation.
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1.3.6: Pax6 in the hindbrain
Pax6 expression is highest in the dorsal hindbrain (Ericson et al., 1997; Stoykova and
Grass, 1994), and is crucial for the correct establishment of neuronal progenitor
domains (Ericson et al., 1997; Takahashi and Osumi, 2002).
At El2.5, proliferative rates are increased in the rat rSey'/rSey2 hindbrain (equivalent
to El 1.5 in the mouse), as measured by BrdU incorporation (Takahashi and Osumi,
2002). This observation implies that Pax6 is acting in the hindbrain to repress
proliferation early in neurogenesis, which is consistent with data from the El2.5
telencephalon (Estivill-Torrus et al., 2002; Warren et al., 1999). In the telencephalon,
this phenotype is reversed by El5.5, but the effects of Pax6 on proliferation in the
hindbrain have not been studied at later ages.
The effect of Pax6 on differentiation in the developing hindbrain has been studied in
greater detail. As in the spinal cord, sonic hedgehog signalling controls the expression
of Pax6, which in turn controls the formation of neuronal subtypes (Briscoe and
Ericson, 1999; Ericson et al., 1997). Whilst somatic motorneurons and VI
intemeurons do form in the Sey/Sey spinal cord, but in abnormally low numbers,
these neuronal subtypes are entirely absent from the rSey/rSey hindbrain (Osumi et
al., 1997; Takahashi and Osumi, 2002), indicating that the requirement for Pax6 is
stronger for correct neuronal differentiation in the hindbrain.
1.3.7: Pax6 in the cerebellum
Pax6 is expressed in the rhombic lip of the hindbrain from El2.5 onwards
(Engelkamp et al., 1999). Post-mitotic neurons migrate away from the rhombic lip,
and give rise to the granule cells of the cerebellum, which also express Pax6
(Kawakami et al., 1997; Waltherand Grass, 1991). Expression persists into adulthood
in the granular layer of the cerebellum, although at reduced levels (Stoykova and
Grass, 1994; Waltherand Grass, 1991).
Unlike other Pax6 expressing tissues, both differentiation and proliferation are largely
unaffected in the cerebellum of Sey/Sey mice, and Pax6 is thought to influence
cellular migration, through the control of cellular adhesion molecules (Engelkamp et
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al., 1999). Cell numbers are drastically decreased in the Sey/Sey cerebellum at E16.5.
Since the percentage of cells labelled by a 1 hour BrdU pulse is the same in Sey/Sey
precerebellar nuclei and granule cells as in the WT, and there is no increase in cell
death in the Sey/Sey cerebellum, the reduction in cell number is likely to be due to
failed migration of cells from the rhombic lip (Engelkamp et al., 1999).
Similar migratory defects are seen in the rat rSey1VrSey2 cerebellum. Dil labelling of
external granule layer (EGL) cells shows that parallel fibres do not form in the
mutant. There is a corresponding increase in the thickness of the EGL, demonstrating
that the migration of cell bodies along parallel fibres seen in the WT cannot occur in
the rSeyVrSey2 cerebellum (Yamasaki et al., 2001).
Pax6 also appears to have a role in controlling neurite outgrowth in the cerebellum of
both mice and rats. Cultured Sey/Sey mouse EGL explants grow fewer neurites than
WT explants (Engelkamp et al., 1999). Similarly, rSey2/rSey2 EGL explants form
shorter, thinner neurites than WT explants (Yamasaki et al., 2001). A role for Pax6 in
regulating cellular morphology and cytoskeletal organisation has not been
demonstrated in any other tissues, and may be unique to the cerebellum.
1.3.8: Pax6 and proliferation
The lack of structures such as the olfactory bulb and the eye in Sey/Sey and
SeyNe"/SeyNeu mutant mice (Hill et al., 1991; Ton et al., 1991), and the fact that these
mice have smaller brains with fewer cells than WT mice (Warren and Price, 1997)
and are smaller overall (Vitalis et al., 2000) suggest that Pax6 might play a role in
promoting cellular proliferation.
Studies of the cell cycle in Sey/Sey mice have provided conflicting insights into the
exact nature of the effects which Pax6 exerts on cellular proliferation.
Proliferative rates are increased in the Sey/Sey cortex at E10.5 and E12.5, as shown
by an increase in the percentage of cells in S-phase (Warren et al., 1999). In contrast,
proliferation is reduced in the Sey/Sey diencephalon at El0.5 (Warren and Price,
1997). There may be cell-type specific differences in the effects of Pax6 on
proliferation.
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A more comprehensive comparison between cell cycle times in the cortex of WT and
Sey/Sey mice showed that WT cortical cells had a longer cell cycle at E12.5, and were
therefore proliferating less rapidly. To further illustrate this, Sey/Sey cortical cells
were cultured ex vivo, and shown to have raised levels of cyclin A, a key regulator of
the cell cycle. By El5.5, however, this effect was reversed; the cell cycle time was
shorter in WT cortex, and Sey/Sey cortical cells were now proliferating less rapidly
that WT cells (Estivill-Torrus et al., 2002). This study indicated that Pax6 can act to
either enhance or repress proliferation, perhaps in a manner that is dependent on the
temporally-regulated expression of other genes.
Pax6 is also thought to be an oncogene. The introduction of Pax6 over-expressing
cells into adult mice leads to tumour formation (Maulbecker and Gruss, 1993).
Ectopic PAX6 expression has since been described in a number of human tumours
(Salem et al., 2000), and tumour formation has also been seen in the pancreas of
PAX77 mice (Yamaoka et al., 2000).
Taken together, these observations suggest that Pax6 plays an important role in
regulating the cell cycle, and thus controlling the proliferation of a number of cell
types during embryonic development.
1.3.9: Pax6 and differentiation
Homozygous Pax6-null mice (Sey/Sey, Seyh!c"/SeyNc" and Pax/1"'7/) display defects
in the differentiation of cells in the pancreas (Dohrmann et al., 2000; St-Onge et al.,
1997), eye (reviewed in Ashery-Padan and Gruss, 2001; Jean et al, 1998; van
Heyningen and Williamson, 2002) and brain (reviewed in Simpson and Price, 2002) .
There is a correlation between the onset of WT Pax6 gene expression and the onset of
neurogenesis, which has been most clearly demonstrated in the mouse (Stoykova and
Gruss, 1994) and quail (Plaza et al., 1995). A similar correlation between the onset of
retinogenesis and WT Pax6 expression is seen in retinal progenitor cells (Marquardt
et al., 2001), whose differentiation is restricted upon the conditional inactivation of
Pax6.
Differentiation of cell types in the hindbrain (Takahashi and Osumi, 2002) and
diencephalon (Warren and Price, 1997) are dependent on Pax6, but the role of Pax6
in neuronal differentiation is perhaps best studied in the developing cortex.
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During cortical development, a proportion of cells in the proliferative VZ undergo
asymmetrical division. This produces two progenitor cells, one of which continues to
divide within the VZ, the other of which exits the cell cycle, migrates out of the VZ
and begins to differentiate (Fujita, 1964; Sidman et al., 1959) (see Figure 1.4). Early
in corticogenesis, the newly differentiated neuron migrates by somal translocation.
Later on, as the cortex thickens, radial glia provide a scaffold for neuronal migration
(Rakic, 1972; reviewed in Nadarajah and Parnavelas, 2002). The proportion of cells
undergoing asymmetrical division in the Sey/Sey cortex from E12.5 to El5.5 is
abnormally high (Estivill-Torrus et al., 2002), indicating that the rates of neuronal
differentiation are increased. In Sey"/SeyNe" mice, cortical plate neurons cease
differentiation abnormally early, at El6.5, and are deficient in axon formation
(Schmahl et al., 1993).
Abnormal differentiation of cells in the absence of Pax6 is also evidenced by the mis-
expression of the differentiation marker Soxl 1 in the developing Sey/Sey brain; Soxl 1
immunostaining is seen across a larger than normal area of the proliferating layers of
the cortex. This could be an indication either that rates of differentiation are higher in
Sey/Sey mice, or that differentiation proceeds normally, but migration is impaired,
and these cells can no longer leave the proliferative layers of the cortex (Warren et
al., 1999).
The role of Pax6 in cortical neuronal differentiation, like its role in proliferation,
appears to vary between tissues and developmental ages. This variation is suggestive
of a complex and as yet undefined interaction with a number of other genes.
As well as being crucial in neurogenesis, Pax6 is also necessary for gliogenesis to
occur in the developing brain. It is expressed in cortical radial glia, and the
morphology of these cells is disrupted in Sey/Sey mice (Stoykova et al., 1996). It has
recently been shown that glial cells can themselves undergo neurogenesis (Heins et
al., 2002; Malatesta et al., 2003; Malatesta et al., 2000), and that Pax6 is also critical
in this process (Heins et al., 2002).
Taken together, these data imply that Pax6 expression is critical for the correct








Figure 1.4 Cortical development (taken from Nadarajah and
Parnavelas, 2002). The ventricular zone (VZ) contains a
proliferating neuronal precursor cell population. Cells either divide
symmetrically (S) and remain proliferative, or divide asymmetrically
(A) to produce one proliferative cell and one post-mitotic neuron.
Postmitotic neurons (red) then migrate through the intermediate
zone (IZ) to the outermost layer of the cortex, just above the
subplate (SP). Early in neurogenesis, this migration occurs via
somal translocation. Later on in neurogenesis, as the cortex
thickens, postmitotic neurons migrate along radial glia (green). CP,
cortical plate. MZ, marginal zone.
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1.3.10: Pax6 and cellular adhesion
Pax6 has been shown to directly regulate the expression of the cellular adhesion
molecules LI (Meech et al., 1999) and NCAM (Edelman and Jones, 1995; Hoist et
al., 1997) and is also thought to act upon R-cadherin (Andrews and Mastick, 2003) in
the developing CNS. Mis-expression of these and other cellular adhesion molecules
in the Sey/Sey mouse has a number of effects on the developing CNS (reviewed in
Simpson and Price, 2002). These effects include abnormal regionalisation due to the
failure of cells to segregate into discrete populations and abnormal migration of either
cell bodies or axons due to differences in the cellular environment through which
migration takes place. Each of these three effects will be discussed in turn.
Firstly, numerous regionalisation defects have been described in Sey/Sey and
SeyNe"/SeyNe" mice, for example in the eye (Baumer et al., 2002), diencephalon
(Grindley et al., 1997) and hindbrain (Takahashi and Osumi, 2002). In particular,
regionalisation appears to be severely affected in the Sey/Sey telencephalon.
A gradient of Pax6 expression, from high rostrolateral to low mediocaudal, is seen in
the developing telencephalon (Stoykova and Gruss, 1994; Vitalis et al., 2000). In
Sey/Sey mice, there is a reduced area of expression of rostrolateral markers of the
telencephalon including the cellular adhesion molecule Cad8, and a concomitant
increase in the area of expression of mediocaudal markers, including Cad6 (Bishop et
al., 2002). This observation implies that Pax6 expression in the anterior forebrain is
crucial for establishing anterior cortical identity, and may do so by altering the
expression of cellular adhesion molecules. Homozygous double-knockout mice for
Pax6 and Emx2, another gene thought to be important in the regionalisation of the
cortex, show an almost complete conversion of cerebral cortex into basal ganglia
(Muzio et al., 2002a; Muzio et al., 2002b), further evidence for a role of Pax6 in
establishing cortical identity.
Studies of Pax6 Pax6" chimeric mice show that Pax6" cells exhibit abnormal
adhesive properties, and are specifically excluded from the mediocaudal domain of
the dorsal telencephalon (Talamillo et al., 2003), various components of the cornea,
and the neural retina (Collinson et al., 2003). Similarly, Sey/Sey cells segregate out
when transplanted into WT cortex (Tyas et al., 2003). Adhesive defects are also
thought to be responsible for the abnormal segregation of Sey/Sey cortical cells grown
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in vitro. Whilst WT cortical and striatal cell aggregates segregate into two separate
populations, this segregation is lost in Sey/Sey cells (Stoykova et al., 1997).
Secondly, mis-expression of cellular adhesion molecules under the control of Pax6
may have an effect on cellular migration, either by regulating the adhesive properties
of the migrating cells, or by regulating the adhesive properties of the cell populations
through which they must pass.
A well defined migratory process in the developing brain is the radial migration of
neuronal precursors from the VZ to the appropriate cortical layer after differentiation
(reviewed in Rakic, 2003; see Figure 1.4). Talamillo et al. (2003) looked at radial
migration in Pax6 <-> Pax6 chimeric mice, and found that many differentiated
Pax6" cells do not leave the VZ. Radial migration is also deficient in Sey/Sey and
Sey^c"/Se}^"' mice, and differentiated cells accumulate in the VZ (Caric et ah, 1997;
Schmahl et ah, 1993; Stoykova et ah, 1996). This effect is dependent on Pax6
expression within the cortical layers, as Sey/Sey cells do not display radial migration
defects when transplanted into a WT cortex (Caric et ah, 1997). Pax6 expression
therefore appears to be necessary for the process of radial migration, and its
expression may alter the adhesive properties of newly-differentiated neurons, or the
radial glia along which they migrate (Rakic, 2003).
Radial migration is not the only form of neuronal migration to be affected by Pax6.
The migration of mitral cell progenitors from the rostral telencephalon is deficient in
rSey2/rSey2 rats, and is though to be the main reason why an olfactory bulb is not
formed in these animals (Nomura and Osumi, 2004). In the mouse and rat
cerebellum, Pax6 is also essential for the correct migration of granule cells
(Engelkamp et ah, 1999; Yamasaki etah, 2001).
A third way in which Pax6 is thought to act via cellular adhesion molecules is in
controlling the formation of axon tracts. Just as the expression of adhesion molecules
can affect the migration of cells, it could also affect the growth and migration of
axons from static cell bodies.
The thalamocortical axon (TCA) tract, which runs between the dorsal thalamus and
the cerebral cortex, does not form in Sey/Sey mice (Jones et ah, 2002; Pratt et ah,
2002; Pratt et ah, 2000). Pax6 is also necessary for the correct formation of the TPOC
(Mastick et ah, 1997). Although this tract is present in Sey/Sey mice, its axons display
33
pathfinding errors, an effect which can be reversed by the addition of R-cadherin
(Andrews and Mastick, 2003). Thus, Pax6 can control axon outgrowth, perhaps by
controlling the expression of cellular adhesion molecules.
1.4: Alternative splicing of the Pax6 gene
The alternative splicing of Pax6 is well documented, and is an important mechanism
by which the Pax6 protein structure is regulated. All known splice variants will be
described in turn, along with their potential effects on Pax6 activity.
1.4.1: Alternative splicing of Pax6 exon 5a
As described in section 1.1.1, alternative splicing of exon 5a (Walther and Gruss,
1991) disrupts the PD (see Figure 1.2), and alters its DNA binding properties
(Epstein et al., 1994a; Epstein et al., 1994b). The phenotypic implications of this
alternative splicing event are largely unknown, but a few recent studies have
attempted to address this issue.
1.4.1.1: Mouse mutants of Pax6 exon 5a
Singh et al. (2002) created a mouse mutant in which exon 5a was constitutively
deleted. The phenotype was different to that observed in the Sey/Sey mouse, and
milder. Rather than having no eyes, as seen in Sey/Sey mice (Hill et al., 1991; Ton et
al., 1991), mice lacking exon 5a displayed iris hypoplasia, alongside defects in the
development of the cornea, lens and retina. No phenotype was described in the brain,
although this does not preclude the possibility that there was one.
In a complementary experiment, Pax6+5a was over-expressed in the mouse lens
(Duncan et al., 2000). This led to the formation of cataracts, and the up-regulation of
the cellular adhesion molecules paxillin, pl20ctn and a5pi integrin.
Both of the studies described above concentrate on the role of alternative splicing of
exon 5a in the eye, and little is known about its involvement in the development of
other Pax6 expressing tissues.
1.4.1.2: Pax6 exon 5a affects PD-DNA binding
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As described in section 1.1.1, the insertion of exon 5a into the PD is thought to act as
a "molecular toggle", switching PD-DNA binding from the PAI subdomain to the
RED subdomain (Epstein et al., 1994b). Although a Pax6+5a consensus binding site
(5aCON) and a Pax6-5a consensus binding site (P6CON) have been described
(Epstein et al., 1994a; Epstein et al., 1994b), it has been shown that both Pax6
isoforms can bind to and activate transcription through both consensus sequences
(Chauhan et al., 2004a; Kozmik et al., 1997; Yamaguchi et al., 1997).
The hypothesis that Pax6-5a and Pax6+5a act on different sets of target genes is
backed up by data from cDNA micro-array experiments performed using WT, Pax6-
5a over-expressing and Pax6+5a over-expressing lens tissue (Chauhan et al., 2002a;
Chauhan et ah, 2002b). A total of 27 transcripts were seen to be differentially
regulated between WT and Pax6+5a over-expressing lens, 13 of which were also
mis-regulated in the Sey/+ lens. The Pax6-5a over-expressing lens was seen to have a
largely different complement of mis-regulated genes, indicating that the two different
Pax6 isoforms exert different roles in the development of the lens.
1.4.1.3: Differential expression of Pax6-5a and Pax6+5a during
embryonic development
Ever since the splice variants Pax6-5a and Pax6+5a were first described (Walther
and Gruss, 1991), Pax6-5a has been thought to be the more abundant of the two
isoforms. Recently, however, evidence has emerged that Pax6+5a exists at higher
levels in some tissues than was previously thought, and the differential expression of
the two splice forms can vary between tissues and developmental stages.
The relative advantages and disadvantages of the techniques used to assess the Pax6-
5a : Pax6+5a mRNA ratio in the following studies will be described in further detail
in Section 2.2.1; here a brief outline of the results from each study will be given.
RT-PCR data suggests that 80% of Pax6 transcripts in the chick retina, but only 2.5%
of Pax6 transcripts in the cornea, contain exon 5a (Koroma et al., 1997). In the bovine
eye, Pax6+5a is seen to be in excess over Pax6-5a in the iris. Levels appear to be
approximately equal in the cornea (Jaworski et al., 1997). Taken together, these
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results show that there are pronounced tissue-specific differences in the regulation of
Pax6-5a and Pax6+5a.
Semi-quantitative RT-PCR showed that Pax6-5a and Pax6+5a exist at equal levels in
adult human lens epithelium and lens fibres (Zhang et al., 2001), whilst Jaworski et
al., (1997) described Pax6-5a as being in excess over Pax6+5a in total bovine lens.
These conflicting data suggest that there may be species-specific differences in
differential Pax6 isoform expression.
RNase protection assay (RPA) has been used to show that Pax6-5a is in 8-fold excess
over Pax6+5a in mouse total head RNA, from El2.5 to El6.5, and in adult brain
RNA (Kozmik et ah, 1997). Although this study did not separate out mRNA
populations from different regions of the head, it is the only absolutely quantitative
evaluation ofPax6-5a and Pax6+5a levels during embryonic development to date.
Protein bands thought to correspond to Pax6-5a and Pax6+5a have been observed by
western blot on tissue from species as diverse as quail, mouse and chick. (Engelkamp
et ah, 1999; Kawakami et ah, 1997; Plaza et ah, 1993), but little effort has been made
to quantitate these bands. As a result, not much is known about the relative
abundance of Pax6 protein isoforms throughout embryonic development, and what
differential roles these isoforms may be playing.
1.4.1.4: The Pax6-5a : Pax6+5a ratio affects transactivation
One consequence of the differential expression of Pax6-5a and Pax6+5a through
development is that the ratio between the two isoforms alters, as well as their absolute
quantities. Intriguingly, recent work suggests that this ratio, rather than the absolute
amount of an isoform, may be an important determinant of Pax6 activity (Chauhan et
ah, 2004a). In a cell culture system, a Pax6-5a : Pax6+5a ratio of either 8:1 or 1:1
leads to strong transcriptional activation from either the P6CON or the 5aCON
consensus binding sequences. Intermediate ratios of 2:1 or 4:1, however, show lower
levels of transactivation. This suggests that either optimal transactivation of all
downstream genes occurs at a ratio of 8:1 or 1:1; or that altering the ratio leads to an
alteration in the preferred target DNA-binding sequences, from 5aCON and P6CON
to other sequences that weren't used in this particular study. In either case, it seems
likely that the Pax6-5a : Pax6+5a ratio is an important determinant of the
transcriptional activity of Pax6.
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1.4.2: Alternative splicing of Pax6 exon 6
A number of instances of Pax6 exon 6 alternative splicing have been documented,
and there seem to be multiple mechanisms by which all or part of this exon can be
excluded from the mature transcript.
RT-PCR for Pax6 on mRNA extracted from a human glioblastoma cell line, U373-
MG, has identified mRNA species lacking the entire exon 6 in both Pax6-5a and
Pax6+5a forms (T.I. Simpson, pers. comm.). An mRNA has also been isolated from
quail neuroretina in which the 3' I98bp of exon 5 (Pax-QNR exon 5 corresponds to
human and mouse Pax6 exon 6) is absent. This is due to the usage of an unusual
splice donor site 15bp into exon 5, allowing splicing straight onto sequence at the 5'
end of exon 6 (human and mouse exon 7) (Carriere et al., 1993). The splice donor site
described in this example is conserved across mouse and man. In addition, Pax6
transcripts lacking exon 6 and also generated by the use of this splice donor site
within exon 6 have been described in the bovine eye (Jaworski et ah, 1997).
A number of human mutations have also been described in which an alternative,
weak splice donor site 3' of exon 6 is used instead of the canonical splice site
(www.hgu.mrc.ac.uk/Softdata/Pax6/). This leads to the exclusion of the majority of
exon 6 from the mature transcript. It is possible that this weak splice donor site could
be employed at a low rate when no mutations are present, leading to a low abundance
transcript missing all but a small portion of exon 6, encoding 36 amino acids of the
RED subdomain.
1.4.3: Other Pax6 transcripts
A "paired-less" Pcix6 mRNA lacking exons 2, 4 to 7, and the first 21 bp of exon 8 has
been described (Mishra et ah, 2002), which is expressed in the murine eye, pancreas
and brain. As this transcript is lacking the first Pax6 ATG residue, translation could
only initiate from within exon 8, leading to an N-terminally truncated protein without
a PD.
This transcript was also isolated using an agarose gel rescue technique (Gorlov and
Saunders, 2002). Two further Pax6 splice variants were found this way. A transcript
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was isolated from mouse eye mRNA in which exons 2 to 8 are absent. A third Pax6
mRNA was found in the mouse brain, with exons 2, 5a to 10, and part of exon 11
missing. It is unclear whether these latter two splice variants represent artefacts or
common Pax6 splice variants, as their relative abundances have yet to be assessed in
vivo.
Pax6 transcription can also begin from a CpG island within intron 7, a process which
has been shown to comprise 1% of Pax6 transcripts in a lens epithelial cell line
(Kleinjan et al., 2004). Again, translation of this mRNA could only begin within exon
8, leading to a "paired-less" Pax6 protein.
As the Pax6 transcript seems particularly prone to alternative splicing events, it is
worth noting that only exons 5a, 6, 8 and 12 could be entirely removed from the
transcript whilst leaving an in-frame Pax6 protein. An mRNA in which the whole of
exon 12 is absent has also been cloned from the U373-MG cell line (B.T. Fenby, pers.
comm.), but this was a single event and may be artefactual.
1.5: Pax6 homoloques in invertebrates
The Pax6 gene is highly conserved in vertebrates. The protein sequence is 100%
identical between mouse and human (Hill et al., 1991; Ton et al., 1991), and
regulatory elements are highly conserved across species as diverse as human,
zebrafish and quail (Griffin et al., 2002; Kleinjan et al., 2004; Morgan, 2004).
This functional conservation of Pax6 is extended across various invertebrates, such as
D. melanogaster, Caenorhabditis elegans and Ciona intestinalis (sea squirt) (Jang et
al., 2003; Mazet et al., 2003; Morgan, 2004; Quiring et al., 1994). The invertebrate
Pax6 homologues that are best understood at a molecular level are those found in D.
melanogaster and C. elegans.
1.5.1 D. melanogaster eyeless and eyegone
The D. melanogaster gene eyeless (ey) is homologous to Pax6-5a, containing a
complete PD, HD and TAD (Quiring et al., 1994). Over-expression of ey in X. laevis
can induce the formation of vertebrate eye-like structures (Onuma et al., 2002), a
demonstration of the high levels of Pax6 conservation between vertebrates and
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invertebrates. Similarly, over-expression of human PAX6 in the D. melcmogaster leg
imaginal disc leads to formation of invertebrate eye-like structures (Haider et al.,
1995). Although invertebrate and vertebrate eyes are structurally dissimilar, Pax6 is
able to induce the formation of either.
There is a second Pax6-5a homologue in D. melcmogaster, twin of eyeless (toy)
(Czerny et al., 1999), which appears to have arisen by gene duplication, toy and ey are
most divergent at the C-terminus, suggesting that they might have different
transactivational properties (Punzo et al., 2004). The two genes are differentially
expressed, implying they play different roles in controlling eye development
(Kammermeier et al., 2001). toy is expressed earlier in development, and activates the
expression of ey, although mutations in either gene have a similar effect (Kronhamn
et al., 2002).
The alternative splicing of exon 5a, a mechanism by which the DNA-binding
properties of vertebrate Pax6 are altered (see Section 1.4.1), is not seen in
invertebrates. Intriguingly, D. melanogaster expresses a third Pax6 gene, eyegone
{eyg), which is homologous to the Pax6+5a splice variant (Jang et al., 2003). The eyg
gene is similar to ey, but has an incomplete PD. The RED subdomain is intact and can
bind target DNA, whilst the PA1 subdomain is partially absent. This has the effect of
constitutively switching PD-DNA binding from the PAI subdomain to the RED
subdomain, an effect which is paralogous to the insertion of exon 5a in vertebrates.
A second Pax6+5a homologue, twin of eyg {toe) is also found in D. melanogaster.
Like toy, this is thought to have arisen by gene duplication (Jang et al., 2003). The
function of toe is largely unknown.
Functional studies of the four D. melanogaster Pax6 homologues have been restricted
to ey and eyg, which are known to have different roles during eye development, eyg is
expressed first in the developing eye, and promotes proliferation of precursor cells, ey
is expressed later, as eyg is switched off. This change in expression is coincident with
a switch from proliferation to differentiation in precursor cells (Dominguez et al.,
2004; reviewed in Rodrigues and Moses, 2004). As further proof of the molecular
similarity between eyg and Pax6+5a, human PAX6+5a was over-expressed in the D.
melanogaster wing, and caused an increase in cellular proliferation, but had no effect
on differentiation (Dominguez et al., 2004).
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In D. melanogaster, the two Pax6 homologues, ey and eyg appear to have distinct
functions in eye development. In vertebrates, the differential functions of Pax6-5a and
Pax6+5a are harder to assess, for two main reasons. Firstly, Pax6-5a and Pax6+5a are
co-expressed in all tissues studied to date (Jaworski et al., 1997; Koroma et ah, 1997;
Kozmik et ah, 1997; Richardson et ah, 1995; Zhang et ah, 2001), making it hard to
assess any differential roles the two isoforms might have. Secondly, whilst ey does
not control the expression of eyg or vice versa (Jang et ah, 2003), murine Pax6-5a can
regulate the expression of Pax6+5a (Plaza et ah, 1993). This interaction can
complicate the interpretation of any investigation into the action of one isoform alone.
1.5.2: C. elegans vab-3 and mab-18
The C. elegans Pax6 homologue, vab-3, is important for formation of the adult male
tail, and the larval and adult head (Lewis and Hodgkin, 1977).
A second transcript, mab-18, is encoded by the same genetic locus, but from an
internal promoter. Translation begins within the vab-3 sequence, resulting in a
"paired-less" protein with an intact HD and TAD (Zhang and Emmons, 1995).
Similar transcripts can be made from the murine Pax6 locus (Kleinjan et ah, 2004;
Mishra et ah, 2002) (see Section 1.4.3), but little is known about the function of these
"paired-less" forms of Pax6.
Mutations in the HD of the mab-18 transcript lead to defects in fate determination of
sensory ray cells, thought to be a result of defects in cellular adhesion (Zhang and
Emmons, 1995). Mutations in the HD of mab-18 would also be present in the HD of
vab-3, therefore it is unclear which aspects of this phenotype are due to the mutation
in mab-18, and which are due to the mutation in vab-3. The presence of a "paired-
less" Pax6 in C. elegans lends potential functional significance to those observed in
other species.
1.6: Pax6 target genes
Pax6 is a transcription factor, containing a PD and a HD that can bind to DNA, and a
TAD to modulate transcription of bound target genes. A number of target genes have
been shown to be directly regulated by Pax6 activity, and more have been implicated
from cDNA micro-array studies.
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1.6.1: Known Pax6 target genes
In the eye, Pax6 is known to bind to the promoters of, and affect the transcription of a
number of crystallin genes, including <yA-crystallin (Cvekl et ah, 1995a), (3-crystallin
(Duncan et ah, 1998), SI-crystallin (Muta et ah, 2002), yE- and yF- crystallins
(Kralova et ah, 2002), and C-crystallin (Richardson et ah, 1995; Sharon-Friling et ah,
1998). Direct interactions between Pax6 and the promoters of both Six3 and Sox2
have also been shown (Goudreau et ah, 2002; Kamachi et ah, 2001), implying that
Pax6 acts on the regulators of eye development as well as its structural components.
In the brain, the genes upon which Pax6 acts can be grouped into four main
categories; other transcription factors, genes involved in neuronal differentiation,
genes involved in cellular proliferation, and genes involved in cellular adhesion.
Transcription factors shown to be directly regulated by Pax6 include Pax2 (Schwarz
et ah, 2000) and Rax (Mikkola et ah, 2001), whilst Engrailed-1 and Wnt-7b are also
thought to be regulated by Pax6 (Kim et ah, 2001; Matsunaga et ah, 2000). These
genes are largely involved in patterning of the brain, which is known to be disturbed
in homozygous Pax6 mutant mice (Bishop et ah, 2002; Mastick et ah, 1997; Muzio et
ah, 2002a; Muzio et ah, 2002b).
The proneural gene Neurogenin2 is also directly regulated by Pax6 (Marquardt et ah,
2001; Scardigli et ah, 2003), as are a number of other basic helix-loop-helix
transcription factors involved in neuronal differentiation such as Math5 and Mashl
(Marquardt et ah, 2001).
Cyclin A and pllKipI are two cell-cycle proteins whose expression is altered in
Sey/Sey cultured cells (Estivill-Torrus et ah, 2002), although it is not known whether
this is a direct effect, or an indication of Pax6 acting elsewhere in the cell cycle. A
direct interaction between Pax6 and c-Mqf an oncogene of the Maf family and a
regulator of cellular proliferation, has also been demonstrated (Sakai et ah, 2001).
The necessity for the Pax6 gene in controlling cellular adhesion in the brain is borne
out by the fact that it directly regulates LI (Meech et ah, 1999) and ATTT/VT (Edelman
and Jones, 1995; Hoist et ah, 1997), and is also thought to control the transcription of
R-cadherin (Andrews and Mastick, 2003).
41
Importantly, Pax6 can also regulate the activity of its own promoters. This will be
discussed in further detail in section 1.6.3.
1.6.2: Potential Pax6 target genes identified from cDNA micro-
array analyses
cDNA micro-array analysis has been used to identify genes which are differentially
regulated between a number of Pax6 mutant and WT mice, with particular emphasis
on the mouse lens.
Transcripts were compared from the lens of WT mice with those over-expressing
Pax6-5a specifically in the lens (Chauhan et al., 2002a) Genes involved in
differentiation (e.g. Hoxa7, Atfl), proliferation (e.g. Pmp22, neural protein 3.1) and
cellular adhesion (e.g. LI, NCAM) were found to be differentially expressed between
the two genotypes. It is important to note, however, that mis-regulation of a gene in
Pax6 mutant mice is not necessarily suggestive of direct transcriptional control.
Despite this, array-based studies are useful in suggesting candidate genes whose
expression may be under the control of Pax6.
A second comparison was made, between WT and Sey/+ lenses (Chauhan et al.,
2002c), and a different cohort of genes involved in differentiation (e.g. Pitx3),
proliferation (e.g. p53, pRb) and cellular adhesion (e.g. (31-integrin) was identified
alongside a large number of crystallin genes.
Comparing WT lenses with those over-expressing Pax6+5a (Chauhan et al., 2002b)
again yielded a set of genes involved in differentiation, proliferation and cellular
adhesion, including Hoxa2, the cyclin gene Ccne2, and paralemmin. A small subset
of these genes was found to be mis-regulated in both Sey/+ lenses and Pax6+5a over-
expressing lenses (e.g. paralemmin and Laminin-associated polypeptide lc).
Although these genes have not previously been associated with Pax6, these array
studies show that they are particularly good candidates for direct Pax6 target genes.
1.6.3: Autoregulation of Pax6
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The Pax6 protein is known to regulate its own promoters, either directly or through
interactions with other proteins, thus affecting transcription of the Pax6 gene.
Two promoters are thought to be responsible for the majority of Pcix6 expression.
They are known as PO and PI in the mouse and quail (Anderson et al., 2002;
Kammandel et al., 1999; Plaza et al., 1993; Plaza et al., 1995), and PA and PB in the
human (Okladnova et al., 1998).
In the quail, it has been shown that PAX-QNR protein (the quail Pax6 homologue),
when transfected into quail neuroretina cells, increases the activity from an
introduced PO promoter (Plaza et al., 1993). A similar result was later shown with the
PI promoter (Plaza et al., 1995). This activation depends on PD-DNA binding, but is
highest when both PD and HD are present, providing further evidence for the
interaction between PD and HD described in section 1.1.2. Only Pax6-5a seems
capable of causing Pax6 autoregulation by this mechanism, as transfection of
Pax6+5a and "paired-less" expressing constructs had no effect on either promoter.
In the human, the promoter PA is thought to correspond to quail and mouse PO, whilst
PB corresponds to PI. Autoregulation via PA has not been studied, but PAX6 protein
has been shown to affect the PB promoter (Okladnova et al., 1998). The effect of this
autoregulation varies between cell lines; PAX6 can act as either an activator or a
repressor if its own transcription, a difference which is presumably dependent on the
presence of co-factors. It is unclear whether these cell-line specific differences are
consistent across phyla, but Pax6 autoregulation appears to be a complex
phenomenon worthy of further study.
1.7: Aims
The main aim of this study is to analyse the role of Pax6 isoforms in embryonic
development. The mouse is used as a model system throughout, as the murine Pax6
locus is well characterised (Walther and Gruss, 1991) and the effects of various
murine Pax6 mutations have been described in detail (Hill et al., 1991; Schmahl et
al., 1993; St-Onge et al., 1997).
In particular, this study focuses on the two most common Pax6 splice variants; Pax6-
5a and Pax6+5a. Little is known about their differential expression patterns
throughout development, or what independent roles these two isoforms might play.
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1.7.1: Pax6-5a : Pax6+5a mRNA ratio in murine embryonic
development
Chapter 2 will describe the use of RNase Protection Assay to determine the relative
abundance of Pax6-5a and Pax6+5a in the olfactory bulb, telencephalon,
diencephalon, eye, spinal cord, hindbrain and cerebellum from E12.5 to El 8.5.
Spatial and temporal alterations in the ratio of Pax6-5a : Pcix6+5a will be related to
alterations in the role that Pax6 is thought to play in the development of different
tissues at different embryological ages.
1.7.2: Pax6 protein isoform expression in Pax6 mutant and WT
mice
Chapter 3 will describe the use of western blot to determine the Pax6 protein content
of the brain and eye of Sey/Sey, Sey/+, WT, PAX77+/~ and PAX77+/+ mice at E12.5.
The relative abundance of each isoform will be compared across the different
genotypes, and the alterations in level will be related to the phenotype observed in
each mouse. In particular, the role of Pax6 autoregulation in controlling the level of
Pax6 protein expression will be discussed.
The Pax6 protein content of Sey/Sey, SeyNe"/SeyNe" and Pox6LacZLac/ mouse brains at
E12.5 will also be described. The Pax6 isoform which is potentially responsible for
any observed protein will be discussed, with reference to the mutation in the Pax6
gene in each mouse strain.
1.7.3: The effects of Pax6-5a and Pax6+5a over-expression in a
cell culture system
Chapter 4 will describe the introduction of Pax6-5a and Pax6+5a expression
constructs into immortalised cell lines both with and without endogenous Pax6
protein.
The effects of over-expression of each isoform will be described, with particular
reference to the effects on Pax6 autoregulation and neuronal differentiation.
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Chapter 2: The Pax6-5a : Pax6+5a ratio in embryonic
development
2.1: Summary
The alternative splicing of exon 5a in the paired domain of the Pax6 gene is well
documented (Epstein et al., 1994b; Jun and Desplan, 1996; Kozmik et ah, 1997;
Walther and Gruss, 1991). This chapter details the use of RNase Protection Assay
(RPA) to characterise the relative amounts of Pax6-5a and Pax6+5a mRNA in
various tissues at various stages of murine embryonic development.
RPA was performed on total RNA from telencephalon, diencephalon, eye, spinal cord
and hindbrain from E12.5, E14.5, E16.5 and E18.5 wild type embryos. From E14.5
onwards, it was also performed on total RNA from the olfactory bulb, and the
cerebellum. At all ages, hindfoot mRNA was used as a Pax6 negative control.
A GAPDH riboprobe was used to confirm mRNA integrity. A Pax6 riboprobe
corresponding to the transcript between exons 7 and 11 was used to demonstrate the
presence of Pax6 in all tissues studied except hindfoot. A second Pax6 riboprobe,
spanning exons 3 to 5a, allowed determination of the ratio between Pax6-5a and
Pax6+5ci.
In all tissues at all ages, the Pax6-5a splice variant is predominant over Pax6+5a.
Elowever, the ratio is consistently lower than previously described in the central
nervous system. All CNS tissues examined in this study have a lower Pax6-5a :
Pax6+5a ratio than the eye.
In the telencephalon, diencephalon, spinal cord and hindbrain, a general trend was
seen; the ratio falls between E12.5 and E16.5, then rises slightly by El8.5. In the
olfactory bulb, on the other hand, the ratio peaks at El6.5. In the eye, the ratio peaks
at El4.5, then drops steeply. In the cerebellum, the ratio remains fairly constant
across all ages studied.
At El2.5, using a riboprobe spanning Pax6 exons 6 and 7, transcripts lacking exon 6
are not detected in any tissues.
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The observed trends in Pax6-5a : Pax6+5a ratio indicate that it is regulated in both a
tissue-specific and a developmental stage-specific manner, and this regulation may be
important in changing the role of Pax6 during development.
2.2: Introduction
2.2.1: Methods previously used to analyse the presence of Pax6
splice variants during embryonic development
A number of methods have been used to assess the prevalence of Pax6-5a and
Pax6+5a transcripts in various tissues. The variation in techniques employed, and in
the species and developmental stages studied, makes it difficult to collate this
information into one coherent data set.
Cloning of Pax6 transcripts after PCR amplification of a cDNA population from adult
mouse lens and brain indicated that Pax6-5a and Pax6+5a were of "similar
abundance" in brain tissue, whilst Pax6-5a "greatly predominated" in the lens
(Richardson et ah, 1995). Such an analysis, however, is at best qualitative, as it
incorporates a PCR step that can lead to the preferential amplification of one cDNA,
and relies on the in-depth analysis of a very small number of cDNA clones.
An estimation of the relative abundance of the two splice forms in chick embryonic
tissues, based on the quantitation of RT-PCR products, suggested that 80% of Pax6
transcript in the retina, but only 2.5% of Pax6 transcript in the cornea, contained exon
5a (Koroma et ah, 1997). In the bovine eye, RT-PCR data indicated that Pax6+5a
was in excess over Pax6-5a in the iris, but the reverse was true in the retina and lens.
Levels appeared to be approximately equal in the cornea (Jaworski et ah, 1997).
Analyses such as these are often highly inaccurate, as they are based on the levels of
RT-PCR product after a high number of amplificatory cycles, and can be affected by
factors such as cDNA salt content, as much as they are by template concentration
(reviewed in Bustin, 2000).
A more rigorous approach, semi-quantitative RT-PCR, involves the use of "mimic"
template fragments, in competitive RT-PCR. The levels of an unknown cDNA
template can be inferred from gel electrophoresis of a PCR product, by comparison
with the levels of a "mimic" fragment of known quantity. This technique allows a
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"quantitative approximation" of Pax6 mRNA content, and showed that Pax6-5a and
Pax6+5a exist at equal levels in adult human lens epithelium and lens fibres (Zhang
et al., 2001). This technique is also not entirely quantitative, as it relies on the levels
of PCR product being proportional to the levels of PCR template.
RNase protection assay (RPA), on the other hand, does not include an amplificatory
step; it can therefore be considered an accurate method of quantitating the mRNA
content of a tissue. This technique has been used to show that Pax6-5a is in 8-fold
excess over Pax6+5ci in total head RNA, from mice at embryonic day 12.5 (El2.5) to
El6.5, and in adult brain RNA (Kozmik et ah, 1997). It is important to note, however,
that the use of whole head RNA will have masked any potential tissue-specific
differences and developmental stage-specific differences within tissues.
2.2.2: RNase Protection Assay
RNase Protection Assay (RPA) is a highly sensitive technique used to analyse the
RNA content of a tissue in a target-specific, non-amp I ificatory manner.
The basic principle behind RPA is illustrated in Figure 2.1. Total RNA is extracted
from a tissue sample, and hybridised with radio-labelled single-stranded RNA
(ssRNA) riboprobes complementary to the mRNA sequence under investigation
(Figure 2.1 B). It is this hybridisation step which is both target-specific and non-
amplificatory, creating a radio-labelled double-stranded RNA (dsRNA) population of
known sequence. Provided that the riboprobe is in molar excess over the target
mRNA, the dsRNA population will also be of the same quantity as the target mRNA
in the original sample. All non-hybridised riboprobe and sample RNAs are digested
away by RNases (Figure 2.1 C), and the remaining dsRNA molecules are resolved
by denaturing polyacrylamide gel electrophoresis (Figure 2.1 D).
2.2.3: Aims
The aim of Chapter 2 was to study the relative expression levels of Pax6-5a and
Pax6+5a in the developing CNS by RNase protection assay.
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Figure 2.1 The basic principle behind RNase
protection assay. A, a radio-labelled ssRNA riboprobe is
synthesised from a sense cDNA template. B, ssRNA
riboprobe is hybridised to target mRNA. C, un-
hybridised ssRNA (either template or riboprobe) is
digested with RNase, leaving only hybridised dsRNA
duplexes of known fragment sizes. D, dsRNA duplexes
are resolved by polyacrylamide gel electrophoresis. Red
and blue bars, exons. Black arrows, ssRNA riboprobes.
Green stars, 32P UTP.
mRNA was obtained from E12.5 to El 8.5, as this corresponds to the peak period of
neurogenesis in the developing mouse (Gillies and Price, 1993; Levers et al., 2001),
and also the period of highest Pax6 expression (Walther and Gruss, 1991).
The Pax6-5a : Pax6+5a ratio was ascertained in WT telencephalon, diencephalon,
eye, spinal cord and hindbrain at E12.5, E14.5, E16.5 and El 8.5. The olfactory bulb
and cerebellum were also studied from El4.5 onwards, when these tissues first
emerge. The presence of Pax6 transcripts lacking exon 6 (Pax6A6) was also assessed
at E12.5.
This analysis aims to correlate differences in the Pax6+5a : Pax6-5a mRNA ratio in
these tissues with discrete processes in which Pax6 activity is thought to be involved.
2.3: Methods
See Appendix 1 for detailed protocols.
2.3.1: RNA extraction from embryonic tissue
CDl mice were used as the wild type strain in this analysis.
For all matings, the day on which a plug was found was designated embryonic day
0.5 (E0.5).
Embryos were harvested at a range of embryonic ages, from E12.5 to El 8.5. See
Figure 2.2 for a detailed description of dissected tissues. All dissections were carried
out within 90 minutes in ice cold, sterile PBS. Tissues were snap-frozen in liquid
nitrogen, and stored at -70°C until RNA extraction.
RNA extractions from embryonic tissue were performed using the RNAgents kit
(Promega). Briefly, tissue was thoroughly homogenised using a motorised
homogeniser with RNase-free disposable pestles, in a denaturing solution containing
guanidium isothiocyantate (GITC). This inhibits RNA digestion by endogenous
RNases, allowing the cellular contents to be released with minimal RNA degradation.
RNA was then separated out of the solution by acid phenokchloroform extraction,
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Figure 2.2 Schematic representation of brain areas from which total
RNA was taken for use in RNase Protection Assays. E14.5 mouse
brain saggital section, taken from Kaufmann (1995). O, olfactory
bulb. T, telencephalon. D, diencephalon. H, hindbrain. C,
cerebellum. At E12.5, olfactory bulb was included with
telencephalon, and cerebellum was included with hindbrain. From
E14.5 to E18.5, tissues were dissected as described here.
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and excess salts were removed by successive isopropanol precipitations. RNA pellets
were resuspended in ddFEO and stored at -70°C for up to 18 months.
2.3.2: RNA quantitation
RNA was quantitated prior to RNase protection assays, to assure even loading
between samples. Quantitations were performed using RiboGreen (Molecular
Probes), a nucleic acid-intercalating agent that fluoresces at 500nm upon binding to
RNA. The intensity of fluorescence is directly proportional to the amount of
RiboGreen bound to target RNA, and thus directly proportional to the total amount of
RNA in a sample.
Fluorescence intensity was measured using a PicoFluor bench-top fluorimeter. Yeast
tRNA standards were used to plot a standard curve of fluorescence against ng RNA,
and a fresh standard curve was generated each time. The RiboGreen reagent is
sensitive down to <lng RNA in 80pl of sample, therefore minimal amounts of RNA
were expended during quantitation.
2.3.3: RNase Protection Assay (RPA)
RPAs were performed on wild type embryonic RNA, to determine the absolute Pax6
content of various tissues.
2.3.3.1: Riboprobe design
Sections of murine Pax6 cDNA were cloned into pCR-Bluntll-TOPO (Invitrogen) to
allow the synthesis of riboprobes for use in RPA. For each riboprobe template, Pax6
cDNA was cloned from whole mouse El2.5 cDNA.
See Figure 2.3 for a graphical representation of Pax6 mRNA sequences protected by
the three riboprobes.
To create a riboprobe spanning exons 3 to 5a, which would differentially recognise
Pax6+5a and Pax6-5a (Probe 5.22), cDNA was amplified with the primers "Pax6
MMu exon 3F" and "'Pax6 MMu exon SaR'' (see Appendix 2 for primer sequences
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218 / 247bp Probe 5.22:
c
Pax6 MMu exon 3F,
Pax6 MMu exon 5aR
166 / 340bp Probe 6.20:
Pax6 MMu exon 6F,
Pax6 MMu exon 7R
Probe 7.23 : 464bp
Pax6 MMu Ribo F,
Pax6 MMu exon 11R
Figure 2.3: Pax6 Riboprobes. Red and blue bars represent Pax6
exons. The alternatively spliced exons 5a and 6 are underlined.
Purple bar: Pax6 open reading frame; canonical translation begins at
the 3' end of exon 4. Orange bar: paired domain. Green bar:
homeodomain. Protected fragments covered by the three riboprobes
are depicted by red (unspliced) and black (spliced) bars, with
predicted fragment lengths in base pairs. Probe names, and the
names of the PCR primers used to create them, are also given.
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To create a riboprobe spanning exons 6 and 7, which would differentially recognise
Pax6 and Pax6A6 (Probe 6.20), cDNA was amplified using the primers "Pax6 MMu
exon 6F" and "Pax6 MMu exon 7R"
To create a riboprobe spanning the unspliced Pax6 exons 7 to 1 I (Probe 7.23), which
would act as a control probe to detect full-length Pax6, cDNA was amplified using
the primers "Pax6 MMu RiboF" and "Pax6 MMu Exon 11R". All PCR amplifications
were performed using Expand DNA polymerase (Roche), combining high-fidelity
amplification by the proofreading Pfu DNA polymerase with the speed of Taq DNA
polymerase, to minimise the risk of amplification errors.
After PCR amplification, blunt-ended fragments were cloned using the Zero Blunt
TOPO cloning system (Invitrogen) into the pCR-Blunt-II-TOPO vector (Jnvitrogen).
Four clones from each cloning reaction were sequenced across the Pax6 insert in both
directions to ascertain the orientation in which the template had entered pCR-Bluntll-
TOPO, and to confirm that their sequence corresponded exactly to European
Molecular Biology Laboratory (EMBL) entry X63963.1.
pJP5.22 (exons 3 to 5a), pJP6.20 (exons 6 and 7), and pJP7.23 (exons 7-11) were
used for all riboprobe synthesis reactions, as they contained the desired Pax6
sequence with no mutations, in the antisense orientation. Transcription from these
templates creates sense-oriented single-stranded RNA, which can bind to and form
duplexes with antisense single-stranded mRNA.
The plasmid pTRI-GAPDH (Ambion) was also used, for synthesis of a murine
glyceraldehyde-3-phosphate dehydrogenase (GAPDF1) riboprobe, to confirm the
presence of non-degraded mRNA in each sample.
2.3.3.2: Sequencing
All Pax6 expression constructs and riboprobe templates were fully sequenced across
the Pax6 locus in both directions. Plasmid backbones were not sequenced, but were
understood to be as described by the supplier. Sequencing was performed on ethanol-
precipitated plasmid DNA obtained by miniprep, using the MWG-Biotech Value
Read sequencing service. For sequencing primers, see Appendix 2.
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2.3.3.3: Riboprobe synthesis
Single-stranded, 32P-labelled riboprobes were synthesised antisense to the target
RNA. Transcription was carried out using SP6 RNA polymerase in the presence of
a-32P-UTP. For GAPDH probes, a small amount of unlabelled UTP was included in
the reaction to decrease the specific activity of the riboprobe, allowing the
visualisation of GAPDH and Pax6 on the same gel, even though GAPDH was, in great
excess over Pcix6. Riboprobes were purified using a sepharose column (Promega) to
remove unincorporated nucleotides, and a small aliquot was analysed by
polyacrylamide gel electrophoresis to confirm the presence of a single labelled RNA
of the expected size. Riboprobes were then quantitated by Cerenkov scintillation
counting.
2.3.3.4: HybSpeed RPA
RPAs were carried out using the HybSpeed kit (Ambion).
Template RNA, riboprobe and yeast tRNA were combined, ethanol co-precipitated,
resuspended in hybridisation buffer, and target RNA - riboprobe hybridisation was
allowed to proceed overnight. See Figure 2.2 for a detailed description of target
RNAs. RNAs represented tissues of the central nervous system that were known to
express Pax6 during development, and were taken from El2.5, El4.5, El6.5 and
E18.5 embryos, spanning the peak period of neurogenesis. At E12.5 and E14.5, lpg
of total RNA was used per reaction. For El 6.5 and El 8.5 samples, this was increased
to 4pg, as total Pax6 expression falls at these ages, but greater amounts of RNA can
be collected. For each reaction, 80,000cpm of Pax6 riboprobes and 40,000cpm of
GAPDH riboprobes were used. Despite GAPDH mRNA being more abundant than
Pax6 mRNA in the tissues analysed, a lower cpm of GAPDH riboprobe was used.
This was because the riboprobe had been spiked with unlabelled UTP, therefore a
lower specific activity still represented a higher amount of riboprobe. Yeast tRNA
was included to make the total amount of RNA up to 50pg in order to aid ethanol co-
precipitation. For each RPA, two control tubes consisting of probe and yeast tRNA
with no target RNA were also prepared.
After overnight target RNA - riboprobe hybridisation, all single-stranded target RNA
(ssRNA) had hybridised to single-stranded probe RNA, making double-stranded
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RNA-RNA (dsRNS) duplexes. Each reaction was treated with a cocktail of RNaseA
and RNase T1 to digest away all unbound ssRNA, leaving only dsRNA and NTPs.
One negative control reaction was also treated in this way to ensure that RNase
digestion progressed to completion. The second negative control reaction was
incubated in RNase digestion buffer without RNase cocktail, allowing whole
undigested riboprobe to be carried through to the end of the reaction. If this
undigested riboprobe was intact on the final polyacrylamide gel, this was an
indication that no RNases were present elsewhere in the procedure, and negative
samples were indeed negative rather than just a result of unwanted RNase digestion.
Double-stranded RNA-RNA duplexes were then isopropanol precipitated to eliminate
digested NTPs, and resuspended in gel loading buffer containing formamide to
denature the duplexes. This process was aided by heating samples to 95°C for 5
minutes. RNA was then resolved on a 6% polyacrylamide, 8M urea denaturing gel,
alongside a a-3:P-label led double-stranded DNA ladder to allow approximate sizing
of bands.
2.3.4: Densitometric analysis of gel films
Bands on X-ray films were quantitated using a BioRad GS-710 densitometer. Gels
were scanned at a high resolution (usually 42.3pm X 42.3pm per pixel), in greyscale
spanning 400-750nm wavelengths, using transmitted light. Analysis was performed
using the Quantity One software {BioRad). Lanes were created, and a rolling disc
background subtraction method was used to ensure data was comparable between
lanes. Bands were then manually created, and peak area was taken as a measurement
of band intensity.
2.4: Results
RNase Protection Assay is a highly sensitive, non-amplificatory, target-specific
technique for analysing the mRNA content of a tissue sample. Pax6 mRNA is
detectable from as little as lpg total RNA at El2.5. As the protocol involves no
amplificatory steps, and theoretically no target RNA is lost during an RPA, it allows
absolute quantitation of mRNA levels. In practice, some mRNA is lost during the
procedure; therefore direct comparison between mRNA samples is not possible.
Within a sample, however, the ratio between splice variants should be an accurate
55
representation of the ratio within a tissue. Careful riboprobe design leads to the
production of dsRNA fragments of known size which can be resolved by
polyacrylamide gel electrophoresis.
2.4.1: GAPDH mRNA is present in all tissues examined
The quality of all total RNA samples was first assessed using a GAPDH riboprobe.
Where a single, discrete band of 316bp was seen, it was an indication that no RNase
digestion had occurred (See Figure 2.4 for a sample gel). Identical amounts of total
RNA were loaded in each lane. Where GAPDH signal was weak, this was a sign that
protein or DNA contamination had led to inaccurate RNA quantitation, and these
samples were excluded from subsequent analyses.
2.4.2: Pax6 mRNA is present in all tissues examined, except
hindfoot
The riboprobe pJP7.23 protects Pax6 mRNA from exons 7 to 11, an area in which no
alternative splicing had been described at the time of probe design. RPA on all tissues
with this probe gave a 464bp, full-length band (Figure 2.5). A second, lower band of
approximately 240bp was occasionally seen, although this was not present in all
samples. It is unclear whether this is a Paxb-specific band.
Exact sizing of this ectopic band is difficult, as the dsDNA ladder only allows an
approximation of dsRNA fragment length. Knowing the predicted size of full-length
GAPDH and Pax6 bands shows that dsRNA is retarded on polyacrylamide gels, when
compared to dsDNA ladder. Therefore a dsRNA band travelling alongside a 242bp
dsDNA band is likely to be slightly smaller than this.
There is no clear explanation for the presence of a ~240bp protected fragment from
the riboprobe pJP7.23. Two Pax6 cDNAs have been cloned from the mouse in which
exons 2 to 8, or 2 to 10 are absent (Gorlov and Saunders, 2002). These would give
predicted fragment sizes of 176bp or 54bp, respectively. Another Pax6 transcript,
beginning in intron 7 (Kleinjan et al., 2004) would give a 447bp protected fragment.
An alternative explanation would involve the alternative splicing of exon 10. In this
case, the probe pJP7.23 would protect a 259bp RNA fragment, covering exons 7, 8
and 9. This is approximately the size of the ectopic band observed in Figure 2.5, but
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Figure 2.4, GAPDH signal in total RNA from telencephalon (lane 1),
diencephalon (2), eye (3), spinal cord (4) and hindfoot (5) at E12.5.
1pg total RNA was used in each sample. In this example, spinal
cord RNA (lane 4) was discarded, as levels were lower than RNA
quantitation suggested, implying protein or DNA contamination,














Figure 2.5, Example of GAPDH and Pax6 signal detected by pTri-
GAPDH and pJP7.23 (Pax6 exons 7-11) in total RNA from E14.5
telencephalon (lane 1), diencephalon (2), eye (3), spinal cord (4),
hindbrain (5) cerebellum (6+7) and hindfoot (8). 1pg total RNA was
used in each sample. In this example, diencephalon RNA (lane 2) was
discarded, as levels were lower than RNA quantitation suggested,
implying protein or DNA contamination. dsDNA ladder (9) allows
approximate sizing of bands, fragment sizes are indicated above bands.
A ~240bp band (*) was occasionally seen with the probe pJP7.23.
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would not leave the Pax6 transcript in-frame, and such a splice event has not been
documented in vivo. Alternative splicing of exon 8 would leave two protected RNA
fragments, one of 83bp corresponding to the 5' portion of the probe, the second of
288bp, corresponding to the 3' portion of the probe. This is probably too large a
predicted fragment size to account for the ~240bp band, and has also not been
documented in vivo.
Pax6 mRNA was shown by the riboprobe pJP7.23 to be present in all tissues studied,
except hindfoot.
2.4.3: Pax6-5a Pax6+5a ratio in the developing mouse
telencephalon, diencephalon, spinal cord and hindbrain
All Pcix6 expressing tissues contained both splice variants (Figure 2.6). This is
consistent with previous studies (Jaworski et ah, 1997; Kozmik et al., 1997; Zhang et
ah, 2001), as exclusive expression of one isoform within a tissue has never been
documented. It is also consistent with data presented in Chapter 4, which indicates
that regulatory mechanisms are in place to ensure that these two isoforms are usually
co-expressed.
The ratio of Pax6-5a to Pax6+5a is similar between telencephalon, diencephalon,
spinal cord and hindbrain between E14.5 and El8.5 (Figures 2.7-2.9). At E12.5 it
varies between these four tissues, and is highest in the diencephalon, where it
approaches 9:1, and lowest in the spinal cord, where it is closer to 3:1. A high degree
of variation is seen in samples from the hindbrain, with values ranging between 18:1
and 2:1, whilst results for the other tissues are more consistent. It is important to note
that El2.5 telencephalon samples included the developing olfactory bulb, which is
shown to behave differently at later ages (see Section 2.4.4). El2.5 hindbrain also
included the developing cerebellum, which also seems to follow a different pattern of
Pax6 expression later in development (see Section 2.4.6).
By El4.5, the ratio has fallen in all four tissues, and is around 3:1 in all cases. It drops
slightly at El 6.5 to 2:1, then rises again by El8.5, back to approximately 3:1.
The other tissues analysed seem to follow separate trends in Pax6-5a : Pax6+5a ratio,
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Figure 2.6, Example of GAPDH and Pax6 signal detected by pTri-
GAPDH and pJP5.22 (Pax6 exons 3 to 5a) in total RNA from E14.5 eye
(lane 1), E14.5 spinal cord (2), E12.5 telencephalon (3), E12.5
diencephalon (4), E12.5 eye (5) E12.5 spinal cord (6), E12.5 hindbrain
(7) and E12.5 hindfoot (8) 1pg total RNA was used in each sample.
dsDNA ladder (9) allows approximate sizing of bands, fragment sizes
are indicated above bands. Lane 10, undigested GAPDH probe. Lane
11, undigested Pax6 probe.
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A Pax6-5a : Pax6+5a mRNA ratio in the telencephalon
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Figure 2.7 Scatter plot of Pax6-5a : Pax6+5a ratio in A, telencephalon
from E12.5 to E18.5. B, diencephalon from E12.5 to E18.5.
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B Pax6-5a : Pax6+5a mRNA ratio in the hindbrain
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Figure 2.8 Scatter plot of Pax6-5a : Pax6+5a ratio in A, spinal cord
from E12.5 to E18.5. B, hindbrain from E12.5 to E18.5.
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Pax6-5a : Pax6+5a ratio in the telencephalon,














Figure 2.9 Scatter plot of Pax6-5a : Pax6+5a ratio in telencephalon,
diencephalon, spinal cord and hindbrain from E12.5 to E18.5.
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2.4.4: Pax6-5a : Pax6+5a ratio in the developing mouse olfactory
bulb
The developing mouse olfactory bulb cannot be distinguished from the telencephalon
at El2.5, therefore at this age the two tissues were pooled, and classed as
telencephalon. From E14.5, separate olfactory bulb mRNA samples could be
obtained. However, sample number is low as the tissue was difficult to collect. The
observed Pax6-5a : Pax6+5a ratio is low, around 2:1 at E14.5 (Figure 2.10 A). This
is similar that seen in the other CNS tissues described above. Unlike these tissues,
however, the ratio rises in the olfactory bulb at E16.5, then falls again at El 8.5. It is
unclear whether variation between the two olfactory bulb samples from El6.5 is real
or experimental, but data from the other two ages is less variable.
2.4.5: Pax6-5a : Pax6+5a ratio in the developing mouse eye
Data from the developing eye (Figure 2.10 B) indicates that the Pax6-5a : Pax6+5a
ratio is higher than that observed in most tissues of the brain and in the spinal cord at
E12.5 and E14.5; it is around 8:1. It then drops, and by E18.5 has fallen to
approximately 3:1. This drop in ratio is similar to that observed in the telencephalon,
diencephalon, spinal cord and hindbrain. In these tissues, however, it is lowest at
El 6.5, whilst in the eye it is still falling at El 8.5.
2.4.6: Pax6-5a : Pax6+5a ratio in the developing mouse cerebellum
The mouse cerebellum is not apparent at El2.5, being indistinguishable from the rest
of the developing hindbrain. By E14.5, a presumptive cerebellum can be seen, and
mRNA samples were collected from this age onwards.
Although there is only one data point at El4.5, there appears to be no change in the
Pax6-5a : Pax6+5a ratio in the cerebellum at the observed ages (Figure 2.11). On
average, the ratio remains at about 4:1. Unlike all the other tissues used in this
analysis, it does not fall throughout development, and is no lower at El8.5 than at
E14.5.
2.4.7: Pax6A6 is not observed in any tissue at E12.5
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Figure 2.10 Scatter plot of Pax6-5a : Pax6+5a ratio in A, olfactory bulb
from E14.5 to E18.5. B, eye from E12.5 to E18.5.
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Figure 2.11 Scatter plot of Pax6-5a : Pax6+5a ratio in cerebellum from
E14.5 to E18.5
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The alternative splicing of exon 6 of the Pax6 gene has been documented a number of
times. Carriere et al. (1993) described an mRNA isolated from quail neuroretina in
which the 3' 198bp of exon 5 (Pax-QNR exon 5 corresponds to human and mouse
Pax6 exon 6) was removed due to the usage of an unusual splice donor site 15bp into
exon 5, allowing splicing straight onto sequence at the 5' end of exon 6 (human and
mouse exon 7). The splice donor site described in this example is conserved across
mouse and man, and this splice variant has also been described in the bovine eye
(Jaworski et al., 1997). Pax6 missing the entire of exon 6 has been cloned from the
U373-MG glioblastoma cell line (T.I.Simpson pers. comm.). Each of these potential
splice variants would be detected by the riboprobe pJP6.20, which spans exons 6 and
7 of the Pax6 transcript.
RPA was performed using this riboprobe on all tissues at El2.5. This age was chosen
for a preliminary screen as it is around the peak of neurogenesis (E13.5) and the peak
of Pax6 expression (El0.5) (Walther and Gruss, 1991). Also, as seen in Chapter 3, a
43KDa Pax6 protein, thought to correspond to Pax6 lacking exon 6 (Carriere et al.,
1993) is present in both brain and eye at El2.5.
A single band of 340bp was observed in all samples (Figure 2.12). Any shorter bands
were low in abundance, and observed in hindfoot RNA, and therefore unlikely to
represent Pax6 splice variants. This result was surprising, as the alternative splicing
of some or all of Pax6 exon 6 is reasonably well documented. It is possible that this
mRNA is present at low levels, below the limits of detection by RPA. However,
western blot data indicates that the 43KDa protein is present in reasonably high levels
in a number of tissues (Carriere et al., 1993; Turque et al., 1994; Chapter 3 of the
present study). This could mean that the protein product of this mRNA is highly
stable, and only low levels of transcript are required to create relatively high levels of
protein. Alternatively, differential antibody binding kinetics could mean that although
this isoform appears quite common by western blot, it is in fact quite rare, but
preferentially detected by anti-Pax6 antibodies. A third explanation is that the 43KDa
protein is not a result of alternative splicing of exon 6. Although these cDNAs have
been described in vivo, and their predicted molecular mass after translation is 43KDa,
they have never been shown to be directly responsible for the 43KDa band observed
by western blot.
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E12.5 E14.5 E12.5 E14.5
Figure 2.12, Example of GAPDH and Pax6 signal detected by pTri-
GAPDH and pJP6.20 in total RNA from E12.5 telencephalon (lane 1),
E12.5 diencephalon (2), E12.5 eye (3), E12.5 spinal cord (4), E12.5
hindbrain (5) E12.5 hindfoot (6), E14.5 eye (7) and E14.5 cerebellum
(8) 1pg total RNA was used in each sample. dsDNA ladder (9) allows
approximate sizing of bands, fragment sizes are indicated above bands.
A single band of 340bp is seen in all tissues except E12.5 hindfoot and
E14.5 cerebellum, where GAPDH signal is weak. Any shorter bands
are present in E12.5 hindfoot, therefore not Pax6 specific. No clear
166bp Pax6A6 band is visible in any tissue.
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2.5: Discussion
2.5.1: Overall trends in Pax6-5a : Pax6+5a ratio in murine
embryonic development
In all tissues, at all ages, Pax6-5a is more abundant than Pax6+5a.
The Pax6-5ci : Pax6+5a ratio is shown to vary both spatially and temporally
throughout murine neurogenesis. The most common pattern is observed in the
telencephalon, diencephalon, spinal cord and hindbrain. In these tissues, the ratio
starts high at E12.5, falls to around 2:1 by E16.5, then rises slightly to 3:1 at E18.5.
Three of the tissues analysed in this study did not conform to that pattern; the
olfactory bulb, the eye and the cerebellum. In the olfactory bulb, ratios are low, about
2:1 at E14.5. They then rise slightly at E16.5, before falling back to 2:1 at E18.5. In
the eye, the ratio starts high, at around 8:1, then falls steadily to around 3:1 at E18.5.
In the cerebellum, the ratio remains constant, at around 4:1.
2.5.2: Limitations of this analysis
Although RPA is theoretically a quantitative technique, in practice it was only
possible to compare the amounts of transcript within a sample. Due to successive
RNA precipitation steps in the protocol, sample was lost in some or all cases. As
equal amounts of Pax6-5a and Pax6+5a mRNA are likely to be lost, their ratio within
a sample should still be an accurate representation of the in vivo ratio.
Had this technique been quantitative between samples, it would have been interesting
to compare data from the riboprobes pJP5.22 and pJP7.23. The former protects
mRNA from exons 3 to 5a, and the latter from exons 7 to 11. Pax6 transcripts have
been described since the design of the riboprobes used here, in which transcription
begins within intron 7 (Kleinjan et al.. 2004), or various exons between 4 and 10 are
absent (Gorlov and Saunders, 2002). These putative transcripts would be at least
partially protected by the riboprobe pJP7.23, but not by pJP5.22. None of them,
however, would give dsRNA fragments of a similar size to the short, ~240bp
fragment observed occasionally with p.(P7.23. A comparison in signal strength
between the two riboprobes would have allowed an estimation of the levels of any 5'-
truncated transcripts, had the technique proven to be quantitative. One RPA, in which
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the two riboprobes were used in tandem on the same RNA samples, indicated that
signal strength was indeed higher with pJP7.23 in the telencephalon and
diencephalon, but not in the eye (Figure 2.13), however this data is likely to be
qualitative at best.
Another obvious problem with assessing the levels of alternatively spliced Pax6
mRNAs is that mRNA levels may not directly mirror protein levels. If one transcript
is more stable, or translated with a higher efficiency, the observed Pax6-5a :
Pax6+5a ratio may not be the same as the ratio between the two proteins. A
comparison between these data and data from western blot analysis of whole brain
and whole eye at El2.5 (see Chapter 3, Figure 3.22 for further detail) implies that the
mRNA ratio is similar to the protein ratio in the eye, and these data are probably an
accurate representation of protein expression. In the brain, there is more disparity
between the two values, which may be indicative of regulation at the protein level.
This will be discussed in more detail in Section 3.6.2.
This technique was informative in looking at the development of the brain, as its
constituent tissues were dissected out and analysed independently. However, the
same is not true of the eye. Accurate conclusions cannot be drawn from the eye data
presented here, as it involved the pooling of a number of different Pax6 expressing
tissues, most notably the neural retina and the lens.
2.5.3: Potential explanations for the developmental^ regulated
changes in Pax6-5a : Pax6+5a ratio
2.5.3.1: The telencephalon, diencephalon, spinal cord and
hindbrain
That the telencephalon, diencephalon, spinal cord and hindbrain follow the same
trends in Pax6-5a : Pax6+5a ratio implies that Pax6 may be playing a similar role in
each tissue. In particular, from E14.5 to El8.5, results from the four tissues are
virtually indistinguishable. It is possible that Pax6 has a different action in each tissue
at E12.5, but the same action from E14.5 onwards.
The fall in the ratio in these four tissues occurs whilst the proliferating precursor cell


























































0.314 0.166 0.547 2.46 1.08 0.20
0.079 0.035 0.150 0.88 0.55 0.16
Figure 2.13, Comparison of Pax6 signal strength from the probes
pJP7.23 (spanning exons 7-11) and pJP5.22 (spanning exons 3-5a),
analysed simultaneously. A, polyacrylamide gel. T, E12.5
telencephalon. D, E12.5 diencephalon. E, E12.5 eye. SC, E12.5 spinal
cord (failed lane). Hf, E12.5 hindfoot. B, Pax6 levels after compensation
for GAPDH.
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Pax6, from promoting proliferation to promoting differentiation. This will be
discussed further in Section 2.5.3.5.
2.5.3.2: The olfactory bulb
The Pax6-5a : Pax6+5a ratio in the developing olfactory bulb is low at El4.5,
coincident with both migration and proliferation contributing to the olfactory bulb
cell population. It rises immediately after, as these proliferative precursor cells begin
to differentiate. This is opposite to the effect seen in other CNS tissues, where the
ratio falls at El6.5, as neuronal differentiation begins. These data suggest that Pax6
may be playing another, as yet undefined role in olfactory bulb development. For
example, the rise in ratio at E16.5 occurs as mitral cell axons begin to leave the
olfactory bulb and innervate the olfactory cortex (Nomura and Osumi, 2004). Thus,
Pax6 may be playing an important role in the regulation of cell adhesion molecules to
control this migration.
By El8.5 the Pax6-5a : Pax6+5a ratio in the olfactory bulb has fallen again, and is
close to that observed in other CNS tissues, about 2:1. By this point, development of
all these structures is largely complete, and Pax6 could be playing a similar,
maintenance role in each.
2.5.3.3: The eye
The eye is the most complex tissue used in this study, in terms of the number of
tissues and cell types present. As such, this mRNA sample represented a number of
Pax6 expressing tissues which were pooled. It is likely that this led to the masking of
some tissue-specific differences in ratio. As described in Section 2.2.1, the Pax6-5a :
Pax6+5a ratio is best understood in the adult eye, largely as a result of two studies on
the bovine eye (Jaworski et ah, 1997) and the human lens, cornea and monkey retina
(Zhang et ah, 2001). Both of these studies indicated that there are indeed tissue-
specific differences in the Pax6-5a : Pax6+5a ratio within the adult eye, an effect that
is likely to extend to the developing murine eye.
Alternative c/.v-regulatory elements downstream of the Pax6 gene direct its
expression specifically in the neural retina (Griffin et ah, 2002), or the lens (Dimanlig
et ah, 2001; Kammandel et ah, 1999). The relative amounts of the Pax6+5a and
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Pax6-5a splice forms vary markedly between these two tissues (Jaworski et ah,
1997), a variation that would have been missed in this analysis.
For this reason, it is difficult to relate the Pax6-5a : Pax6+5a ratio observed in the
eye to any specific role in development. What this data does show, however, is that
there is a clear regulation of the ratio through murine eye development, and the
general trend is similar to that observed in the majority of CNS tissues.
2.5.3.4: The cerebellum
Unlike all the other tissues analysed in this study, the Pax6-5a : Pax6+5a ratio does
not appear to differ in the cerebellum between E14.5 and El8.5. One explanation for
the difference in Pax6 alternative splicing in the cerebellum when compared to other
tissues is that Pax6 may be playing a different role here. As in the olfactory bulb,
Pax6 is thought to be important for controlling cellular migration in the cerebellum
(Engelkamp et ah, 1999).
Unlike many of the other tissues analysed in this study, the cerebellum is known to
continue developing beyond El 8.5, and high levels of neurogenesis are known to
occur postnatally (Altman and Bayer, 1978a; Altman and Bayer, 1978b). Pax6
continues to be expressed at high levels in the adult mouse cerebellum (Stoykova and
Gruss, 1994; Yamasaki et ah, 2001), whilst expression in other brain tissues has
fallen significantly. The maintenance of a relatively high Pcix6-5a : Pcix6+5a ratio in
the cerebellum at El8.5 when compared to other brain tissues is consistent with the
hypothesis that a high ratio is required for proliferation, whilst a lower ratio is
required for subsequent neuronal differentiation.
2.5.3.5: Overall conclusions
Chauhan et al. (2004a) demonstrated that different Pax6-5a : Pax6+5a ratios had
different transactivational activities on consensus Pax6 target sequences, within a cell
culture system. Transactivation at both the P6CON and 5aCON sequences was
highest with a ratio of 8:1 or 1:1, but lower at intermediate ratios. Two conclusions
could be drawn from this information. It may be that transactivation of all Pax6 target
genes is highest at ratios of 1:1 and 8:1. This would imply that Pax6 is most potent as
a transcription factor in the diencephalon, for example, at El2.5 and El6.5, but less
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so at E14.5 and El8.5. Alternatively, the change in ratio might lead to a switch in
target genes, with the highest levels of transactivation at ratios of 2:1 and 4:1
occurring at sequences that were not analysed in that particular study. The latter
scenario is consistent with the idea of the alternative splicing of exon 5a acting as a
"molecular toggle", changing the set of Pax6 target genes (Epstein et al., 1994b).
The results described above suggest that an alteration in the Pax6-5a : Pax6+5a ratio
in the majority of CNS tissues may be involved in a switch in Pax6 activity, from
promoting cellular proliferation to promoting differentiation.
A good model system to study the actions of Pax6-5a and Pax6+5a in these two
processes is the fruit fly, Drosophila melanogaster. Rather than regulating PD-DNA
interactions by alternative splicing, Drosophila have two Pax6 homologues, eyeless
(ey) and eye gone (eyg) (Jang et al., 2003). ey is homologous to Pax6-5a, whilst eyg is
homologous to Pax6+5a, as it has a truncated PD containing only the C-terminal
DNA-binding domain, thought to be the main DNA-binding domain in Pax6+5a (Xu
et al., 1999). Expression of ey appears to promote proliferation in the developing eye,
whilst a switch to expression of eyg promotes differentiation (Dominguez et al., 2004;
Rodrigues and Moses, 2004).
Although the actions of Pax6-5a and Pax6+5a are likely to be more complex than
those of ey and eyg, and the two isoforms are expressed together rather than
independently, it is still a possibility that an alteration in the ratio between the two
isoforms leads to a similar developmental switch; from proliferation to
differentiation. It may be that the drop in ratio allows Pax6 to act upon a different set
of target genes, rather than just changing the level of transactivation of a constant set
of targets, as suggested by Chauhan et al. (2004).
In the majority of the tissues analysed here, the Pax6-5a : Pax6+5a ratio has fallen by
El8.5, shortly before birth, but transcript is still detected in all tissues at this age. The
ratio is around 2:1 in all tissues except the cerebellum, which is still actively
proliferating at E18.5 (Altman and Bayer, 1978a; Altman and Bayer, 1978b). That




An alternative technique for assessing mRNA levels in a tissue is quantitative RT-
PCR (Q-PCR). Although this would allow direct comparison of mRNA levels
between samples, it is less reliable for comparing the ratio of splice variants within a
sample. PCR kinetics can vary between cDNAs, and one splice variant may be
preferentially amplified over another. For this reason, Q-PCR could be used to
compare the absolute levels of a transcript between tissues, but not the ratio of
transcripts within a tissue.
A combination of RPA and Q-PCR could potentially address both factors in tandem;
for example if RPA were used on a number of reference samples to determine the
Pax6-5a : Pax6+5a ratio, followed by Q-PCR with primers specific to each isoform.
The ratios observed by RPA could then be applied to all Q-PCR data, based on the
assumption that two cDNAs may be amplified with different efficiencies, but this
efficiency does not vary between repeats. This would be easier to achieve than RPA
analysis of a large number of tissues, and could facilitate a much more extensive
analysis, but is likely to be prone to error as it would involve significant extrapolation
of data.
Another useful experiment would be to obtain RNA samples corresponding to
different Pcix6 expressing components of the eye. Most notably, it would be
interesting to compare the Pax6-5a : Pax6+5a ratio in the neural retina, a
neurectoderm-derived structure, and the lens, a facial epithelial-derived structure.
It would also be interesting to extend this analysis to adult tissues. Pax6 expression is
seen in adult corneal stem cells, and studies of Sey/Sey <-> WT chimaeras have shown
that it is necessary for the constant repair and replacement of damaged corneal cells
(Collinson et al., 2003). Neural stem cells in the adult spinal cord also express Pax6
(Yamamoto et al., 2001), and it is possible that continued low-level expression of
Pax6 in a number of CNS tissues after birth is essential for the maintenance of a stem
cell population.
Ultimately, although the description of the relative levels of Pax6-5a and Pax6+5a is
fundamental to our understanding of the role of these splice variants in embryonic
development, it is also important to understand the regulation of Pax6 protein levels,
and the functions of these proteins. These two issues will be addressed successively
in Chapters 3 and 4.
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Chapter 3: Analysing the Pax6 protein expression
pattern in mice with various Pax6 alleles
3.1: Summary
Pax6 protein, as visualised by western blot, appears to exist as up to eight different
isoforms. The presence or absence of these isoforms was characterised in Pax6
mutant (Sey) mice, Pax6 over-expressing (PAX77) mice and WT mice at El2.5.
Whole brain and whole eye extracts were analysed, and the relative amount of each
isoform was compared across genotypes.
El2.5 was chosen for analysis of Pax6 protein expression for a number of reasons.
Firstly, it is near to the peak period of neurogenesis (usually regarded as E13.5), a
process in which Pax6 is involved. Secondly, levels of Pax6 mRNA expression peak
at El0.5, as measured by northern blot (Walther and Gruss, 1991). Although levels
have fallen slightly by El2.5, this was considered an easier age to study, as tissue is
more abundant, therefore more protein could be extracted. Also, as RPA data was
collected for WT samples at El2.5 (see Chapter 2), comparisons could be made
between RNA and protein data.
Two Pax6 isoforms were observed in brain extracts from El2.5 Sey/Sey mice, which
contain a mutation in the Pax6 locus, and were thought to be effectively Pax6-null. In
order to determine the exact nature of these isoforms, their expression was compared
to that seen in other Pax6 knockout mice, Pax6lacZLacZ and SeyNc"/SeyN"'. A 32kDa
Pax6 isoform was seen in each, whilst a 43kDa isoform was seen in Sey/Sey, but not
Pax6lacZlacZ or SeyNe"/SeyNe" brains.
3.2: Introduction
3.2.1: Pax6 protein isoforms
As described in Section l .4, the alternative splicing of Pcix6 is well documented, and
leads to the creation of a number of Pax6 protein isoforms.
The Pax6 cDNA is described in Figure 1.2. The 422 amino acid protein resulting
from translation of Pax6-5a has a molecular weight of 46kDa, whilst the 436 amino
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acid Pax6+5a protein has a predicted molecular weight of 48kDa (Walther and Gruss,
1991). Both isoforms are visible by western blot, as a 46/48kDa doublet (Carriere et
al„ 1993).
A number of studies have looked at Pax6 protein isoform expression. Western blot
analyses of Pax6 were first performed on quail neuroretina cells, using a series of
polyclonal antibodies directed against the PD, PST-rich linker, HD and C-terminus of
the Pax6 protein (Carriere et al., 1993; Turque et ah, 1994). As well as the predicted
46/48kDa doublet, lower molecular weight bands were seen which appeared to be
alternative Pax6 protein isoforms.
A single band was described at 42kDa, and is thought to correspond to Pax6A6, in
which exon 6 of the transcript has been spliced out (Carriere et ah, 1993; Jaworski et
ah, 1997). A band of approximately 42kDa is also seen in the adult mouse brain using
a different anti-Pax6 C-terminus primary antibody (Davis and Reed, 1996). This band
could also be due to the use of a cryptic splice site within intron 7, leading to a
protein missing 36 amino acids of the PD, an event which has been documented in
humans with mutations in the PAX6 locus (www.hgu.mrc.ac.uk/Softdata/PAX6/).
Two further bands have been reported at 32/33kDa, and shown to be the result of
internal translation initiation from an unspecified in-frame ATG residue within the
Pax6 transcript (Carriere et ah, 1993). "Paired-less" Pax6 transcripts have since been
described in the mouse (Gorlov and Saunders, 2002; Kleinjan et ah, 2004; Mishra et
ah, 2002) in which translation could only begin from an internal ATG, implying that
the shorter Pax6 isoforms may be regulated at the transcript level as well as at the
level of translation.
There is also a possibility that any Pax6 protein bands visible by western blot might
be protein cleavage or degradation probucts.
3.2.2: Previous analyses of the Pax6 protein content of Sey/Sey,
Sey/+, WT, PAX77+/" and PAX77+/+ mice
Pax6 protein expression has been mainly studied in the WT mouse by
immunohistochemistry (e.g. Dellovade et ah, 1998; Ericson et ah, 1997; Vitalis et ah,
2000). Although this technique is useful in describing complex expression patterns
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within a tissue, as well as local gradients of protein expression, it provides little
information as to the protein isoforms that are being expressed.
In order to visualise the differential expression of Pax6 protein isoforms, the protein
content of a tissue must be analysed by western blot, with a primary antibody that can
detect all known isoforms. This has been performed in depth on protein extracts from
the quail neuroretina (Carriere et al., 1993; Turque et ah, 1994), (see Section 3.2.1)
and the developing chick eye (Duncan et ah, 2000; Koroma et ah, 1997). Although
these studies are fundamental to our understanding of the various Pax6 isoforms, this
understanding remains largely confined to the quail neuroretina and chick eye model
systems. The role of Pax6 has been most widely studied in murine development,
therefore it is important to gain greater knowledge of the distribution of Pax6
isoforms in the developing mouse.
An antibody directed against the C-terminus of Pax6, and therefore likely to
recognise all Pax6 isoforms, has been used for western blotting on a number of adult
mouse tissues (Davis and Reed, 1996). A 46/48kDa doublet was seen in protein
extracts from whole brain, whole eye, olfactory bulb and olfactory turbinates,
indicating that both Pax6-5a and Pax6+5a were present in each of these tissues.
Interestingly, the presence of lower molecular weight Pax6 proteins varied between
tissues, in particular between brain and eye. A band of approximately 43kDa was
seen exclusively in the brain, whilst a lower band of approximately 33kDa was seen
exclusively in the eye, indicating that there may indeed be tissue-specific differences
in Pax6 isoform expression (Davis and Reed, 1996).
A second study, using a different C-terminal Pax6 antibody, showed no obvious
differences in Pax6 isoform content between adult mouse brain and adult mouse lens
(Richardson et al., 1995). The disparity between results from the eye in these two
studies is probably due to the use of whole eye extract in one (Davis and Reed, 1996),
and lens extract in the other (Richardson et al., 1995), indicating that there may also
be differences in Pax6 isoform expression between constituent tissues of the eye.
Using a set of antibodies directed against the N-terminus of Pax6, Engelkamp et al.
(1999) demonstrated the presence of 46kDa and 48kDa Pax6 isoforms in the PI
mouse cerebellum. No other isoforms were seen in this case, as these antibodies
would not pick up Pax6 proteins lacking the PD.
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Whilst the current knowledge of differential Pax6 isoform expression in the WT
mouse is limited, even fewer studies have been made of the Pax6 protein content of
Sey/Sey, Sey/+, PAX77+/" or PAX77+/+ mice. As the autoregulation of Pax6 has been
demonstrated in a number of systems, (Okladnova et ah, 1998; Plaza et ah, 1993;
Plaza et ah, 1995; see Section 1.6.3), it seems pertinent to ask whether Sey/+ mice do
indeed express Pax6 at 50% of WT levels, and whether PAX77 hemizygote and
homozygote mice express 4-fold and 7-fold more Pax6 than WT, as might be
expected from genomic Pax6 copy number. Knowledge of the Pax6 protein content
of these mice is crucial to the correct interpretation of their phenotype.
3.2.3: Potential Pax6 protein synthesis in the Sey/Sey mouse
A Pax6 protein has been seen in the Sey/Sey mouse brain by immunohistochemistry
with an antibody directed against the PD, which is thought to be an N-terminal
fragment translated as far as the mutant STOP residue, and is detectable at low levels
(Engelkamp et ah, 1999). The functional capabilities of this protein have not been
assessed, nor has its relative abundance.
There is also a possibility that an N-terminally truncated Pax6 protein could be made
via internal translation initiation in the Sey/Sey and Pox6LacZLacZ mouse. Figure 1.3
describes the mutations found in the Pax6 locus of the Sey, Pax6'acZ, and SeyNeu mice.
There are four in-frame ATG residues within the central portion of the Pax6 gene,
from which translation could theoretically initiate. Where the mutation lies 5' of one
or all of these internal ATG residues (Figure 1.3 B and D, Sey and Pax6lacZ), an N-
terminally truncated Pax6 could be made.
3.2.4: Aims
The aim of Chapter 3 was to study the levels of each Pax6 protein isoform in the
El2.5 mouse brain and eye, by western blot.
The expression level of each isoform was compared between WT mice and Sey/+,
Sey/Sey, PAX77+ ~ and PAX77' + mice. This was done firstly to ascertain whether
Pax6 protein levels were representative of Pax6 copy number, and secondly to see if
all Pax6 isoforms were regulated in the same manner across all five mouse strains.
79
Protein was taken from the brain and the eye at E12.5. The brain and the eye were
chosen as they are both known to express high levels of Pax6, and the protein is
thought to have a different role in the development of each. Protein was taken at
E12.5 as this is during the peak period of neurogenesis (Gillies and Price, 1993;
Levers et al., 2001), and also thought to be the age at which Pax6 expression is
highest (Walther and Gruss, 1991). Thus, Pax6 is likely to be active in neurogenesis
at this age.
The Pax6 protein content of El2.5 SeyNc"/SeyNc" and Pax6lacZL"cZ mouse brain was
also determined by western blot. Any Pax6 protein isoforms seen in these mice were
explained with reference to current knowledge of the mutation in each genotype, and
of the molecular structure of the Pax6 locus.
3.3: Methods
See Appendix 1 for detailed protocols and lists of reagents.
3.3.1: Mouse strains used in this study
For all matings, the day on which a plug was found was designated embryonic day
0.5 (E0.5). Mice were harvested at El2.5.
CDl mice were used as the wild type strain in this analysis. The Sey and PAX77
mutations were both maintained on the CDl background, to allow an accurate
comparison of Pax6 protein content between genotypes whilst minimising the risk of
variation between strains contributing to the observed effects.
Sey/+, Sey/Sey, PAX77+/", PAX77+/+, Se/C'"/Sefeu and Pox6LacZLacZ mice were also
used (see Section 1.2 for a full description of Pax6 mutant mouse strains). All
embryos were phenotyped by visual inspection, Sey/+ embryos were genotyped by
J.C. Quinn. Pax6laLZ embryos were provided by D.A. Kleinjan (MRC Human
Genetics Unit, Edinburgh).
For a diagrammatical representation of the Pax6 mutations in Sey, SeyNc" and
Pax6IacZ, see Figure 1.3.
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3.3.2: Extracting protein from murine embryonic tissues
All dissections were performed in ice-cold, sterile PBS. All tissues were collected
within 90 minutes, and snap-frozen in liquid nitrogen as dry samples in cryovials.
These were then stored at -70°C for up to 6 weeks before protein was harvested.
Whole brains were collected from all genotypes at El2.5. For each protein sample,
two brains of the same genotype were combined.
Eyes were collected from all genotypes at E12.5. All eyes of the same genotype from
a litter were pooled to obtain a high enough protein yield for immunoblotting.
Tissues were defrosted on ice, triturated in 50-200pl TENT buffer with protease
inhibitors, and homogenised. Cells were allowed to lyse for 20 minutes at 4°C, then
cellular debris was pelleted out by centrifugation at 13,000rpm for 15 minutes at 4°C.
The supernatant, containing cellular proteins, was then decanted and stored at -70°C.
3.3.3: Quantitating protein samples
1 pi and 2.5pl of each protein sample were quantitated alongside BSA standards.
BSA standards were made by dissolving lOpg.ml"1 to lOOOpg.mf1 BSA in PBS, and
stored at 4°C for up to 6 weeks.
Quantitations were performed in 96-well plates using the colorimetric BCA assay,
where OD at 565nm is proportional to protein concentration.
3.3.4: Protein denaturing polyacrylamide gel electrophoresis
(SDS-PAGE)
All protein samples were resolved on 12% pre-cast tris-glycine gels. These were
advantageous as they had high resolving power between bands of very similar
molecular weight, and gave highly consistent results across repeats.
50pg of brain total protein or lOpg of eye total protein was loaded per well, made up
to 20pl with 4X sample loading buffer and TENT buffer, and heated to 95°C for 5
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minutes before loading, to denature all proteins. Gels were run for 1 hour 40 minutes
at 150V, and each included 0.4pl of MagicMark (Invitrogen), a molecular weight
ladder of bacterially-expressed proteins conjugated to protein G, and therefore
detected by all secondary antibodies.
3.3.5: Protein transfer and western blotting
After resolution by SDS-PAGE, proteins were transferred onto either a PVDF (if
using anti-Pax6 C-terminus primary antibody, see below), or a nitrocellulose (if using
anti-Pax6 HD primary antibody, see below) membrane. Transfers were run at 50mA,
4°C overnight or 225mA, at room temperature for 2Vi hours. Transfer efficiency was
determined by staining the membrane in Ponceau's solution followed by two
successive de-stains in ddffO.
Membranes were blocked in TBS-tween with 10% dried milk for 1 hour at room
temperature. Primary antibodies were allowed to bind overnight at 4°C in sealed
plastic bags.
Figure 3.1 shows the anti-Pax6 primary antibodies used for western blotting. Serum
13 anti-Pax6 HD (Carriere et ah, 1993) was a kind gift from S.Saule (Institut Curie,
Paris, France), and is a polyclonal antibody raised in rabbit and directed against the
homeodomain of quail Pax6, PAX-QNR. The anti-Pax6 C-terminus antibody
(Chemicon) is also a polyclonal antibody raised in rabbit, which is directed against
the C-terminal TAD of mouse Pax6.
Following incubation in primary antibody, membranes were washed 3 times in TBS-
tween to remove unbound antibody. Secondary antibodies were centrifuged and
diluted in 10ml blocking buffer, and allowed to bind for one hour at room
temperature on a shaking platform. All secondary antibodies were conjugated to
horseradish peroxidase to allow chemiluminescent detection of bound primary
antibody.
Membranes were washed 3 times in TBS-tween, to remove unbound secondary
antibody. Bound antibody was then detected using the ECL+ chemiluminescent
detection kit. Membranes were bathed for 5 minutes in ECL+ substrate, which was
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Figure 3.1: Anti-Pax6 primary antibodies. The Pax6 cDNA is shown
to scale. Red and Blue bars: Pax6 exons. Orange bar: Paired
domain. Green bar: homeodomain. Black and white bars: internal
ATG residues from which protein translation could initiate. Black
lines: Pax6 polypeptide fragments against which the primary
antibody was raised. N.B. Antibodies have not been epitope
mapped.
broken down by horseradish peroxidase, causing the emission of light. Signal was
then detected by exposure to photographic film for 1-45 minutes.
Where relative quantitation of Pax6 protein levels was required, membranes were
washed 3 times in TBS-tween after chemiluminescent detection and re-probed for P-
actin as described above. Densitometric analysis of gel films was performed as
described in Section 2.3.4.
3.3.6: Cloning of Pax6+5a and Pax6-5a
Total RNA was obtained from the U373-MG human glioblastoma cell line using an
RNeasy mini kit (Qiagen). cDNA synthesis was performed on total RNA using oligo
d(T) primers, to amplify all poly(A)+ mRNA species.
PCR was then performed using the "Human Pax6 Full 5' Xbal" and "Human Pax6
Full 3' Xbal" primers (see Appendix 2 for primer sequences and optimal annealing
temperatures) to amplify full-length Pax6 with Xbal recognition sites both 5' and 3'
of the gene. This PCR was performed using Expand DNA polymerase, combining
high-fidelity amplification by the proofreading Pfu DNA polymerase with the speed
of Taq DNA polymerase. PCR products of approximately 1.3kb, corresponding to
full-length Pax6+5a and Pax6-5a combined, were purified by agarose gel extraction.
Expand DNA polymerase {Roche) yields PCR products that have a mixture of blunt
ends from Pfu DNA polymerase amplification, and A-overhanging ends from Taq
DNA polymerase amplification. Cloning can be aimed at either of these DNA
sequence types. In this case, blunt-ended fragments were cloned using the Zero Blunt
TOPO cloning system (Invitrogen). The reaction product was transformed into
chemically-competent TOP-IO E.coli and grown on LB agar plates with kanamycin
selection (50pg.mf'), allowing only transformed bacteria to grow.
After 24 hours at 37°C, 14 bacterial clones were isolated. These were frozen as
glycerol stocks at -70°C, and colony PCR was performed to confirm the presence of
Pax6 sequence, and ascertain whether Pax6+5a or Pax6-5a was present.
Of the 14 clones isolated, 5 appeared to correspond to Pax6+5a, 7 to Pax6-5a








Figure 3.2: Colony PCR on plasmids pJP1.1 - pJP1.14 using the
"Pax6 Exon 5F", and "Pax6 Exon 7R" primers. A 427bp PCR product
indicates Pax6+5a. A 385bp PCR product indicates Pax6-5a. The
~170bp fragment from pJP1.10 could correspond to Pax6-5aA6, with a
predicted size of 169bp.
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of the PCR reaction. One gave a band of approximately 170bp, which appeared to
correspond to the Pax6-5aA6 splice variant, giving a predicted size of 169bp.
Clones pJP1.3 (Pax6+5a) and pJPl.ll (Pax6-5a) were sequenced across the Pcix6
insert in both orientations. Both had sequence corresponding exactly to EMBL entry
BX640762, except for a single synonymous substitution. pJP1.3 contained an A—* C
substitution at cDNA residue 1251, predicted to change a GTT (valine) codon to GTC
(valine). pJPl.l 1 contained aA-^C substitution at cDNA residue 1257, predicted to
change a CCA (proline) codon to CCC (proline). Neither of these synonymous
substitutions affect the protein sequence. Clones pJP1.3 and pJPl.ll were used as
Pax6+5a and Pax6-5a clones for all further work.
See Figure 3.3 for a plasmid map of pJP1.3 and pJPl.l 1
3.3.7: Inserting Pax6+5a and Pax6-5a into pSP64 for in vitro
protein synthesis
Full length Pax6-5ci and Pax6+5a were cloned into pSP64 (Promega) for in vitro
protein synthesis. Pax6 clones pJP1.3 and pJPl.ll were used, as they had been
sequence-verified. The pSP64 vector was chosen as it has an SP6 transcription site
immediately 5' of the multiple cloning site, with no intervening ATG start codons,
from which ectopic protein translation could initiate. There is also a Poly(A) stretch
immediately 3' of the multiple cloning site, to encourage efficient mRNA processing
by the rabbit reticulate lysate in the TNT system.
Full length Pax6 was removed from pJP1.3 and pJPl.l 1 by digestion with Xba\, and
inserted into linearised pSP64 using T4 DNA ligase. Figation products were used to
transform chemically-competent TOP-10 E.coli, and colonies were grown overnight
at 37°C with ampicillin (lOOpg.mf ) to allow only the growth of transformed
bacteria.
Clones pJP8.6 (Pax6-5a) and pJP9.3 (Pax6+5a) were found to have Pax6 inserted in
the correct orientation for in vitro protein synthesis. The full length Pax6 insert in
both pJP8.6 and pJP9.3 was then sequenced in both directions to confirm that the
intended Pax6 sequence was present, and that no mutations had been introduced
during the cloning process. As expected, the same synonymous substitutions were
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Figure 3.3: pJP1.3 / pJP1.11, full-length Pax6+5a / Pax6-5a in pCR-
Bluntll-TOPO. Red arrows: Human Pax6 sequence, and the
Kanamycin resistance gene.
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found as in the donor plasmids pJP1.3 and pJPl.l 1. The plasmids pJP8.6 and pJP9.3
were used for all further in vitro protein synthesis applications.
See Figure 3.4 for plasmid maps of pJP8.6 and pJP9.3
3.3.8: in vitro protein synthesis
Pax6+5a and Pax6-5a were synthesised in vitro from the plasmid templates pJP9.3
and pJP8.6, to act as positive controls for western blotting analysis. Proteins were
synthesised using the TNT Quick Coupled Transcription / Translation System
(Promega). The TNT system then allowed simultaneous transcription from the SP6
site and translation of Pax6.
3.4: Results: Pax6 protein isoforms in the brain of various Pax6
mutant mice at E12.5
3.4.1: Western blot analysis of Pax6 protein isoforms in the E12.5
mouse brain
Up to six El2.5 whole brain samples (each containing 2 brains) were obtained from
Sey/Sey, Sey/+, WT, PAX77+/" and PAX77+/l mice. Samples were analysed a number
of times by western blot to detect the presence of Pax6, and allow its quantitation.
Each sample was analysed by western blot between 2 and 6 times, and data from all
repeats of all samples was pooled and analysed together.
Two whole brains were obtained from E12.5 SeyNc" SeyNe" and Pctx6,'ac2!'"cZ mice, and
each was analysed by western blot twice, alongside Sey/Sey, Sey/+ and WT brain
samples.
Figure 3.5 shows the result of a typical western blot on El2.5 whole brain protein
extract using both anti-Pax6 HD (Fig 3.5 A) and anti-Pax6 C-terminus (Fig 3.5 B)
primary antibodies. All indicated bands were up-regulated in PAX77 mice compared
to WT, therefore it is very likely that they are Pax6-specific rather than a result of
non-specific antibody binding. The results from western blots using both antibodies
were combined, as each appeared to recognise the same set of Pax6 isoforms.
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Figure 3.4: pJP8.6 / pJP9.3, full-length Pax6-5a / Pax6+5a in
pSP64. Red arrows: Human Pax6 sequence for in vitro protein
synthesis, and the Ampicillin resistance gene. Blue bars: SP6
promoter and Poly(A) sequences that allow efficient transcription
and post-transcriptional modification of the insert.
89




Figure 3.5: Typical results from western blot of E12.5 whole brain
protein extract across a number of genotypes. A) Using serum 13 anti-
HD primary antibody. B) Membrane seen in A, re-probed for p-actin. C)
Using anti-Pax6 C-terminal primary antibody. Arrows indicate the
bands observed, and their estimated mass in Kilodaltons (KDa).
Bands with asterisks (*) were either not resolved on all gels, or not
observed on all gels due to low sensitivity of the western. +ve, in vitro-
synthesised positive controls. L, molecular weight ladder.
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The highest molecular weight bands, a 46/48kDa doublet, correspond to Pax6-5a and
Pax6+5a, respectively (Fig 3.6 B, C) (Carriere et ah, 1993; Walther and Grass, 1991).
The observed differences in molecular weight between this doublet and that of the in
vz'/ro-synthesised positive control doublet, which is slightly retarded on all gels, is
probably due to the absence of post-translational modification in the TNT rabbit
reticulate lysate system. Pax6 is known to be phosphorylated in the zebrafish, at
residues within the C-terminal transactivation domain which are highly conserved
between species as diverse as sea urchin and man (Mikkola et ah, 1999).
Phosphorylation of the quail Pax6 homologue, Pax-QNR, has also been demonstrated
(Carriere et ah, 1993). In addition to this, there is evidence for O-glycosylation in
Pax-QNR in the quail neuroretina (Lefebvre et ah, 2002), possibly at sites within the
paired domain. Any of these post-translational modifications could account for
differences in size between endogenous and in vz'Ro-synthesised Pax6 proteins.
A second doublet is seen at approximately 42/43kDa. In some cases this appears as a
single band, but this is probably due to a lack of resolution on the gel rather than
absence of one of the bands. A 43kDa Pax6 band was first described by Carriere et ah
(1993), using the serum 13 anti-Pax6 HD antibody. It was also seen with antibodies
against the Gln/Gly-rich linker sequence between the PD and the HD (serum 12), and
against the C-terminus of the protein (serum 14). This band was not observed,
however, with an antibody directed against the PD. Using an antibody directed
against the C-terminus of Pax6, Davis and Reed (1996) described a 43kDa band in
adult mouse eye. As antibodies directed against the Pax6 HD and C-terminus can
detect the 42/43kDa Pax6 doublet, but those directed against the PD cannot, it is
thought to correspond to forms of Pax6 lacking the paired domain.
The most obvious mechanism leading to a "paired-less" form of Pax6 is alternative
splicing of exon 6. As described in Chapter 2, the removal of the majority of exon 6
has been documented in both quail and cow (Carriere et ah, 1993; Jaworski et ah,
1997). RT-PCR for Pax6 on mRNA extracted from the human glioblastoma cell line
U373-MG has identified mRNA species lacking the entire of exon 6 in both Pax6-5a
and Pax6+5a forms (T.I. Simpson, pers. comm.). Both mechanisms of excluding this
exon would give a predicted protein of approximately 43kDa (Fig 3.6 D, E). The
existence of a doublet could be explained by the presence or absence of exon 5a, or
could be due to post-translational modification.
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Figure 3.6 Possible explanations for the numerous Pax6 bands
seen by western blot. Red and blue bars represent Pax6
exons. Orange bar: paired domain, Green bar: homeodomain,
Black bars: internal ATG codons 2, 3, 4 and 5 (SeySTOP
ATG). Canonical translation from ATG1 begins at the 3' end of
exon 4. A, Full-length Pax6 cDNA. Magenta arrow, location of
Sey STOP codon. B-K, translated exons found in each isoform.
Predicted molecular weight was calculated using the Protein
Molecular Weight algorithm at the Sequence Manipulation Suite
(www.ualberta.ca/~stothard/javascript/)
The third set of bands picked up by both anti-Pax6 antibodies appears to be a triplet,
migrating at approximately 32-33kDa, with a fourth, weaker band at 30kDa. Like the
43kDa bands, these were first described by Carriere et al. (1993), where they were
detected by sera 12 (anti-linker region), 13 (anti-HD) and 14 (anti-C-terminus). In
this case, a doublet was described, but again this could be due to lack of resolution
rather than absence of bands. These bands are thought to be the result of internal
translation initiation. To confirm this, Carriere et al. (1993) created a 5'-truncated
Pax6 cDNA missing the first ATG start codon, and used it as a template for in vitro
protein synthesis. The product migrated as a 32/33kDa doublet. There are four in-
frame ATGs within the Pax6 gene from which translation initiation could occur, all of
which lie in the Gln/Gly-rich linker sequence between the PD and the HD (Fig 3.6 H-
K). Two studies have described Pax6 mRNA species lacking the 5' portion of the
gene, in which translation could only initiate from an internal ATG residue (Kleinjan
et al., 2004; Mishra et al., 2002).
There are also nine more in-frame ATGs at the 3' end of the cDNA, but these would
all lead to a protein less than 15kDa in molecular weight, the presence of which has
not been demonstrated by western blotting using any of the available anti-Pax6
primary antibodies.
It is worth noting that where predicted protein molecular weights do not agree exactly
with observed molecular weight after gel electrophoresis, this could be due to
inaccuracies in the protein molecular weight algorithm, or most likely due to post-
translationai modification of the protein.
Other Pax6 splice variants have been isolated by RT-PCR on total RNA from mouse
brain and eye (Gorlov and Saunders, 2002), but their abundance has not been
assessed in vivo, and it is still unclear whether these are due to low-frequency splicing
errors, or whether they represent functional, regulated splice variants. For this reason,
these newly-isolated splice variants were not considered to be likely explanations for
Pax6 bands seen by western blotting.
3.4.2: Quantitation of bands observed by western blot
Although the relative levels of each Pax6 isoform within a sample are similar using
either serum 13 or anti-Pax6 C-terminus primary antibodies (i.e. in all cases the upper
33kDa band of the triplet gives the strongest signal, compare Figure 3.5 A with Fig
3.5 B), this cannot be taken as an indicator of the relative abundance of each isoform
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within a sample. Differential antibody-binding kinetics might lead to one protein
isoform binding more efficiently to the antibody than a different isoform. For this
reason, it may be inappropriate to compare relative abundances of the various Pax6
forms within a sample. However, it is worth noting that the shorter forms of Pax6 (i.e
<46kDa) do appear to make a significant contribution to the Pax6 content of the
brain, albeit on a qualitative level.
The only likely exception to this rule is the comparison between Pax6+5a and Pax6-
5a. These two isoforms are known to be responsible for the 46/48kDa Pax6 doublet
seen by western blot (Carriere et al., 1993; Walther and Gruss, 1991). Both antibodies
used in this analysis were raised against peptide fragments within the C-terminal
portion of the protein (see Figure 3.1), whilst the insertion of exon 5a should only
affect protein structure at the N-terminus of the protein, in the paired domain. For this
reason, it is likely that the two full-length isoforms have the same antibody-binding
kinetics, and their relative abundance can be compared within a sample. As the exact
protein sequence responsible for the other Pax6 bands has not been determined, and
the explanation for each is an estimation based on known mRNA splice variants and
sequence analysis, the same assumption cannot be made for other bands observed by
western blot.
The amount of each isoform detected by western blot was quantitated, and compared
between samples. Each different molecular weight band was considered as a separate
entity, and compared across all genotypes. The relative intensity of each band was
determined, and divided by the intensity of the P-actin band (Figure 3.5 C) obtained
for that sample, to account for inaccurate protein quantitation and problems with gel
loading.
The intensity of the WT bands (usually two WT samples were included per gel) was
then averaged, and assigned an arbitrary value of 1. The intensity of the
corresponding band in each sample was divided by that of the WT samples, to give
the relative concentration of a Pax6 isoform within each protein sample, as compared
to WT. For example, the amount of Pax6+5a in the PAX77/+ mouse could be
compared to the amount of Pax6+5a in the WT (given a value of 1), or the amount of
Pax6+5a in the Sey/+ mouse, but could not be compared to the amount of 33kDa
Pax6 in the same PAX77+/+ sample.
Analysis of Variance (ANOVA) was performed on the values for each protein
isoform, using the InStat software package, to determine whether there was
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statistically significant variance within the data set. If the ANOVA yielded a P-value
<0.05, this was deemed significant, and /-tests were carried out. Protein levels were
compared between all genotypes and WT, between Sey/Sey and Sey/+ and between
PAX77+/"and PAX77+/+. /-tests were carried out in Microsoft Excel.
3.4.3: Pax6 protein levels in the brain of E12.5 Sey/Sey, Sey/+, WT,
PAX77+/ and PAX77"'" mice
The most immediately striking observation is that PAX77+/+ and PAX77+" brains
contain higher levels of all Pax6 isoforms than WT and Sey/+, and that most isoforms
are absent from the Sey/Sey brain (Figure 3.5, Figure 3.7).
For more detailed analysis of the relative expression of Pax6 across genotypes, each
band will be considered in turn.
3.4.3.1: 48kDa band, Pax6+5a
A 48kDa band corresponding to full-length Pax6+5a was observed in all PAX77+/+,
PAX774/~, WT and Sey/+ brain extracts, but not Sey/Sey extracts (Figure 3.8 A).
Relative levels of Pax6+5a were averaged from 16 repeats, and error was calculated
as Standard Error of the Mean (SEM).
There are error bars on WT values, even though all other samples have been
normalised to WT=1. This is because each individual western blot contained two WT
samples, and the value for each was normalised to the average value of the two
samples.
Significant differences in the level of Pax6+5a are seen between Sey/Sey and Sey/+
brains (P<0.001), and between Sey/Sey and WT brains (P<0.001). This is to be
expected, as there is no Pax6+5a present in the Sey/Sey mouse. Surprisingly, there is
also more Pax6+5a in the Sey/+ brain than in the WT (P<0.05).
Both PAX77+/~and PAX77+/+ brains contain more Pax6+5a than WT, by three-to four¬
































































































































Sey/Sey Sey/+ WT PAX77+/" PAX77+/+
1.93 1.00 3.24 3.87
ANOVA P<0.0001, considered extremely significant
B
f-test P-value
Sey/Sey vs. Sey/+ <0.001
Sey/Sey vs. WT <0.001
Sey/+ vs. WT <0.05
WT vs. PAX77+/" <0.001
WT vs. PAX77+/+ <0.001
PAX77+/* vs. PAX77+/+ >0.05
Figure 3.8: Full-length Pax6+5a in E12.5 mouse brain. A, Mean
values. All values are normalised to WT=1. The number of samples
analysed is shown above each bar. Error bars represent SEM.
Values are given in numerical form below each bar. B, Results of
paired f-test between genotypes. Significant results are highlighted.
*=P<0.05; **=P<0.01; ***=P<0.001 "
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In general, results for Pax6+5a in E12.5 brain show it is absent in Sey/Sey mice. Sey/+
mice express it at higher levels than WT. Both PAX77+/~ and PAX77+/ mice express
significantly more than WT, but there is no clear difference in the levels of Pax6+5a
between PAX77+/"and PAX77+/+brain.
3.4.3.2: 46kDa band, Pax6-5a
A 46kDa band corresponding to full-length Pax6-5a was observed in all PAX77++,
PAX77+/\ WT and Sey/+ brain extracts, but not Sey/Sey extracts.
Results for Pax6-5a are similar to those observed for Pax6+5a (compare Figures 3.8
3.9). In both cases, Significant differences are seen between Sey/Sey and Seyl+
(P<0.001), and Sey/Sey and WT samples (P<0.001), as would be expected, given that
Sey/Sey mice cannot produce this protein. Unlike Pax6+5a, there is no significant
difference in Pax6-5a levels between Sey/+ and WT brains.
PAX77*" and PAX77r" mice both express more Pax6-5a in the brain than WT
(P<0.05), and again there is no difference between PAX77 hemizygotes and
homozygotes.
Differences between the level of Pax6+5a and Pax6-5a in the PAX77 mice compared
to WT can be interpreted as a difference in the ratio between the two isoforms, which
will be discussed in more detail in section 3.4.5.
3.4.3.3: 43kDa band, Pax6+5aA6
A 43kDa Pax6 band, thought to correspond to Pax6+5aA6, was observed in E12.5
brain extract from all genotypes, including Sey/Sey (Figure 3.10).
Results for the 43kDa band are very different to those seen for full-length Pax6.
Sey/Sey, Sey/+ and WT all express similar levels of this isoform. PAX77+'~ and
PAX77+/+, on the other hand, express 144- and 56-fold more than WT. Due to this
high level of over-expression, there were likely to be inaccuracies in the data
collected from both PAX77 genotypes for this isoform. Where a WT band was visible
on a film, the PAX77 band was often saturated. An accurate densitometric value for





















ANOVA P<0.0001, considered extremely significant
B
f-test P-value
Sey/Sey vs. Sey/+ <0.001
Sey/Sey vs. WT <0.001
Sey/+ vs. WT >0.05
WT vs. PAX77+/" <0.05
WT vs. PAX77+/+ <0.05
PAX77+/" vs. PAX77+/+ >0.05
Figure 3.9: Full-length Pax6-5a in E12.5 mouse brain. A, Mean
values. All values are normalised to WT=1. The number of samples
analysed is shown above each bar. Error bars represent SEM. Values
are given in numerical form below each bar. B, Results of paired t-test
between genotypes. Significant results are highlighted. *=P<0.05;
**=P<0.01; ***=p<0.001






























































ANOVA P=0.0028, considered very significant
B
f-test P-value
Sey/Sey vs. Sey/+ >0.05
Sey/Sey vs. WT >0.05
Sey/+ vs. WT >0.05
WT vs. PAX77+/" <0.05
WT vs. PAX77+/+ <0.05







Figure 3.10: 43KDa Pax6 in E12.5 mouse brain. A, Mean values. All
values are normalised to WT=1. The number of samples analysed is
shown above each bar. Error bars represent SEM. Values are given in
numerical form below each bar. B, Results of paired t-test and Mann-
Whitney U-test where appropriate between genotypes. Significant results
are highlighted. *=P<0.05; **=P<0.01; ***=P<0.001
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longer visible, therefore the value could no longer be normalised to WT, and accurate
comparisons could no longer be drawn. Due to this saturation of bands, the PAX77
data for 43kDa Pax6 is unlikely to be normally distributed, therefore the /-test is no
longer valid. Instead, Mann-Whitney U-tests were performed using the SPSS
software package, to compare PAX77+/" and PAX77+/+ with WT and with each other.
The Mann-Whitney U-test shows that both PAX77+/" and PAX77+/+ brains have
higher levels of 43kDa than WT (P<0.01, P<0.001), but there is no difference
between the two genotypes.
As the Sey mutation would render Sey/Sey mice incapable of producing Pax6+5aA6
protein, an alternate explanation for the presence of this band in the brains of Sey/Sey
mice must be sought. It seems likely that the 43kDa band seen in the other samples is
a form of Pax6, as it is highly up-regulated in the Pax6-overexpressing PAX77 mice.
One explanation is that a non-specific band is being recognised by both antibodies,
which co-migrates with the 43kDa Pax6 band. This seems unlikely, however, as the
two primary antibodies were raised against different peptides.
RPA data from Chapter 2 (Figure 2.12) show that the alternative splicing of exon 6 is
undetectable in a number or Pax6 expressing tissues at El2.5. If this isoform is
indeed less common than had been previously suggested, a different explanation for
the 43kDa Pax6 protein band seems likely.
Pax6 resulting from internal translation initiation 3' of the Sey STOP codon would
yield a protein with a predicted molecular weight of 24kDa, and even after extensive
post-translational modifications, an 18kDa discrepancy between predicted and
observed molecular weight seems unlikely. 3'-truncated Pax6 resulting from
translation initiation at the canonical ATG in exon 4 and running until the STOP
codon in exon 8 would give a protein with a predicted molecular weight of 22kDa.
Again, the discrepancy between predicted and observed molecular weight rules this
out as an explanation.
It is possible that exon 8 could be spliced out of the Pax6 transcript, thus bypassing
the Sey mutation entirely. This would leave the protein in-frame, and would give a
predicted molecular mass of 41/42kDa (-/+5a). This is one possible explanation for
the presence of a 43kDa band in Sey/Sey brain, although this splicing event has not
been documented in vivo.
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3.4.3.4: 42kDa band, Pax6-5aA6
A 42kDa Pax6 band, thought to correspond to Pax6-5aA6 (Carriere et al., 1993), was
observed in E12.5 brain extract from all genotypes, except Sey/Sey (Figure 3.11).
As the 43kDa band runs very close to the 42kDa band on a polyacrylamide gel, it was
often difficult to resolve the two. Where a single band was seen, this was classed as a
43kDa band, as the higher band was much more abundant in all samples, and tended
to obscure the 42kDa band. For this reason, only one value was recorded in PAX77+/+
brain. Although this shows that the 42kDa isoform is indeed present, ANOVAs and /-
tests cannot be performed on data including PAX77++, as a sample number >1 is
needed for these statistical tests. All analyses were therefore performed on Sey/Sey,
Sey/+, WT and PAX77+/~ samples alone
The ANOVA, excluding PAX77+/+, gives a P value <0.001, considered extremely
significant, so there is variation within the data set and /-tests are valid.
As the Sey/Sey brain does not contain 42kDa Pax6, /-tests are significant between
Sey/Sey and Sey/+, and between Sey/Sey and WT (both, P<0.001). Although the
values do not appear very different in Figure 3.11, and the number of repeats is lower
than seen for other bands, the comparison between Sey/+ and WT is statistically
significant (P<0.001). 42kDa Pax6 is only expressed at 61% of WT level in Seyl+
brain at El2.5. Levels of 42kDa Pax6 in PAX77+/" and PAX77+/+ mice seem
comparable to those observed in WT.
3.4.3.5: 33kDa band, 5'-Truncated Pax6
A 33kDa Pax6 band, thought to correspond to 5'-truncated Pax6 after internal
translation initiation, was observed in E12.5 brain extract from all genotypes, except
Sey/Sey (Figure 3.12).
The Sey/Sey brain contains no 33kDa Pax6. There are reduced levels of 33kDa Pax6
in the Sey/+ brain when compared to WT (P<0.05).
Both PAX77 genotypes contain more 33kDa Pax6 than WT (P<0.01, P<0.001), but



















Sey/Sey Sey/+ WT PAX77+/" PAX77*/+
0.61 1.00 0.80 0.81




Sey/Sey vs. Sey/+ <0.001
Sey/Sey vs. WT <0.001
Sey/+ vs. WT <0.001
WT vs. PAX77+/- >0.05
WT vs. PAX77+/+ n/a
PAX77+/" vs. PAX77+/+ n/a
Figure 3.11: 42KDa Pax6 in E12.5 mouse brain. A, Mean values. All
values are normalised to WT=1. The number of samples analysed is
shown above each bar. Error bars represent SEM. Values are given in
numerical form below each bar. B, Results of paired Mest between
genotypes. Significant results are highlighted. ANOVA and t-tests


















































ANOVA P<0.0001, considered extremely significant
B
f-test P-value
Sey/Sey vs. Sey/+ <0.001
Sey/Sey vs. WT <0.001
Sey/+ vs. WT <0.05
WT vs. PAX77+/" <0.01
WT vs. PAX77+/+ <0.001
PAX77+/" vs. PAX77+/+ >0.05
Figure 3.12: 33KDa Pax6 in E12.5 mouse brain. A, Mean values. All
values are normalised to WT=1. The number of samples analysed is
shown above each bar. Error bars represent SEM. Values are given in
numerical form below each bar. B, Results of paired f-test between
genotypes. Significant results are highlighted. *=P<0.05; **=P<0.01;
***=P<0.001
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In general, this result differs from those seen for Pax6+5a, Pax6-5a and 43kDa Pax6,
in that levels appear lower in both Sey/Sey and Sey/+ than in WT. As observed with
all other isoforms, levels are similar between PAX77+/" and PAX77+/+. Levels of
33kDa Pax6 are raised in both PAX77 genotypes when compared to WT, as observed
with most isoforms.
3.4.3.6: 32.5kDa band, 5'-Truncated Pax6
A 32.5kDa Pax6 band, thought to correspond to 5'-truncated Pax6 after internal
translation initiation, was observed in El2.5 brain extract from all genotypes, except
Sey/Sey (Figure 3.13).
There is no 32.5kDa Pax6 in the Sey/Sey brain. There is no difference in levels od
32.5KDa Pax6 between Sey/+ and WT brains.
Although t-tests are significant between both PAX77 genotypes and WT, the high
level of 33kDa Pax6 in these samples suggests that, as is the case for the 43kDa Pax6
isoform, these bands are in fact saturated. For this reason, the data are unlikely to be
normally distributed, therefore the Mann-Whitney U-test was used to compare
PAX77+/" and PAX77+/+ data with WT and with each other. Only PAX77+/I brains
contain more 33kDa Pax6 than WT (P<0.05), and no differences are seen between
PAX77 hemizygotes and homozygotes.
In general, this result conforms to those seen for Pax6-5a and 43kDa Pax6, in that
levels appear lower in both Sey/Sey and Sey/+ than in WT, but there are no
differences between Sey/+ and WT. As observed with all other isoforms, levels are
similar between PAX77+/" and PAX77+/+, and levels are raised in PAX77+/+ when
compared to WT. In this case, however, there was no up-regulation in the PAX77+"
brain.
3.4.3.7: 32kDa band, 5'-Truncated Pax6
A 32kDa Pax6 band, thought to correspond to 5'-truncated Pax6 after internal
translation initiation, was observed in E12.5 brain extract from all genotypes,












































0.48 1.00 48.3 18.6
ANOVA P=0.0019, considered very significant
B
f-test P-value
Sey/Sey vs. Sey/+ <0.05
Sey/Sey vs. WT <0.01
Sey/+ vs. WT >0.05
WT vs. PAX77+/- <0.01
WT vs. PAX77+/+ <0.001







Figure 3.13: 32.5KDa Pax6. in E12.5 mouse brain. A, Mean values. All
values are normalised to WT=1. The number of samples analysed is
shown above each bar. Error bars represent SEM. Values are given in
numerical form below each bar. B, Results of paired f-test and Mann-
Whitney U-test where appropriate between genotypes. Significant



















ANOVA P=0.0033, considered very significant
B
f-test P-value
Sey/Sey vs. Sey/+ >0.05
Sey/Seyvs. WT >0.05
Sey/+ vs. WT >0.05
WT vs. PAX77+/" <0.01
WT vs. PAX77+/+ <0.05







Figure 3.14: 32KDa Pax6 in E12.5 mouse brain. A, Mean values. All
values are normalised to WT=1. The number of samples analysed is
shown above each bar. Error bars represent SEM. Values are given in
numerical form below each bar. B, Results of paired f-test and Mann-
Whitney U-test where appropriate between genotypes. Significant
results are highlighted. *=P<0.05; **=P<0.01; ***=P<0.001
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Sey/Sey, Sey/+ and WT brains all express similar levels of 32kDa Pax6. As with the
33kDa and the 32.5kDa bands, levels appear to rise dramatically in both PAX77+/"and
PAX77+ + samples. Again, Man-Whitney U-tests were used to analyse these data, due
to the problems with densitometric analysis described in Section 3.4.3.3. Both
PAX77+/" and PAX77+/+ brains contain more 32kDa Pax6 than WT (P<0.01, P<0.05),
but there is no difference between the two genotypes.
In general, this result conforms to that seen for the 43kDa band. Both isoforms are
present in the Sey/Sey brain, and are found at similar levels in Sey/Sey, Sey/+ and
WT. Both PAX77 homozygotes and hemizygotes express more 32kDa Pax6 than
WT, but there is no difference between the two.
3.4.3.8: 30kDa Pax6, unexplained
A 30kDa band was observed in some western blots. It is likely to be a Pax6-specific
band, as it was observed most frequently in just PAX77+~ and PAX77+/+ samples
(n=2), and once in WT, PAX77+/" and PAX77+/+ samples (Figure 3.15). This is
indicative of an up-regulation in PAX77 mice. Unfortunately, a comparison between
PAX77 and WT levels is only possible using one data set, so statistical analyses could
not be performed in the same manner as for the other Pax6 isoforms.
Figure 3.15 A appears to show a higher level in PAX77+/+than in PAX77+/", but that
is contradicted by Figure 3.15 C. Fig 3.15 B, which includes WT, seems to show that
levels do not vary greatly between the three genotypes, although this would not
explain why the band was observed more often in the PAX77 brain samples.
The difficulties in detecting this band were largely due to its low abundance, being at
the limits of detection by western blot. This could also be why a trend was not seen
between the three genotypes, as weaker bands can be harder to quantitate
densitometrically.
The presence of a 30kDa Pax6 band is difficult to explain given the current
knowledge of Pax6 isoforms. The only known variants that would give Pax6 bands of
approximately this size are those resulting from internal translation initiation.
However, the smallest of these four possible proteins would be initiated from the















30KDa Pax6 in E12.5 brain (1)
PAX77+/" PAX77+/" PAX77+/+ PAX77+/+
30KDa Pax6 in E12.5 brain (2)
WT WT PAX77+/" PAX77+/" PAX77+/+ PAX77+/+
30KDa Pax6 in E12.5 brain (3)
PAX77+/" PAX77+/" PAX77+/+ PAX77+/+
Figure 3.15: 30KDa Pax6 in E12.5 mouse brain. A, B, C, three separate
western blots on which a 30KDa band was visible. All values are
normalised to p-actin expression. Values are not directly comparable, as
westerns 1 and 3 could not be normalised to WT.
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band seen in all genotypes. A smaller, 30kDa band is not easily explained in this
manner.
3.4.3.9: Overall patterns of Pax6 protein expression in E12.5
Sey/Sey, Sey/+. WT, PAX77+/' and PAX77+/+ brain
The results described above follow a number of clear trends. Most obviously, the
majority of Pax6 isoforms are not expressed in the Sey/Sey brain. Those which are
expressed will be discussed in more detail in Section 3.7.
Protein levels of most Pax6 isoforms in the Sey/+ brain are largely similar to those in
the WT brain, although there are some notable exceptions. Intriguingly, Pax6+5a is
up-regulated in the Sey/+ brain. In contrast, the 42kDa and 33kDa bands are down-
regulated.
The observation that all other Pax6 isoforms are expressed at the same levels in Sey/+
and WT brains correlates well with the lack of an obvious phenotype in the Sey/+
brain. Although some heterozygous effects have been described, they are far less
pronounced than those seen in the homozygote brain. It is possible that the Sey/+
brain has a regulatory mechanism in place by which it compensates for the lower
Pax6 copy number by increasing the amount of protein produced by the remaining,
intact locus. In the Sey/Sey mouse, I'ax6 mRNA is easily detected by in situ
hybridisation (Warren and Price, 1997), and Pax6 <-> Pax6" chimeras show higher
levels of Pax6 expression in Pax6" cells than their WT counterparts (Collinson et al.,
2003). Although this is not an accurate method of quantitating mRNA levels, this
observation is consistent with an attempt to compensate for the absence of Pax6
protein by up-regulating Pax6 mRNA transcription from the single remaining intact
Pax6 locus. Pax6 autoregulation is also suggested by the rise in levels of Pax6+5a in
the Sey/+ brain described here, and this is an indication that autoregulatory effects
may be isoform-specific.
The existence of a brain phenotype, albeit a mild one, in the Sey/+ brain can be
reconciled with the data described above in two ways. Firstly, there may be regional
variations in the regulation of Pax6. The protein samples used in this analysis were
whole brain extracts, and any subtle variation in levels between brain regions would
have been masked. It is therefore possible that the levels of all Pax6 isoforms differ
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between Sey/+ and WT in a tissue-specific manner not detected using the methods
described here. Alternatively, the heterozygote brain phenotype may be entirely due
to the differences in levels of Pax6+5a, 42kDa Pax6, and 33kDa Pax6, which do
differ between Sey/+ and WT.
Levels of all Pax6 isoforms are raised in the PAX77+/+ mouse brain, and all but two
are also up-regulated in the PAX77+/" brain. This is to be expected, as these mice
carry 6 and 12 extra copies of the Pax6 locus. What is unexpected is the similarity in
Pax6 levels between the two genotypes. No statistically significant differences were
observed between PAX77+/~ and PAX77+/+ brain extracts. This could again be due to
autoregulation of Pax6 levels in the developing mouse brain, an argument which is
supported by the fact that a number of isoforms are not expressed at 6- or 12-fold WT
levels, as would be expected from the Pax6 copy number. Just as the Sey/+ brain
appears to up-regulate the expression of most isoforms to near WT levels, similar
mechanisms may down-regulate the expression of some Pax6 isoforms in the PAX77
brain. This is an indication that Pax6 dosage is important in the developing brain, and
mechanisms exist to keep protein levels close to those found in the WT.
The degree of Pax6 up-regulation in PAX77 brains seems to vary between isoforms,
with the most striking increases in protein level occurring for the shorter isoforms,
rather than the better understood Pax6-5a and Pax6+5a isoforms. It is clear that the
levels of Pax6 protein are being regulated in these mice, but the mechanism behind
this regulation is not known.
Despite a clear upregulation of most Pax6 isoforms in PAX77 brain samples, the
PAX77 brain does not exhibit an obvious phenotype (Schedl et al., 1996; M.Manuel,
pers. comm.). The reason for this is unclear, but it is possible that the relative levels
of expression of the different isoforms are an important factor. In particular, it may be
the case that the ratio of Pax6-5a to Pax6+5a is as important as the absolute levels of
these isoforms in controlling the activity of Pax6 (Chauhan et ah, 2004a). This will be
discussed in greater detail in Section 3.6.
3.5: Results: Pax6 protein isoforms in the eve of various Pax6
mutant mice at E12.5
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3.5.1: Pax6 protein levels in the eye of E12.5 Sey/Sey, Sey/+, WT,
PAX77+/"and PAX77+/+mice
Up to four El2.5 eye samples (each containing up to 12 eyes) were obtained from
Sey/Sey, Sey/+, WT, PAX77+/" and PAX77+/+ mice. Each sample was analysed by
western blot 3 times, and data from all repeats of all samples was pooled and
analysed together.
Figure 3.16 shows the typical Pax6 content of El2.5 mouse eye across the five
genotypes. Protein loading was less even than for brain extracts (Figure 3.5), as eye
protein extracts were lower in concentration, therefore more prone to error in
quantitation. Pax6 is more abundant in the eye, so a lower amount of total protein was
used than for brain extracts (10pg as opposed to 50pg).
Both anti-Pax6 HD primary antibody (Fig 3.16A) and anti-Pax6 C-tenninus primary
antibody (Fig 3.16B) revealed an identical set of bands. This indicates that they are
all Pax6-specific.
Both antibodies detect more 43/42kDa Pax6 and 33/32kDa Pax6 than full-length
48/46kDa Pax6. It is invalid to compare the intensity of bands within a lane, as the
binding kinetics of the antibody may differ for different isoforms, and this result does
not necessarily mean that the two full-length Pax6 forms are not the most abundant in
the eye. However, a visual comparison can be made between Fig 3.5, with whole
brain protein extracts and Fig 3.16, with eye extracts. The protein composition of the
two tissues is different, and the shorter forms make a more significant contribution in
the eye than in the brain.
Due to difficulties in collecting enough El2.5 eye protein from the five genotypes,
the number of repeats in the eye was lower than in the brain. For this reason, error
was higher, and fewer of the results are statistically significant. Only those seen for
full-length Pax6+5a are significant by ANOVA. These will be described first,
followed by a general discussion of the qualitative expression levels of other Pax6
forms in the eye.
3.5.2: 48kDa band, Pax6+5a in the eye
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Figure 3.16: Typical results from western blot of E12.5 whole eye
protein extract across a number of genotypes. A) Using serum 13 anti-
HD primary antibody. B) Using anti-Pax6 C-terminus primary antibody.
Arrows indicate the bands observed, and their estimated mass in
Kilodaltons (KDa). Bands with asterisks (*) were either not resolved on
all gels, or not observed on all gels due to low sensitivity of the
western. +ve, in wfro-synthesised positive controls. L, molecular mass
ladder.
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A 48kDa band corresponding to full-length Pax6+5a was observed in all PAX77+/+,
PAX77+/~, WT and Sey/+ eye extracts, but not Sey/Sey extracts (Figure 3.17A).
As with brain extracts, /-tests were carried out between all genotypes and WT,
between Sey/Sey and Sey/+ and between PAX77+/"and PAX77+/+ (Figure 3.17 B).
The only statistically significant result is the comparison between WT and PAX77+/+
(P<0.05), in which levels are raised.
On a qualitative level, Pax6+5a protein expression appears to correspond more tightly
to Pax6 copy number in the eye than in the brain (compare Figure 3.8 with Figure
3.17).
3.5.3: Other Pax6 isoforms in the eye
Although none of the results for other Pax6 bands in the El2.5 eye are statistically
significant, all bands seem to follow similar trends, implying that the expression of
each is regulated in a similar way across the five genotypes.
Unlike in the developing brain, the 42kDa band is only seen in one PAX77+/+ sample.
However, this could be due to the much higher abundance of the 43kDa band,
obscuring the lower band in all cases.
Each graph (Figures 3.18-3.20) shows a similar pattern. In all cases, Sey/+ eyes
express less Pax6 protein than WT. This is to be expected, given that there is only one
functional copy of the gene, but is not seen in El 2.5 whole brain. The autoregulatory
mechanism which is hypothesised to up-regulate the amount of Pax6 protein in a
heterozygous brain seems to be absent from the heterozygous eye. For most bands,
the level observed in Sey/+ eye is approximately half that of the WT. The only
isoforms obviously differing from this pattern are the 32.5kDa and 32kDa bands,
expressed at 14% (32.5kDa) and 7% (32kDa) of WT levels.
PAX77+/~ and PAX77+/+ eyes both contain more Pax6 than WT. Unlike in the brain,
Pax6 levels in the eye seem to vary between PAX77+~ and PAX77' 1 mice. All but













































ANOVA P=0.0141, considered significant
B
f-test P-value
Sey/Sey vs. Sey/+ >0.05
Sey/Sey vs. WT >0.05
Sey/+ vs. WT >0.05
WT vs. PAX77+/- >0.05
WT vs. PAX77+/+ <0.05
PAX77+/" vs. PAX77+/+ >0.05
Figure 3.17: Pax6+5a in E12.5 mouse eye. A, Mean values. All
values are normalised to WT=1. The number of samples analysed is
shown above each bar. Error bars represent SEM. Values are given
in numerical form below each bar. B, Results of paired f-test
between genotypes. Significant results are highlighted.
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ANOVA P=0.317, not considered significant
Figure 3.18: Pax6-5a (A) and 43KDa Pax6 (B) in E12.5 mouse eye.
All values are expressed as means, normalised to WT=1. The
number of samples analysed is shown above each bar. Error bars
represent SEM. Values are given in numerical form below each bar.
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ANOVA P=0.317, not considered significant
Figure 3.19: 33KDa Pax6 (A) and 32.5KDa Pax6 (B) in E12.5 mouse
eye. All values are means, normalised to WT=1. The number of
samples analysed is shown above each bar. Error bars represent










































































ANOVA P=0.4286, not considered significant
Figure 3.20: 32KDa Pax6 (A) and 30KDa Pax6 (B) in E12.5 mouse
eye. All values are means, normalised to WT=1. The number of
samples analysed is shown above each bar. Error bars represent
SEM. Values are given in numerical form below each bar.
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an autoregulatory mechanism which is hypothesised to stabilise Pax6 levels in the
brain appears to be absent in the eye at E12.5.
The level of upregulation seen in PAX77+/" and PAX77+/+ eyes seems to vary highly
between isoforms. This is most dramatic in homozygotes, where upregulation ranges
from 8-fold (30kDa band) to 77-fold (43kDa band). This may be due in part to the
large error in these samples, but it seems likely that in some cases, upregulation is
greater than the 12-fold which might be expected in a mouse with 12 extra copies of
the gene.
Both 43kDa and 32kDa bands were observed in the brain of Sey/Sey mice at El2.5.
The 43kDa band was not observed in the eye at this age, and the 32kDa band was
only seen once. This might represent a genuine absence of these proteins in the
Sey/Sey eye, or it may be due to the fact that levels are below the limits of detection.
Given the high levels of 43kDa Pax6 in the eye of other genotypes, it seems likely
that its absence from Sey/Sey samples is a genuine result. The lower 32kDa band is
less abundant in other genotypes, and was observed once in Sey/Sey, so might be
present at very low levels.
3.6: Results: The Pax6-5a : Pax6+5a protein ratio
As discussed in Chapter 2, the ratio between the two full-length Pax6 mRNA splice
variants, Pax6+5a and Pax6-5a, is an important aspect of the role of Pax6 as a
transcription factor. Despite this, the differential distribution of Pax6-5a and Pax6+5a
proteins has yet to be studied in any organism, at any age.
3.6.1: Pax6-5a : Pax6+5a ratios in the eye and brain of E12.5 Sey/+,
WT, PAX77+/"and PAX77+/+mice
In the brain, the ratio of Pax6-5a : Pax6+5a protein is 4: l for WT, and 3:1 for Sey/+
(Figure 3.21 A). These two results are not significantly different. The comparisons
between WT and PAX77 brains, however, are statistically significant. In the
































ANOVA P=0.0058, considered very significant
B























ANOVA P=0.490, not considered significant
Figure 3.21: Ratio of Pax6-5a:Pax6+5a in all genotypes at E12.5 in
the brain (A) and eye (B). The ratio is expressed as total amount
Pax6-5a / total amount Pax6+5a, thus a positive number indicates
Pax6-5a in excess over Pax6+5a.AII values are expressed as means.
The number of samples analysed is shown above each bar. Error bars
represent SEM. Values are given in numerical form below each bar. *
t-test significant to P<0.5. **P<0.01
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The WT figure of 4:1 is somewhat different from the Pax6-5a : Pax6+5a mRNA
ratios described in the literature. A comparison between these figures and those seen
for Pax6 mRNA in Chapter 2 indicates that ratios observed for RNA are indeed
recapitulated at the protein level. The relationship between Pax6 mRNA levels and
Pax6 protein levels as determined by this study will be discussed in more detail in
section 3.6.2. Richardson et al. (1995) cloned full-length Pax6 cDNAs from adult
mouse brain, and found an equal representation of Pax6+5a and Pax6-5a, although
this analysis was by no means quantitative. In contrast, Kozmik et al. (1997) saw a
ratio of 8:1 in whole head from El2.5 - El 6.5, and in adult whole brain. Although
RPA, the technique used in this analysis (see Chapter 2) is quantitative, any ratio
from whole head RNA would include eye, brain and nasal epithelia, and thus is not
directly comparable with the results presented here.
In the eye, the ratio between Pax6-5a and Pax6+5a is 5:1 in the WT, and
approximately 4.5:1 in Sey/+, results that are not significantly different (Figure 3.21
B). In the PAX77+/~ eye this rises to 10:1, similar to the 8:1 seen in PAX77+/+ eye.
Although these figures are higher than in the WT eye, they are not significantly
different.
As with the brain, the Pax6-5a : Pax6+5a ratio in El2.5 WT eye described here
differs from some previously published data. Two studies have addressed this issue in
the eye, although both were conducted at the mRNA level. The relative abundance of
Pax6 protein isoforms has not been studied to date. Jaworski et al. (1997) used RT-
PCR to amplify Pax6 exons 4 to 7 from bovine retina, lens, iris and cornea. Based on
the intensity of PCR products as visualised by agarose gel electrophoresis, they
described a prevalence of Pax6-5a in the retina and lens, whilst the two isoforms
were more equally represented in the iris and cornea. Zhang et al (2001) looked in the
adult human lens and cornea, and the monkey retina, using RT-PCR reactions spiked
with known amounts of "mimic" fragments, to obtain semi-quantitative results. Equal
amounts of the two isoforms were seen in all tissues. Whilst these results seem
contradictory, it is worth bearing in mind the different species being examined, and
the different methods used. The results described here are an average of the ratio
across whole eye, so tissue-specific effects will be masked, but are consistent with
Pax6-5a being preferentially expressed.
It is interesting to note that the brain of PAX77+/" and PAX77+/ mice appears
unaffected by the presence of extra copies of the Pax6 gene (Schedl et al., 1996;
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M.Manuel, pers. comm.), whereas the eye is severely affected in both cases (Schedl
et al., 1996). It is clear that the absolute levels of Pax6 protein have an effect on the
PAX77 mouse phenotype, but it is also possible that the difference in Pax6-5a :
Pax6+5a ratio may play a part in this phenotype.
In the brain, the ratio drops significantly, from around 4:1 in the WT to below 2:1 in
PAX77 mice. This is because Pax6-5a is up-regulated by less than two-fold, whereas
Pax6+5a shows a higher level of up-regulation in both PAX77+/~and PAX77+/+brain,
by a factor of 3 or 4. The alteration of the Pax6-5a:Pax6+5a ratio could alter the
transcriptional activity of Pax6 protein, as seen in Chauhan et al. (2004), and may
have an effect on Pax6 autoregulation.
In the eye, the ratio between Pax6-5a and Pax6+5a in PAX77 mice does not alter
significantly (Figure 3.21 B). The PAX77 eye displays micropthalmia (Schedl et al.,
1996), and thus appears to be sensitive to Pax6 dosage.
In contrast to the eye, there is no discernible PAX77 hemizygous or homozygous
brain phenotype (Schedl et al., 1996; M. Manuel pers. comm.), and thus the brain is
less sensitive to Pax6 gene dosage. Here, the Pax6-5a : Pax6+5a ratio does differ
significantly from that in the WT (Figure 3.21 A). It is possible that this alteration in
ratio is the result of an autoregulatory mechanism, and one of the reasons for the lack
of a strong brain phenotype.
3.6.2: Comparing Pax6-5a : Pax6+5a ratios at the mRNA and the
protein level
Figure 3.22 allows a general comparison between the WT Pax6-5a : Pax6+5a
mRNA ratios described in Chapter 2, and the WT protein ratios described here. The
easiest comparison to make is that between whole eye mRNA and whole eye protein.
The ratios are 6.8:1 and 5:1 respectively. When compared by t-test, these two results
are not significantly different (P=0.35), indicating that the Pax6-5a : Pcix6+5a mRNA
ratio is representative of the Pax6-5a : Pax6+5a protein ratio. This suggests that
regulation of the Pax6-5a : Pax6+5a protein ratio in the eye occurs largely at the
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Figure 3.22: Comparison between Pax6-5a : Pax6+5a mRNA ratio
and protein ratio at E12.5. A, mRNA ratio as determined by RPA.
Error bars represent SEM. Values are given in numerical form above
each bar. B, protein ratio as determined by western blot
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mRNA level rather than the protein level, although it is still unclear whether this
regulation occurs via changes in alternative splicing or changes in transcript stability.
In the brain the comparison between mRNA data and protein data becomes more
complex, as mRNAs were divided by tissue to allow more in-depth analysis, whereas
whole brain protein samples were used, as the technique was less sensitive. Pax6
mRNA is expected to be most abundant in the telencephalon and diencephalon at
El2.5, so a ratio from total brain will be skewed towards the ratio in these two
tissues. At the protein level, the ratio is 4.1:1 (Figure 3.22 B). The ratio in the brain
tissues analysed varies between 6.3:1 in the telencephalon and 9.7:1 in the
diencephalon. The difference between the mRNA ratio and the protein ratio could be
due to differential regulation of the two protein isoforms.
3.7: Results: Pax6 in the brain of E12.5 Sey/Sey, Pax6LacZ/LacZ and
Sev//e7Se/,e" mice
The 43kDa and 32kDa Pax6 bands were observed in E12.5 Sey/Sey brain extracts on
10 and 13 occasions, respectively. Figure 3.23 shows three of these western blots. All
three clearly show the 32kDa band, and Fig 3.23 B + C also show the 43kDa band in
Sey/Sey samples.
As described in 3.4.3.3 and 3.4.3.7, these isoforms seem as common in the Sey/Sey
brain at E12.5 as they are in the WT brain.
In order to determine the protein responsible for these two bands, western blots were
performed on El2.5 brain samples collected from two other Pax6 mutants,
Pax6LacZL"cZ and SeyNc"/SeyNe" (Figure 3.24). All genotypes appear to contain the
32kDa band, whilst only Sey/Sey, Sey/+ and WT brains contain the 43kDa band.
Although the nature of the 43kDa band seen in the Sey/Sey brain is unknown, the fact
that it is highly upregulated in the PAX77+/"and PAX77+/t brain and eye (Figure 3.11
and Figure 3.19) is evidence for it being a Pax6-derived protein. One possible
explanation is that the 43kDa band may be due to the splicing out of exon 8, which
contains the Sey STOP codon. The corresponding protein would not be made in either
Pax6,McZLacZ or Sey'c"/SeyNc" mice, and the band would not be observed in either
sample.
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Figure 3.23: Typical results from western blot of E12.5 whole brain
protein extract from Sey/Sey and Sey/+ mice. A, B, C, three separate
repeats. All show the presence of the 32KDa band in Sey/Sey brain. B
and C also show the presence of the 43KDa Pax6 band. Arrows





Pax6LacZJLacZsey"*" + Sey+ Sey WT +ve L
B SeylSey/ SeylSey/ Sey"eu/ +ve"









Figure 3.24: Typical results from western blot of E12.5 whole brain
protein extract from Pax6LacZ/LacZ, SeyNeu/SeyNeu, Sey/Sey, Sey/+ and
WT mice. A, B, separate repeats on the same samples. All genotypes
show the presence of the 32KDa band. The 43KDa Pax6 band, on the
other hand, is only seen in Sey/Sey, Sey/+ and WT. Arrows indicate
the bands observed, and their estimated mass in Kilodaltons (KDa).
Bands over 50KDa are assumed to be non-specific. +ve, in vitro-
synthesised positive control Pax6. L, molecular weight ladder.
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The predicted molecular weight of a Pax6 protein resulting from translation of the Sey
Pax6 transcript from the first ATG to the STOP mutation (as described in Engelkamp
et al., 1999) is 22.5kDa, making this an unlikely explanation for the 43kDa Pax6
Sey/Sey band. Indeed, no band of this molecular weight was seen in Sey/Sey brain or
eye at El2.5, implying that the truncated protein is not made in sufficient quantities to
be functionally significant.
As it is present in Pax6lacZ,'acZ and SeyNe"/SeyNe" mouse brain extracts, the 32kDa Pax6
band can no longer be explained as a result of internal translation initiation. Although
this would still be possible in the Pax6LatZLacZ mouse, the SeyNc" mutation would
disrupt the 5'-truncated protein. The 32kDa band in the SeyNc"/SeyNc" brain may be the
result of an unknown form of Pcix6 mRNA or protein processing, or it may be a non¬
specific band migrating at the same molecular weight as a Pax6-specific band. Given
either explanation, it is still entirely plausible that the 32kDa band observed in
Pax6LacZ,'acZ and Sey/Sey brain at El2.5 is a genuine /ford-derived protein.
3.8: Discussion
3.8.1: Overall trends in Pax6 protein isoform expression in the
embryonic brain and eye across genotypes
At least eight isoforms of Pax6 can be detected by western blot of brain and eye
tissue from E12.5 mice. The majority of isoforms are upregulated in both PAX77+/~
and PAX77+/4 mice. In the brain, there is no significant difference in expression levels
between hemizygous and homozygous PAX77 mice. In the eye, levels of all but one
of the Pax6 proteins are higher in the PAX77'7' mouse than in the PAX77+" mouse.
This is to be expected from the extra six copies of the Pax6 gene in this mouse.
The Sey/+ mouse brain shows similar expression levels to the WT for most Pax6
isoforms, which is surprising given that it is missing one copy of the gene. In the eye,
expression levels of all isoforms appear to be reduced in the Sey/+ mouse.
The only isoforms which do not seem to conform to this general rule are the Pax6+5a,
42kDa and 33kDa forms. Pax6+5a is the only isoform to be expressed at higher levels
in the Sey/+ brain than in the WT brain. Unlike the other isoforms, both the 42kDa
127
and the 33kDa Pax6 proteins are found at reduced levels in the Sey/Sey and the Sey/+
brain when compared to WT.
The 43kDa isoform shows a very different expression pattern, as it is dramatically
upregulated in PAX77 mice, by 144-fold in hemizygotes, and 56-fold in
heterozygotes. It is also expressed in Sey/Sey mice, at a level that is not significantly
different from the WT level.
At times the 42kDa and 43kDa bands were difficult to resolve by SDS-PAGE, and
when a single band was seen, this was designated a 43kDa band. For this reason, it is
possible that some signal from the 42kDa band may have been included as data for
the 43kDa band. However, the 43kDa band was in great excess over the 42kDa band
on all gels (see Figure 3.5), so this is unlikely to have contributed to the massive up-
regulation of the 43kDa band observed in PAX77 mice. Also, where the 42kDa band
was clearly resolved in one lane of a gel, it was clearly resolved in all lanes.
Comparisons in its levels between these lanes were therefore valid, and not
contaminated with information from the 43kDa band.
The Pax6-5a : Pax6+5a ratio in the eye is similar at the protein level to that observed
at the RNA level by RNase protection assay. This indicates that control of expression
of these two isoforms occurs largely at the mRNA level, and direct studies of mRNA
levels, in this case at least, are a valid indicator of the protein content of a cell. It is
difficult to compare mRNA data to protein data collected from the brain, as the brain
was divided into constituent Pax6 expressing tissues for mRNA analysis, whilst
protein was analysed across the whole brain. There do, however, appear to be
discrepancies between the Pax6-5a : Pax6+5a mRNA ratio and the corresponding
protein ratio in the brain. This may be indicative of regulation of the Pax6 isoforms at
the protein level.
The Pax6-5a : Pax6+5a protein ratio in the brain is consistent between Sey/+ and WT
samples. The ratio falls significantly in the PAX77 brain, both in hemizygotes and
homozygotes. In the eye, there are no significant differences in the Pax6-5a : Pax6+5a
protein ratio across all genotypes studied.
That the ratio between the two major Pax6 isoforms varies in the brain but not in the
eye is consistent with the conclusion that Pax6 is more tightly autoregulated in the
brain. A mechanism appears to be in place whereby the differential regulation of
128
Pax6 isoforms in the developing brain varies dependent on Pax6 copy number. In the
eye, this does not occur; Pax6-5a and Pax6+5a are not differentially regulated.
3.8.2: Limitations of this analysis
Analysis of Pax6 isoforms in whole brain and eye by western blot is a powerful tool
for furthering our understanding of the roles of the various Pax6 isoforms in
embryonic development. Pax6 protein level is not always representative of Pax6 copy
number, therefore insights into the autoregulation of Pax6 can be gained. Despite this,
there are a number of limitations which must be borne in mind when discussing the
results of this analysis.
Most obviously, protein extracts were taken from whole brain and whole eye at
E12.5. Using just one embryonic age allows us to view a snapshot of development,
around the peak of neurogenesis, but offers no indications as to whether the levels of
any of these isoforms alter through development. The results from RNase protection
assays (Chapter 2) clearly show that Pax6 expression varies throughout development,
an observation that is unlikely to be confined to Pax6-5a and Pax6+5a, the 46kDa
and 48kDa protein isoforms. Understanding this developmental variation may give
further insights into the roles of Pax6 isoforms in embryonic development.
The analysis of PAX77+" and PAX77++ samples alongside the same amount of total
protein from WT samples led to difficulties in comparing signal strength between
lanes. Where photographic film was exposed for sufficient length of time to observe
some bands in the WT (e.g. the 43kDa, 33kDa and 32.5kDa bands), these bands were
saturated in PAX77 samples, and could not be accurately quantitated.
Retrospectively, this problem could have been solved by loading less PAX77 protein
than WT protein, but this may have led to difficulties in relative quantitation where
the levels of protein did not vary as markedly between genotypes (e.g. the 42kDa and
30kDa bands).
Comparisons with mRNA expression data from Chapter 2 reveal another weakness of
this type of analysis. Figure 2.9, for example, shows a clear difference in Pax6
isoform expression between telencephalon and diencephalon at El2.5. For western
blot analysis, these two tissues were pooled as part of a whole brain protein extract.
This was because western blot is a much less sensitive technique than RPA, and more
tissue is needed to obtain accurate results.
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Pooling such diverse tissues as lens and retina to obtain whole eye protein samples, or
hindbrain and telencephalon to obtain whole brain protein samples, is likely to mask a
number of interesting variations in Pax6 expression. For example, differential
regulation of Pax6 transcripts has been well documented in the developing eye, as
described in Section 2.2.1. Alternative c/s-regulatory elements downstream of the
Pax6 gene direct its expression specifically in the neural retina (Griffin et ah, 2002),
or the lens (Dimanlig et ah, 2001; Kammandel et ah, 1999). The relative amounts of
the Pax6+5a and Pax6-5a splice forms vary markedly between these two tissues
(Jaworski et ah, 1997), and it seems likely that this differential regulation extends to
the other alternative Pax6 isoforms, which this analysis would not have picked up.
Although differential regulation of most Pax6 isoforms is seen between the genotypes
analysed, it is difficult to draw conclusions based on their roles in embryonic
development without being entirely sure what Pax6 isoforms these bands represent.
Studies have indicated what some of these bands might be (Carriere et ah, 1993;
present study) by over-expression of in vitro synthesised proteins in immortalised cell
lines, but this is by no means proof of their identity. Unexpected Pax6 protein bands
may exist as the result of a number of mechanisms, including protein cleavage, post-
translational modifications, or unknown splice variants. Had the western blot
technique been successful with the anti-Pax6 PD antibody, it would have been
possible to differentiate between proteins created by these mechanisms, and those
which were the result of internal translation initiation. Ultimately, until the precise
protein sequence of these bands, has been determined, it is difficult to draw accurate
and detailed conclusions from studies such as these.
3.8.3: Autoregulation of Pax6 protein in the E12.5 brain
PAX77" " mice contain approximately 6 inserted copies of the human PAX6 locus,
and PAX77+/+ mice contain approximately 12 extra copies. If there were a linear
relationship between copy number and protein expression level, the PAX77+ " mouse
brain would express four times more Pax6 than the WT brain (with eight total copies,
as opposed to two), and the PAX77+/t mouse brain seven times more (with fourteen
total copies, as opposed to two). Although Pax6 protein is clearly overexpressed in
the PAX77 brain, the rise in expression of many isoforms, such as Pax6+5a and
Pax6-5a is not that dramatic. In particular, no statistically significant increases in
expression were detected between hemizygotes and homozygotes; if anything,
hemizygotes express slightly more of most isoforms than homozygotes. This is likely
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to be due to autoregulation. The mechanism behind this is unclear, but it may also
help explain why there is no obvious brain phenotype in these mice (Schedl et al.,
1996; M.Manuel, pers. comm.).
The majority of Pax6 isoforms are expressed at the same level in Sey/+ and WT
brains at El2.5, despite Sey/+ mice only having one functional copy of the Pax6
gene. In this case, a regulatory mechanism is seen to increase the levels of Pax6, up to
those seen in the WT. Unlike the PAX77 brain, the Sey/+ brain does have a
phenotype (Estivill-Torrus et ah, 2001; Mastick et ah, 1997), but it is very subtle
when compared to that seen in the Sey/Sey brain. It is possible that the upregulation of
Pax6 to normal levels in the Sey/+ brain is tissue-specific, and this technique would
not be sensitive enough to detect regional variances in Pax6 levels. Alternatively, the
brain phenotype in Sey/+ mice could be due to the effects of the three isoforms,
Pax6+5a, 42kDa Pax6 and 33kDa Pax6, that are seen at different levels between
Sey/+ and WT brains.
In the eye, this autoregulation is no longer evident. Pax6 expression levels seem to
correlate much more tightly with Pax6 copy number, and regulatory mechanisms to
control its levels do not seem to be present. Expression of all Pax6 isoforms appears
to be reduced in the Sey/+ eye when compared to WT. Reduced transcription of Pax6
has been previously demonstrated in the Sey/+ lens (Chauhan et ah, 2004b), which is
consistent with the reduced levels of Pax6 protein observed here. All Pax6 isoforms
except the 30kDa form are found at higher levels in the PAX77+ + eye than in the
PAX77+/" eye, again indicating that a relationship between Pax6 copy number and
Pax6 protein expression is maintained in the eye.
Sey/+ eyes are severely reduced in size (Hill et ah, 1991), as are those of the
PAX77+/" and PAX77+/+ mice, although eye size is more variable in the PAX77
mutant (Schedl et ah, 1996). This similarity in phenotype is difficult to explain,
given the large differences in Pax6 protein levels, but it is clear that the eye is highly
sensitive to Pax6 protein dosage.
3.8.4: Over-expression of the human Pax6 locus in mice
An important issue to bear in mind when comparing Pax6 expression between WT
and PAX77 mice is that the extra copies of PAX6 are under the control of the human
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regulatory elements contained in the 420kb YAC. This is a possible explanation for
differences in Pax6 regulation between WT and PAX77 mice.
Whilst most Pax6 isoforms are expressed at levels which are loosely comparable to
Pax6 copy number in the PAX77+ ' brain and eye, extremely high levels of the 43kDa
band are found in both tissues (56-fold more than WT in the brain, and 77-fold more
in the eye). The PAX77+" brain also exhibits very high levels of this isoform (144
times more than found in the WT brain), although no great upregulation is seen in the
PAX77+" eye. This is a much higher increase in protein level than would be predicted
by Pax6 copy number alone, and it remains a possibility that this isoform is expressed
at higher levels because it is under the control of human regulatory sequences that
differ markedly from those present in the mouse.
This is also a possible explanation for the difference in Pax6-5a : Pax6+5a ratio
observed in the brain of both hemizygous and homozygous PAX77 mice.
Although most studies of Pax6 expression have been conducted in mouse (e.g.
Kozmik et al., 1997; Richardson et ah, 1995), a few have analysed expression in other
species, such as cow (Jaworski et ah, 1997) and monkey (Zhang et ah, 2001). It is
difficult to make direct comparisons between these studies, as they involve mRNA
characterisation of a number of tissues using different techniques. However, there are
indications that species-specific differences may well occur. Zhang et ah (2001)
described a 1:1 ratio between Pax6-5a and Pax6+5a in human lens epithelium, whilst
Jaworski et al. (1997) and Richardson et ah (1995) observed more Pax6-5a in the
cow and mouse lens. No other studies have yet been conducted comparing protein
isoform expression between species.
3.8.5: Pax6 protein expression in the Sey/Sey mouse, and other
Pax6 mutants
Some isoforms of Pax6 protein are present in the Sey/Sey brain at El2.5, but they are
not detectable in the eye. The 43kDa band is expressed at similar levels to WT, whilst
the 32kDa band is upregulated by approximately four-fold. If these bands are
functional in the WT mouse, they may therefore also be contributing to the phenotype
of Sey/Sey mice. The increased levels of Pax6 mRNA in the Sey/Sey mouse
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(Collinson et al., 2003; Warren and Price, 1997) may also explain the increased levels
of32kDa Pax6 protein.
43KDa Pax6 is found in the Sey/Sey brain at El2.5, but is not detectable in Sey/Sey
eye, or in either tissue from Pox6LacZLacZ or Sey^e"/SeyNe" mice. The absence of this
Pax6 band from two of the three Pax6 mutant mice could be due to expression below
the limits of detection by western blot, or it could indicate that these two genotypes
are incapable of producing a 43kDa Pax6 protein.
The 43kDa Pax6 protein was previously thought to be the result of alternative
splicing of exon 6 (Carriere et al., 1993), but two lines of evidence from this study
suggest that an alternative explanation for the 43kDa band must now be sought.
Firstly, it is present in the Sey/Sey brain, which is theoretically incapable of producing
full-length Pax6A6 protein due to the presence of an internal STOP codon. Secondly,
RPA data from Chapter 2 (Figure 2.12) show that the alternative splicing of exon 6 is
undetectable in a number of Pax6 expressing tissues at E12.5; unless the Pax6A6
protein is significantly more stable than other Pax6 isoforms at this age, other Pax6
proteins must be contributing to the 43kDa Pax6 band. One possible explanation is
the alternative splicing of exon 8, leaving an in-frame protein with a predicted
molecular mass of 41/42kDa (-/+5a).
32kDa Pax6 is present in the brain of Sey/Sey, Pax/)1"' 71'" 7 and SeyNc"ISeyNc" mice at
El2.5, but is not detected in the eye. Again, protein may have been present in the eye
of these strains, but at below the limits of detection by western blot. An explanation
for the presence of this short Pax6 isoform in all three Pax6 mutant mouse strains is
harder to come by, but it is likely to be a Pax6 protein product, as it is over-expressed
in the PAX77 brain and eye. One possibility is that it may result from internal
translation initiation, giving rise to an N-terminally truncated Pax6 isoform, lacking
the PD. Another is that it may be a protein cleavage product.
Although the protein sequence of the 43kDa and 32kDa Pax6 bands is unknown, it is
clear that Pax6 protein is present at detectable levels in the brain of Sey/Sey,
Pax6LacZLacZ and Sey''c"/SeyNc" mice, and may be contributing to their phenotype. The
presence of 43kDa Pax6 isoform in just one of these mouse strains, Sey/Sey, also
suggests that any differences in phenotypes between the strains might be explained by
the presence of a short Pax6 isoform.
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A possible role for N-terminally truncated Pax6 protein will be discussed further in
Chapter 4.
3.8.6: Future work
Data from RNase protection assays on Pax6 mRNA (Chapter 2) show tissue-specific
and developmental stage-specific variations in the Pax6-5a : Pax6+5a ratio. For
example, the ratio falls with time in the telencephalon and diencephalon, whilst it
remains constant in the cerebellum. Although it would be impractical to extend this
protein expression analysis to all Pax6 expressing tissues at all time points, a detailed
protein expression analysis could be conducted in tissues or at time points which
show interesting patterns of Pax6 mRNA regulation. Tissues such as the
telencephalon, from which large amounts of protein could easily be obtained, are
particularly amenable to this type of analysis. It would be interesting to look at the
levels of the shorter Pax6 isoforms in the developing telencephalon, to establish
whether this fall in Pax6-5a : Pax6+5a ratio is coincident with changes in the levels
of other Pax6 proteins, which would shed some light on their roles in cortical
development.
Pax6 is known to have multiple roles, even within the developing cortex, it is
expressed in both neural progenitor cells and glia (Gotz et al., 1998) and the different
cell types may well express the various Pax6 isoforms at different levels. Double
immunocytochemistry with a neural progenitor cell marker such as MAP2 and a glial
cell marker such as RC2 would permit flow cytometric sorting of these two cell types.
The two separate populations could then be subjected to western blot analysis, and an
expression profile of the different Pax6 isoforms across cell types could be obtained.
The present analysis of El2.5 mouse brain has revealed that a 43kDa Pax6 isoform is
present in the Sey/Sey mouse, but not SeyNc"/SeyNe" or Pax6LacZLacZ mice. A 32kDa
Pax6 isoform is present in all three genotypes. A tissue-specific analysis of regions of
the embryonic brain may highlight areas in which this short isoform is seen at
relatively high levels. A phenotypic comparison between the three Pax6 mutant mice
in this tissue would shed further light on the in vivo roles of these short proteins.
It is difficult to draw conclusions as to the role of the Pax6 isoforms described here
without knowing their exact protein sequence. By performing 2-dimensional gel
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electrophoresis on PAX77 brain samples, these Pax6 bands could be separated from
other proteins present in whole brain extract. Alternatively, samples could be
enriched for Pax6 by immunoprecipitation. If two polyacrylamide gels were run
simultaneously, western blot for Pax6 could be performed on one, to determine the
exact location of each isoform. They could then be excised from the second gel, and
N-terminal and C-terminal sequencing could be used to obtain an exact protein
sequence for each, including post-translational modifications.
Finally, after characterisation of the expression levels of Pax6 isoforms, the next step
is to define a functional role for each isoform. Although it is likely that the various
Pax6 proteins interact with each other in a complex manner, an initial analysis could
be conducted by forcing their expression in a cell culture system. Full-length Pax6-5a
and Pax6+5a, alongside an N-terminally truncated Pax6 have been overexpressed in
two cell lines, and preliminary analysis of the phenotype of these cell lines is
described in Chapter 4.
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Chapter 4: Analysing the effects of Pax6-5a and Pax6+5a
over-expression in immortalised cell lines
4.1: Summary
Four cell lines were selected for preliminary study. These were H36CE2, a human
lens cell line; Neuro2A, a murine neuroblastoma cell line; NIH3T3, a murine
fibroblast cell line, and U373-MG, a human glioblastoma cell line. The levels of Pax6
expression were determined in each cell line, and transient transfections were
performed with over-expression plasmids containing EGFP and Pax6, to determine
transfection efficiency.
Two cell lines were then selected for the creation of stable transgenic Pax6-
overexpressing cell lines. Neuro2A was selected as it expresses endogenous Pax6, is
easy to culture, grows quickly, and is highly amenable to lipofection. N1H3T3 was
selected as it expresses no endogenous Pax6 protein, but is also easy to culture, grows
quickly, and is highly amenable to lipofection.
It was found that, in both cell lines, the addition of either Pax6-5a or Pax6+5a led to
the over-expression of both splice variants. Cell lines were selected that over-
expressed Pax6 at varying levels.
Pax6 over-expression was found to promote neuronal differentiation in the Neuro2A
cell line, an effect which was most profound in the cell line with highest levels of
Pax6 protein.
4.2: Introduction
4.2.1: Methods previously used to analyse the effects of Pax6
over-expression on cellular behaviour
The over-expression of Pax6 was first studied by Maulbecker and Gruss (1993), who
transplanted Pax6 over-expressing cells into WT mice, and observed tumour
formation, implying that Pax6 has a role in controlling cellular proliferation. The
Pax6 expression construct used by Maulbecker and Gruss contained Pax6-5a, and no
similar experiments have been carried out to date using other Pax6 isoforms.
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Duncan et al. (2002) created a transgenic mouse in which Pax6+5a was specifically
over-expressed in the lens, which led to the formation of cataracts, and the up-
regulation of the cell adhesion molecules paxillin, pl20ctn and a5pl integrin, but
again the reciprocal experiment was not performed with Pax6-5a.
The PAX77 transgenic mouse (Schedl et al., 1996) (see Section 1.5.4) was
engineered to allow the over-expression of all isoforms of PAX6 in all tissues with
endogenous Pax6 expression. This was achieved by the addition of a number of
copies of a YAC containing the human PAX6 locus, and all known surrounding
regulatory elements. Chapter 3 of the present study describes raised levels of Pax6
protein in both hemizygous and homozygous PAX77 mice, proving that all PAX6
isoforms were indeed over-expressed. The phenotype of the PAX77+'" and PAX77+/+
mice mirrors that of the Sey/+ mouse, with a reduction in eye size and no obvious
phenotype in the brain (Schedl et al., 1996; M. Manuel, pers. comm.).
Little work has been done on the PAX77 mouse line to further characterise the effects
of Pax6 over-expression, which would shed valuable light onto the normal function of
Pax6 during development.
l lie effects of Pax6 over-expression have been more extensively studied in vitro, by
transient transfection of immortalised cell lines. Most of these studies have focussed
on the effects of Pax6 on various promoters, in particular the Pax6 P0 and PI
promoters (Aota et al., 2003; Plaza et al., 1993; Plaza et al., 1995) and the effects of
Pax6 on the canonical binding sequences P6CON and 5aCON (Epstein et al., 1994b;
Yamaguchi et al., 1997). Little work has been done to assess the cellular behaviour of
Pax6 over-expressing cells. In a number of studies, conclusions have been made from
the phenotype of cells after the introduction of one Pax6 isoform, without any attempt
to characterise the protein content of transfected cells (Carriere et al., 1995; Chauhan
et al., 2004a; Heins et al., 2002; Yamaguchi et al., 1997). Given that Pax6 is known to
transactivate its own promoter (Okladnova et al., 1998; Plaza et al., 1993; Plaza et al.,
1995; see Section 1.6.3), it is difficult to assess the effects of Pax6 over-expression in
vitro without first characterising the Pax6 protein content of transfected cells.
4.2.2: Stable cell lines as a model system for studying Pax6 over-
expression
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Cell lines are a good model system for studying the effects of gene over-expression.
Circularised plasmid constructs containing the gene of interest, in this case Pax6, can
be transiently transfected into cell lines, leading to very high levels of over-
expression which peaks 48-72 hours after transfection. Alternatively, linearised
plasmid constructs containing the gene of interest and a second gene conferring
resistance to gentamycin (G-418) can be transfected into a cell line using the same
protocol, and G-418 selection can be used to create stable transgenic lines.
Stable cell lines are particularly useful, as they are clonal in origin, and should
express consistent levels of the transgene. Repeated experiments can be performed on
stable cell lines to look at the effects of transgene over-expression, without the risk of
inconsistent levels of over-expression leading to difficulties in the interpretation of
results.
Cell lines can be chosen which endogenously express the gene of interest, and are
therefore likely to be expressing co-factors necessary to mediate an over-expression
phenotype. In addition, cell lines can also be chosen which do not endogenously
express the gene of interest, in order to assess the effects of ectopic introduction of a
gene.
NIH3T3 (European Collection of Cell Cultures, ECACC 93061524) is a murine
fibroblast cell line (Jainchill et al., 1969) which does not express endogenous Pax6
(Okladnova et ah, 1998; Turque et ah, 1994). The necessary co-factors to mediate a
Pax6 over-expression phenotype might not be present in this cell line. If a phenotype
were seen, this would be an indication that Pax6 was acting as a "master regulator" of
transcription (Haider et ah, 1995; Harris, 1997; Onuma et ah, 2002), and activating a
cascade of downstream genes that might not already be expressed by N1H3T3 cells.
Neuro2A (ECACC 89121404) is a murine neuroblastoma-derived cell line. As the
phenotype of these cells is thought to mirror that of partially differentiated neurons
(Fischer et ah, 1986; Prasad and Hsie, 1971), they are likely to express Pax6, as it is
crucial for neuronal differentiation (Heins et ah, 2002; Mastick and Andrews, 2001;
Plaza et ah, 1995; Takahashi and Osumi, 2002; Warren et ah, 1999). This cell line is
likely to express co-factors that are necessary to mediate a Pax6 over-expression
phenotype. Any effect of Pax6 over-expression on the behaviour of this cell line
should provide an insight into the role of Pax6 in neuronal differentiation.
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U373-MG (ECACC 89081403) is a human glioblastoma-derived cell line (Ponten
and Macintyre, 1968). The process of glial differentiation requires Pax6 (Heins et al.,
2002), and this cell line is known to express Pax6 (C.T.Yap, Pers. Comm.).
Therefore, it is also likely to be expressing co-factors necessary to mediate a Pax6
over-expression phenotype. Any effect of Pax6 over-expression on the behaviour of
this cell line should provide an insight into the role of Pax6 in glial differentiation.
H36CE2 (a kind gift from A. Seawright, MRC Human Genetics Unit, Edinburgh) is a
human lens-derived cell line (Lengler et ah, 2001). As the human lens is known to
express Pax6 (Glaser et ah, 1992; Nishina et ah, 1999), this cell line is likely to also
express Pax6, alongside co-factors necessary to mediate a Pax6 over-expression
phenotype. Any effect of Pax6 over-expression on the behaviour of this cell line
should provide an insight into the role of Pax6 in lens formation.
4.2.3: The use of dbcAMP to promote neuronal differentiation in
the Neuro2A cell line
In culture, a low percentage of Neuro2A cells spontaneously differentiate down a
neuronal lineage, but the effect is enhanced by the addition of dibutyryl adenosine
3':5'-cyclic monophosphate (dbcAMP; Prasad and Hsie, 1971). The cells form axon-
like processes (Fischer et ah, 1986) which express neurofilament proteins (Shea et ah,
1988), and the axonal markers MAP IB and Taul (Shea and Beermann, 1994).
Pax6 is known to be important in the process of neuronal differentiation (Heins et ah,
2002; Plaza et ah, 1997; Scardigli et ah, 2003; Warren and Price, 1997), but the exact
role of Pax6 in this process is still unknown. If the over-expression of Pax6 is
sufficient to induce neuronal differentiation in the Neuro2A cell line, the effects of
this over-expression should be similar to the effects of dbcAMP treatment.
4.2.4: The role of N-terminally truncated Pax6
Chapter 3 describes the use of western blot to detect Pax6-specific protein bands in
Sey/Sey mice. These mice have a mutation in the Pax6 gene, leading to the
introduction of a STOP codon just 5' of the HD (see Figure 1.3).
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As shown in Figure 3.23, a 32kDa protein is seen in E12.5 Sey/Sey brain extract,
which could potentially be the result of internal translation initiation from an ATG
residue 3' of the STOP mutation. This short Pax6 protein is also observed in WT
El2.5 brain, and is therefore likely to be a functional Pax6 isoform (see Figure 3.5).
The protein produced from such an internal translation initiation event would have a
functional DNA-binding domain, the HD, and a functional TAD. However, it would
lack the N-terminal DNA-binding domain, the PD. The existence of Pax6 transcripts
in the mouse which are lacking the PD (Gorlov and Saunders, 2002; Kleinjan et al.,
2004; Mishra et al., 2002), and of a "paired-less" form of Pax6 in C. elegans (Zhang
and Emmons, 1995) lend further functional significance to this putative protein.
Dimerisation of Pax proteins via the HD has been demonstrated (Wilson et al., 1993).
Although many Pax6 HD-DNA interactions are thought to occur co-operatively with
an intact PD (Mikkola et al., 2001; Mishra et al., 2002; Singh et al., 2000), this PD
can be provided in trans by a different Pax6 molecule (Miskiewicz et al., 1996).
Therefore, it is possible that "paired-less" Pax6 can dimerise with full-length Pax6, or
other HD-containing genes, and affect the transactivation of target sequences. It is
also not inconceivable that a "paired-less" Pax6 could bind DNA as a monomer, via
the HD, and also exert a transactivational effect.
4.2.5: Aims
The aim of Chapter 4 was to study the effects of Pax6 over-expression in a cell
culture system.
In particular, Pax6-5a, Pax6+5a and 5'-truncated Pax6 constructs were introduced
into cell lines both with and without endogenous Pax6 expression. If a difference in
phenotype was seen after the introduction of these three constructs, this could be
taken as an indication that different Pax6 isoforms had different effects on cellular
behaviour.
Phenotypic analysis of Pax6 over-expressing cell lines was carried out with two main
aims, to assess the effects of Pax6 isoform over-expression on autoregulation, and on
neuronal differentiation.
140
4.3: Materials and Methods
4.3.1: Routine cell culture techniques
4.3.1.1: Maintenance of immortalised cell lines
The murine neuroblastoma line, Neuro2A, was obtained from the European
Collection of Cell Cultures (ECACC; 89121404) and maintained in Minimal
Essential Medium (MEM). The murine fibroblast line, NIH3T3 was also obtained
from ECACC (93061524) and maintained in Dulbecco's Minimal Essential Medium
(DMEM). The human lens cell line, EI36CE2, was a kind gift from A. Seawright
(MRC Human Genetics Unit, Edinburgh), and maintained in DMEM. The human
glioblastoma line, U373-MG was obtained from ECACC (89081403), and maintained
in DMEM.
All cells were routinely cultured at 37°C, 5% CO?. When confluent, cells were
dissociated in trypsin-EDTA, resuspended in 10 volumes of culture medium, and
seeded onto fresh culture dishes at 1:2 (H36CE2) or 1:10 (Neuro2A, NIH3T3, U373-
MG).
4.3.1.2: Freezing and defrosting cell lines
Cells were grown to confluence, dissociated in trypsin-EDTA and resuspended in 10
volumes of culture medium. They were then pelleted by centrifugation at lOOOrpm
for 5 minutes. Pellets were resuspended in lml freezing medium and transferred to a
sterile cryovial. Freezing was achieved slowly to minimise cell damage, with
cryovials being placed at -20°C for 2 hours, -70°C for up to 4 weeks, and stored in
the long term in liquid nitrogen.
96-well plates were frozen by aspirating all culture medium, adding 200pl freezing
medium per well, and freezing as above.
Cells frozen in cryovials were defrosted at 37°C, rescued in culture medium and
seeded in a 25cm2 flask. Cells were allowed to adhere overnight, and culture medium
was aspirated and replaced after 24 hours to avoid DM SO toxicity.
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Cells frozen in 48-well plates were defrosted at 37°C, and rescued in 1ml culture
medium. This medium was immediately aspirated to remove most DMSO, leaving
~100pl in each well to ensure cells did not shear off. Fresh medium was added, and
cells were allowed to recover overnight.
4.3.1.3: Transfection
Transient transfections were carried out initially to assess the efficiency with which
cell lines overexpressed introduced genes. After the selection of appropriate cell lines,
these were transfected with Pax6-5a and Pax6+5a over-expression constructs, and
stable cell lines were created.
Cells were transfected with the plasmid pEGFPNl (Clontech), which contained
Enhanced Green Fluorescent Protein (EGFP) under the control of the strong viral
CMV promoter. This allowed high levels of EGFP protein expression, and
successfully transfected cells were easily visualised by microscopy after exposure to
UV light at 488nm.
Cells were transfected using Lipofectamine 2000, according to the manufacturer's
protocol. Briefly, cells were seeded at 5X105 cells per well in 6-well plates 24 hours
prior to transfection, in transfection medium. No antibiotic was added, as the
lipofection reagent permeabilises cell membranes, and can render penicillin /
streptomycin toxic to eukaryotic cells. Transfection efficiencies were highest using
8j.il Lipofectamine and lOpg plasmid DNA (NIH3T3, U373-MG, H36CE2) or 8pl
Lipofectamine and 4pg plasmid DNA (Neuro2A).
Transiently transfected cells were harvested 24 or 48 hours after introduction of the
plasmid DNA.
4.3.2: Reverse-Transcriptase Polymerase Chain Reaction (RT-
PCR)
RT-PCR was performed on tissue culture cells to assess their mRNA content (see
Appendix 2 for primer sequences, product sizes and optimal annealing temperatures).
4.3.2.1: cDNA synthesis
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In order to assess the presence or absence of Pax6 mRNA in tissue culture cells, or to
isolate Pax6 cDNA for cloning, cDNA was synthesised from total RNA using
Superscript reverse transcriptase (Invitrogen) and oligo d(T) primers. Oligo d(T)
primers are complementary to poly(A) stretches found at the 3' end of all mRNAs,
allowing synthesis of a cDNA population representing the entire mRNA population
of a cell line.
cDNA synthesis was performed on 5pl total RNA. RNA was not quantitated prior to
cDNA synthesis, as most RT-PCRs were designed only to measure the presence or
absence of Pax6 mRNA, and in the case of real-time quantitative RT-PCR, a GAPDH
internal standard was used to facilitate quantitation.
4.3.2.2: RT-PCR
To assess the Pax6 mRNA expression status of cell lines, PCR was performed using
Taq DNA polymerase. This allowed fast cDNA amplification, where high fidelity
was not required as the product was not being used in any downstream cloning
applications. Typically, lpl cDNA was used in a 20pl PCR reaction with a 250nM
concentration of each primer, and 200pM of each dNTP.
Colony PCRs were performed on bacterial clones to test for the presence of a cloned
sequence, and assess cloning efficiency. PCRs were performed using Taq DNA
polymerase. The proofreading ability of Pfu polymerase was not required, as the PCR
products were not being used for any downstream applications. PCR reactions were
conducted in 20pl volumes, and a sterile pipette tip was dipped in each bacterial
colony, then in the corresponding PCR reaction. In this way, enough bacterial DNA
was transferred to ensure amplification of target DNA if the transformation reaction
had been successful.
4.3.2.3: Agarose gel electrophoresis
Agarose gel electrophoresis was used to visualise PCR products, and in some cases to
separate target bands for gel extraction and cloning. For PCR products below 600bp,
1.5% agarose gels were used. For larger fragments, 0.8% gels were used. All gels
contained ethidium bromide to allow visualisation of DNA under ultraviolet light.
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Where PCR products were required for downstream cloning applications, gels were
visualised with short exposures to low levels of ultraviolet light, in order to minimise
DNA damage. Bands were excised using sterile scalpel blades to avoid
contamination.
DNA was removed from agarose gel using a gel extraction kit (■Qiagen). This
involved dissolving the agarose in buffer at 55°C, running the solution through a
column to allow binding of DNA, washing away salts and other contaminants, and
eluting the DNA in 50pl ddlTO.
4.3.3: Quantitative RT-PCR (Q-PCR)
Quantitative RT-PCRs were performed using an Opticon DNA engine, to determine
the relative levels of Pax6 mRNA in transiently and stably transfected cells. Separate
primers were specifically designed for use in Q-PCR (see Appendix 2 for primer
sequences, product sizes and optimal annealing temperatures). The optimal product
size is 120bp, and Q-PCR reactions were optimised to proceed without the formation
of primer dimmers or ectopic bands, which would interfere with quantitation.
PCRs were carried out in the presence of SYBR Green (Qiagen), a DNA intercalating
reagent which binds to the minor groove of double-stranded DNA. In solution,
fluorescence by the SYBR Green reagent is minimal. When double-stranded DNA
PCR products are created, SYBR Green can bind, and fluoresces at 495nm.
After 35 PCR cycles, a melting curve of the PCR product was obtained by measuring
the fluorescence emitted at decreasing temperature increments. At high temperatures,
all DNA-DNA duplexes are denatured. SYBR Green cannot bind, therefore
fluorescence falls to baseline levels. As the temperature falls, DNA-DNA duplexes
can form at the optimal annealing temperature of the PCR product, SYBR Green can
bind, and a rise in fluorescence is seen. A plot of fluorescence against temperature
should form a sigmoidal curve. If a smooth sigmoid was seen, this was an indication
that the only double-stranded DNA present in the PCR product was dimerised
product, and no primer dimers or ectopic bands were contaminating the reaction. All
fluorescence was therefore a result of the desired PCR product. Reaction conditions
were optimised until a smooth sigmoidal melting curve was seen after each reaction.
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A calibration standard was created for each primer set by serial dilution of the most
concentrated DNA template. The number of cycles after which the fluorescence of a
reaction rose above baseline was designated as the cycle threshold, c(t). As more
DNA was included in a reaction, the c(t) dropped, and a calibration curve of volume
of DNA against c(t) was plotted. The c(t) of each sample DNA was then plotted onto
this calibration curve, thus allowing relative DNA quantitation across PCR reactions.
4.3.4: Inserting full-length Pax6+5a and Pax6-5a into pCMV-Script
for over-expression analysis
Full-length Pax6+5ci and Pax6-5a were cloned into pCMV-Script {Stratagem) for
use in protein over-expression studies. The pCMV-Script vector contains a multiple
cloning site 3' of the human cytomegalovirus (CMV) immediate early promoter, and
5' of an SV40 polyadenylation site. This allows over-expression of any gene placed
in the correct orientation in the multiple cloning site. The vector also contains a
neomycin-resistance gene which confers resistance to G-418, allowing selection for
stable transfectants.
Full-length Pax6 was removed from pJP1.3 and pJPl.l 1 (see Chapter 3) by digestion
with XJiol and Bam\\\, and inserted into linearised pCMV-Script using T4 DNA
ligase. Ligation products were used to transform chemically-competent TOP-10
E.coli, and colonies were grown overnight at 37°C with kanamycin (50pg.ml"') to
allow only the growth of transformed bacteria. The human and murine Pax6 proteins
are identical in sequence, therefore cDNAs cloned from the U373-MG cell line were
appropriate for over-expression analysis in both human and murine cell lines.
The full length Pax6 insert in both pJP13.1 (pCMV-Pax6+5a) and pJP 14.1 (pCMV-
Pax6-5a) was then sequenced in both directions to confirm that the intended Pax6
sequence was present, and that no mutations had been introduced during the cloning
process. As expected, the same synonymous substitutions were found as in the donor
plasmids pJP1.3 and pJPl.l 1 (see Section 3.3.6). The plasmids pJP13.1 and pJP 14.1
were used for all further over-expression studies, and for the creation of stable cell
lines over-expressing Pax6.
See Figure 4.1 for plasmid maps of pJPl 3.1 and pJP 14.1
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Figure 4.1: pJP13.1 / pJP14.1, full-length Pax6+5a / Pax6-5a in
pCMV-Script. Red arrows: Human Pax6 sequence for
overexpression, and the Kanamycin resistance gene. Blue bars:
Strong viral CMV promoter and SV40 Poly(A) sequences that allow
efficient transcription and post-transcriptional modification of the
insert.
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4.3.5: Inserting 5'-truncated Pax6 into pCMV-Script for over-
expression analysis
pJP15.12 was created to force Pax6 translation initiation from the internal ATG at
amino acid residue 216 of the full-length protein. This ATG is 3' of the stop codon in
the Sey mutation, and a hypothetical Pax6 protein could be made in the Sey/Sey
mouse if translation could initiate here (see Figure 1.3)
Figure 4.2 outlines the cloning strategy used to construct pJP 15.12. The donor
plasmid pJP 14.1 (Fig 4.2, A), containing full-length Pax6-5a in pCMV-Script, was
first cut with BcNI. BcNI cuts within the Pax6 locus, 5' of the ATG from which
translation could initiate in the Sey/Sey mouse, but 3' of all other internal ATGs. In
that way, if translation were seen from this product, it could only have initiated from
the desired start codon. A protein made from this plasmid should be identical in
sequence to the hypothetical protein that could be produced by internal translation
initiation in the Sey/Sey Pax6 gene.
The host vector, pCMV-Script (Fig 4.2, D) had no i?c7VI-compatible restriction
endonuclease sites, therefore the insert needed to be modified before ligation could
take place. All BcN I fragments were treated with T4 DNA polymerase, taking
advantage of the fact that this enzyme possesses 3' exonuclease activity, to cut off the
single base pair 3' overhang created by BcN 1 digestion.
All four modified BcN I digestion products were then subjected to a second
restriction endonuclease digestion with Xho\ (Fig 4.2, B). This cuts only once within
pJP 14.1, immediately 3' of the Pax6 gene, thus cutting the largest BcNI fragment in
two, and producing an 820bp stretch of DNA with a blunt 5' end, and a Xho\-
compatible 3' end (Fig 4.2, C). All other fragments present at this stage had two blunt
ends.
pCMV-Script was then digested with Xho\ and the blunt-cutting enzyme EcoRV,
leaving a blunt DNA end 5' of the desired insertion site, and a A7/oI-compatible end
3' of the insertion site.
A ligation was performed between the four modified BcNI digestion products and

























Figure 4.2: Construction of pJP15.12, 5'-truncated Pax6 in pCMV-
Script. A, pJP14.1 donor plasmid showing in-frame ATGs within
Pax6 (green arrows), and the STOP codon mutation in the Sey
mouse (magenta X). B, ScA/l digestion product. C, 5'-truncated
Pax6. D, pCMV-Script host plasmid. E, pCMV-Script after
linearisation. F, pJP15.12
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between the compatible 5'-truncated Pax6 fragment and the host vector. This ligation
was directional, as the insert could only ligate into the vector in the sense orientation.
Ligation products were used to transform chemically-competent TOP-10 E.coli, and
colonies were grown overnight at 37°C with kanamycin (50pg.mf') to allow only the
growth of transformed bacteria.
The short Pax6 insert in pJP 15.12 was then sequenced in both directions to confirm
that the intended Pax6 sequence was present, and that no mutations had been
introduced during the cloning process. As expected, the same synonymous
substitution was found as in the donor plasmid pJP 14.1. The plasmid pJP 15.12 was
used for all further over-expression studies, and for the creation of stable cell lines
overexpressing 5'-truncated Pax6.
4.3.6: Creating stably transfected lines
Neuro2A and NIH3T3 cells were transfected as described in Section 4.2.1, with
plasmids pJP 13.1 and pJP 14.1. Neuro2A was also transfected with pJP15.12. All
plasmids were linearised with A7?oI to allow integration into the host genome.
Cells were dissociated after 48 hours, and seeded in 10cm Petri dishes at 1:50, 1:100
and 1:200, in order to obtain clonal colonies of cells. Culture media were then
supplemented with G-418 at 500pg.pT1 (NIH3T3) (Roccato et al., 2003; Santos-
Ocampo et al., 1996) or 600pg.pl"1 (Neuro2A) (Goshima et al., 1993; Kojima et al.,
1996).
The active component of G-418, Geneticin, is derived from the antibiotic gentamicin
and is usually toxic to eukaryotic cells. All over-expression plasmids contained the
Neo DNA sequence, driven by the strong SV40 viral promoter. In successfully
transfected cells, transcription of the Neo sequence led to expression of the bacterial
aminoglycoside phosphotransferase 3' (I) gene, conferring G-418 resistance.
Untransfected cells were killed.
Clones were allowed to grow for up to 2 weeks, before being picked with a sterile




Protein extracts from cell lines were immunoblotted for Pax6 to establish endogenous
levels of expression, and to demonstrate and quantitate over-expression in stable cell
lines.
4.3.7.1: Harvesting protein from tissue culture cells
For routine protein extraction, cells were seeded at 1X106 cells.well*1 in 6-well plates,
and collected after 48 hours.
All steps were carried out at 4°C to avoid protein degradation
Cells were washed twice in ice-cold PBS to remove all traces of foetal bovine serum
from the culture medium. Cells were then bathed in lml ice-cold PBS, scraped off
using a sterile, disposable cell scraper, and pelleted. The pellet was then resuspended
in 20-100pl TENT buffer with protease inhibitors. The mixture was homogenised
using a motorised homogeniser and a disposable mini-pestle to break cellular and
nuclear membranes, and left to lyse for 20 minutes. The lysate was then clarified by
centrifugation, and the supernatant was stored at -70°C.
Immunoblotting was carried out as described in Chapter 3.
4.3.8: Immunocytochemistry on tissue culture cells
Immunocytochemistry was performed on fixed monolayers of tissue culture cells to
determine the sub-cellular localisation of both endogenous and over-expressed Pax6
by light- and confocal-microscopic analysis. This technique was also used to analyse
the expression of genes whose expression is thought to be affected by Pax6, in order
to determine the specific effects of Pax6 over-expression in immortalised cell lines.
In addition, immunocytochemistry was performed on fixed, dissociated tissue culture
cells to ascertain the level of heterogeneity of Pax6 over-expression, and as a second
measure of the level of over-expression, alongside immunoblotting.
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Stably transfected cells were seeded at 5X105 cells.weH"1 on glass coverslips in 6-well
plates, or 5X104 cells.weH"1 in 4-well dishes, and fixed after 48 hours. To assess
transient transfections, cells were seeded at 1X105 cells.well"' on glass coverslips in
6-well plates, and transfections were performed 24 hours later.
Cells were fixed 48 hours after transfection, to allow maximal transcription and
translation from the over-expression construct.
Monolayer cells were either fixed in situ for analysis by microscopy, or they were
trypsinised, resuspended in PBS, and fixed as dissociated cells in solution to allow
visualisation by flow cytometry.
All cells were fixed in 4% PFA for 30 minutes at room temperature and
penneabilised in 100% ice-cold methanol for 10 minutes (anti-Pax6 PD) or 0.1%
triton-X-100 (all other primary antibodies). Primary antibody incubations were
carried out at 4°C overnight in blocking buffer. Secondary antibody incubations were
carried out at room temperature for an hour in the dark to avoid bleaching. For
confocal microscopy, cells were counter-stained with TOPR03, a fluorescent nuclear
marker. Pax6-positive cells were visualised by fluorescence using either confocal
microscopy for cells on coverslips or in 4-well plates, or an Epics-XL sorter (Coulter)
for dissociated cells.
4.3.9: cAMP-lnduced differentiation of Neuro2A cells
Neuronal differentiation was induced in the Neuro2A murine neuroblastoma cell line,
both in stably transfected cells and negative, untransfected cells. The aim of this
experiment was to see whether the introduction of Pa\6+5a or Pax6-5a affected their
capacity for neuronal differentiation.
2'-0-dibutyryladenosine 3', 5'-cyclic monophosphate (dbcAMP) was introduced to
cells at a concentration of ImM, and cells were harvested after 72 hours. Cells were
then fixed in 4% PFA, and immunostained for a number of markers of neuronal
differentiation. After counterstaining to visualise unstained cells, all cells were
counted, and the number of differentiated cells was compared across genotypes, both
with and without the addition of dbcAMP.
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4.4: Results: Assessing the suitability of the cell lines H36CE2,
Neuro2A, NIH3T3 and U373-MG for the creation of stable Pax6
transfectants
4.4.1: Morphology
All four cell lines cells grew well in standard tissue culture conditions, although the
human lens cell line, H36CE2, grew more slowly than the other three, and could not
be seeded at below 50% density without detrimental effects. The morphology of each
cell line was as previously described (Figure 4.3), with a certain amount of
heterogeneity in the H36CE2 and Neuro2A cell lines.
4.4.2: Pax6 expression by western blot
Western blot was performed on whole cell extract from each cell line to assess their
Pax6 expression status. The anti-Pax6 HD antibody (see Figure 3.1 for an
explanation of the anti-Pax6 primary antibodies used in this study, and the epitopes
against which they are directed) was used, as it detects all known Pax6 isoforms.
Results of this western blot analysis are shown in Figure 4.4. As described by Turque
et al. (1994) and Okladnova et ah, (1998), the NIH3T3 line does not express Pax6.
The other three cell lines, however, did contain Pax6 protein. Chapter 3 contains a
detailed description of the Pax6 bands observed by western blotting, and the protein
sequence thought to be responsible for each. Full-length Pax6+5a and Pax6-5a
migrate as a 48/46kDa doublet, and their location on each gel is clear from a
comparison with the positive control lanes, which contain in vitro synthesised Pax6-
5a and Pax6+5a. Shorter Pax6 forms are seen in all three cell lines, but are most
abundant in U373-MG.
4.4.3: Pax6 expression by immunocytochemistry
Anti-Pax6 immunocytochemistry was performed on all four cell lines to determine
the subcellular location of Pax6 expression, and whether either location or expression
levels varied between cells (Figure 4.5). NIH3T3 cells are entirely negative, as
supported by western blot data. Neuro2A cells do express Pax6, but at low levels.
Expression appears to be nuclear, and mostly uniform. U373-MG cells contain very
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Figure 4.3 Morphology of untransfected cell lines, as observed
by light microscopy. A, B, NIH3T3: Murine fibroblast cell line.
Cells are homogeneous in size and shape, with a long
cytoplasm that tapers away from the nucleus. C, D, Neuro2A:
Murine neuroblastoma cell line, the majority of cells are
homogeneous in size and shape, most are rounded with little
cytoplasm, and have short dendrite-like processes.
Occasionally larger cell types are observed (arrow). E, F,
U373-MG: Human glioblastoma-derived cell line. Cells are
largely homogeneous in size and shape, and have a thick,
ruffling membrane at one pole. Lamellipodia are also seen
(arrow). G, H, H36CE2: Human immortalised lens cell line.
Cells were highly heterogeneous, often multinucleate, and
spontaneously produced aggregates of lens-like, reflective
material (arrow).
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U373-MG Neuro2A H36CE2 NIH3T3 +ve
B
U373-MG NIH3T3 Neuro2A H36CE2 +ve
Figure 4.4: Pax6 expression in untransfected cell lines, by western
blot. Two independent cell extracts from each line were analysed. A,
B, separate repeats. +ve, in vitro synthesised positive control Pax6+5a
(upper band) and Pax6-5a (lower band). Molecular weight of bands is
indicated, in kDa. See Chapter 3 for further description of the
numerous Pax6 bands. Full-length Pax6+5a and Pax6-5a are present
in three of the four cell lines, with the highest concentration seen in the
human lens line, H36CE2. Lower molecular weight Pax6 bands are
seen in all three Pax6-positive lines, but are most abundant in the
human glioblastoma cell line, U373-MG.
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Figure 4.5 Anti-Pax6 immunocytochemistry on untransfected cell
lines. A, NIH3T3 TOPRO-3 nuclear counterstain. B, NIH3T3 anti-
Pax6 immuno, showing no detectable Pax6 (Pax6 signal would be
green). C, Neuro2A TOPRO-3 nuclear counterstain. D, Neuro2A
anti-Pax6 immuno, showing low-level Pax6 expression throughout
all cells (Pax6 signal is green). E, U373-MG transmitted light image.
F, U373-MG anti-Pax6 immuno, showing Pax6 signal just at the
limits of detection (Pax6 signal is green). G, H36CE2 TOPRO-3
nuclear counterstain. H, H36CE2 anti-Pax6 immuno, variable, but


















low levels of Pax6, at the limits of detection by immunocytochemistry. This is in
contrast with western blot data, which shows reasonably high Pax6 expression in
comparison with Neuro2A and H36CE2 protein extracts. This discrepancy may be
due to the different primary antibodies used for the two techniques. For western blot,
the anti-Pax6 FID antibody was used. This picks up a number of bands, and it is clear
that a shorter form of Pax6 (~42/43kDa) is the most abundant in U373-MG cells. For
immunocytochemistry, anti-Pax6 PD primary antibody was used. It is possible that
the 42/43kDa band represents a "paired-less" form of Pax6, not recognised by this
primary antibody. If that were the case, a weak signal might be expected from the low
levels of full-length Pax6 present in the U373-MG cell line. The highest levels of
Pax6 expression are seen in the H3CE2 cell line. As expected of a transcription
factor, signal is largely nuclear. There is greater heterogeneity of Pax6 expression
levels in this cell line, consistent with the greater heterogeneity of cell types.
4.4.4: Transfection efficiency
All four cell lines were transiently transfected with pEGFPNl in order to qualitatively
assess their transfection efficiency. Figure 4.6 allows comparison of transfection
efficiencies between the three cell lines. Transient transfections are most efficient in
the Neuro2A line. A high percentage of cells are transfected, and EGFP expression is
stronger than in the other three lines. The U373-MG line was also transfected with
high efficiency on some occasions, as seen in Fig 4.6, but this was less repeatable.
The NIH3T3 cell line consistently took in EGFP with a reasonably high efficiency,
but protein expression is lower than seen in the other two lines. H36CE2 is the cell
line least amenable to transfection, probably due to the heterogeneity of cell type,
making it difficult to optimise conditions. Although some cells are seen to express
high levels of EGFP, most are either untransfected, or only appear to express low
levels of EGFP.
4.4.5: Selecting two cell lines for further study
On the basis of the above data, two cell lines were selected for further study, and to
make stable clones with the Pax6+5a, Pax6-5a and 5'-truncated Pax6 over-
expression plasmids, pJP 13.1, pJP 14.1 and pJP 15.12.
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Figure 4.6 Cell lines after transient transfection with pEGFPNI. A,
NIH3T3. B, Neuro2A. C, U373-MG. D, H36CE2
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Neuro2A was chosen as it is easy to culture, grows rapidly, allows a high transfection
efficiency, and endogenously expresses moderate levels of Pax6. NIH3T3 was chosen
as it is easy to culture, grows rapidly, allows a reasonable transfection efficiency, and
does not express endogenous Pax6.
These two cell lines also complement each other well as both are murine in origin;
therefore species-specific differences could not interfere with the interpretation of a
Pax6 over-expression phenotype.
The U373-MG cell line was excluded at this stage, because of its unreliable
transfection efficiency.
The H36CE2 cell line was also excluded at this stage, because there were difficulties
in culturing these cells. As their growth appears to be contact dependent, assays
involving seeding at a low cell density and studying cell growth would be difficult to
conduct.
4.5: Results: Transient over-expression of Pax6+5a and Pax6-5a in
Neuro2A and NIH3T3 cells
Before making stable cell lines, Pax6 expression vectors were transiently transfected
into NIH3T3 and Neuro2A cells. This was done to verify that Pax6 over-expression
was indeed possible from the plasmids pJP 13.1 and pJP 14.1.
4.5.1: Quantitative RT-PCR (Q-PCR) analysis of Pax6 over-
expression in transiently transfected cells
The ability of the two plasmids to act as expression vectors was first assessed by Q-
PCR. Figure 4.7 and Figure 4.8 show the results of PCR with primers specific to
either Pax6+5ci or Pax6-5a, after transfection with pJP 13.1 (Pax6+5a) or pJP 14.1
(Pax6-5a). All results are normalised to Pax6 levels in the cell line with the lowest
expression levels.
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A) Pax6+5a levels in transfected and
untransfected NIH3T3 cells
Cells Pax6+5a mRNA
NIH3T3 + Pax6-5a 1.00
NIH3T3 + Pax6-5a 9.83
NIH3T3 + Pax6+5a 3230
NIH3T3 + Pax6+5a 13600
NIH3T3 5.17
NIH3T3 1.49
B) Pax6-5a levels in transfected and
untransfected NIH3T3 cells
Cells Pax6-5a mRNA
NIH3T3 + Pax6-5a 387
NIH3T3 + Pax6-5a 1420
NIH3T3 + Pax6+5a 1.67
NIH3T3 + Pax6+5a 25.7
NIH3T3 28.4
NIH3T3 1.00
Figure 4.7: Q-PCR analysis of Pax6 overexpression in transiently
transfected NIH3T3 cells. A, Pax6+5a levels in NIH3T3. B, Pax6-5a
levels in NIH3T3. RNA was collected from two separate
transfections for each permutation. RNA levels that would be
expected to rise are highlighted. All Pax6 mRNA levels are
normalised to the lowest level, given an arbitrary value of 1 (All
values expressed to 3 s.f.).
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A) Pax6+5a levels in transfected and
untransfected Neuro2A cells
Cells Pax6+5a mRNA
Neuro2A + Pax6-5a 1.27
Neuro2A + Pax6-5a 1.10
Neuro2A + Pax6+5a 85.4
Neuro2A + Pax6+5a 159
Neuro2A 0.961
Neuro2A 1.04
B) Pax6-5a levels in transfected and
untransfected Neuro2A cells
Cells Pax6-5a mRNA
Neuro2A + Pax6-5a 17.2
Neuro2A + Pax6-5a 15.1
Neuro2A + Pax6+5a 0.778
Neuro2A + Pax6+5a 1.47
Neuro2A 0.780
Neuro2A 1.22
Figure 4.8: Q-PCR analysis of Pax6 overexpression in transiently
transfected Neuro2A cells. A, Pax6+5a levels in Neuro2A. B, Pax6-
5a levels in Neuro2A. RNA was collected from two separate
transfections for each permutation. RNA levels that would be
expected to rise are highlighted. All Pax6 mRNA levels are
expressed as a proportion of untransfected Neuro2A levels (All
values expressed to 3 s.f.).
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Transfection efficiencies varied between runs, and these results are taken from just
one run, but the effects of Pax6 over-expression were clear. The introduced Pax6
cDNA was upregulated by approximately 100-fold (Pax6+5a) or 16-fold (Pax6-5a)
in the Neuro2A cell line. The N1H3T3 cell line also demonstrated marked up-
regulation of the introduced transcript. Although this cell line does not express Pax6
protein, low levels of Pax6 mRNA were occasionally observed by RT-PCR.
Introduction of a Pax6 over-expression construct caused a dramatic up-regulation in
this mRNA level, by up to 13,000-fold.
Due to the different PGR kinetics of the two reactions, comparisons could not be
drawn between Pax6-5a and Pax6+5a levels, even within the same sample. It was
consistently seen, however, that Pax6+5a up-regulation was more dramatic than
Pax6-5a up-regulation in both cell types.
These results prove that the Pax6 expression vectors pJP13.1 and pJPl4.1 were
capable of inducing Pax6 mRNA over-expression in transfected cells.
4.5.2: Immunocytochemical analysis of Pax6 over-expression in
transiently transfected Neuro2A cells
Transient transfections were performed to introduce pJP 13.1 (Pax6+5a), pJP14.1
(Pax6-5a) and pJP 15.12 (5'-truncated Pax6) into both the NIH3T3 and the Neuro2A
cell lines. Over-expression was then analysed by immunocytochemistry, to ensure
that a Pax6 protein product was indeed over-expressed in transfected cells, to get an
idea of levels of over-expression within a successfully transfected cell, and to look at
sub-cellular localisation of Pax6.
Untransfected NIH3T3 cells have no detectable Pax6 protein (Figure 4.5).
Introduction of all three constructs leads to a high level of Pax6 expression in a few
successfully transfected cells. The level of Pax6 expression seems high, as a
comparison between Figure 4.9 B, C, D and Figure 4.9 E demonstrates.
Untransfected Neuro2A cells express some Pax6, but signal is much weaker than in
transfected NIH3T3 cells. Signal is mostly nuclear, which is consistent with the role
of Pax6 as a transcription factor, but some cytoplasmic staining is observed.
Interestingly, signal is observed in cells transfected with pJP 15.12 (5'-truncated
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Figure 4.9 Anti-Pax6 immunocytochemistry on cell lines
transiently transfected with pJP13.1 (Pax6+5a), pJP14.1 (Pax6-
5a), and pJP15.12 (5'-truncated Pax6). Blue, TOPRO-3 nuclear
counterstain. Green, anti-Pax6 PD immunocytochemistry. A,
NIH3T3 untransfected. B, NIH3T3 + Pax6+5a. C, NIH3T3 +
Pax6-5a. D, NIH3T3 + 5'-truncated Pax6. E, Neuro2A
untransfected. F, Neuro2A + Pax6+5a. G, Neuro2A + Pax6-5a.






Pax6; Figure 4.9 D, H). The primary antibody used for immunocytochemistry is
directed against the Pax6 paired domain, but the protein product from pJP 15.12 is a
pairedless form, with translation initiating just 5' of the homeodomain. Therefore,
any Pax6 signal seen in over-expressing cells must be a result of N-terminally
truncated Pax6 acting to up-regulate full-length Pax6 from the endogenous genomic
locus. This was later verified in stable cell lines (see Section 4.6.2).
Although levels are low, Pax6 signal is observed in untransfected Neuro2A cells, as
was also seen in Figure 4.5. Introduction of all three constructs leads to a high level
of Pax6 expression in a few successfully transfected cells. Signal is again largely
nuclear, but some cytoplasmic staining is seen. Fig 4.9 G shows Pax6 labelling in a
cellular process, which was observed on a number of occasions. Again, as with the
NIH3T3 cell line, introduction of pJP15.12 into Neuro2A cells leads to an up-
regulation of endogenous, full-length Pax6.
4.5.3: Western blot analysis of Pax6 over-expression in transiently
transfected Neuro2A cells
Transient transfections were also performed to introduce pJP 13.1 and pJP 14.1 into
the Neuro2A cell line, followed by western blot analysis (Figure 4.10). This was
done to ascertain that Pax6 protein was over-expressed, to get an idea of levels of
over-expression within a population of successfully and unsuccessfully transfected
cells, and to check that the correct isoform was being expressed, i.e. Pax6+5a from
pJP 13.1, and Pax6-5a from pJP14.1.
Untransfected Neuro2A cells can be seen to express both splice variants, at a low
level. Cells transfected with Pax6-5a express higher levels of Pax6-5a, as would be
expected; however they no longer appear to express Pax6+5a, indicating that the
addition of Pax6-5a might lead to the down-regulation of the other isoform. Cells
transfected with Pax6+5a express higher levels of both splice variants than
untransfected cells. This is likely to be due to Pax6+5a up-regulating the cell's
endogenous Pax6-5a. It is not possible to ascertain whether the raised Pax6+5a levels
in this case are entirely due to expression of the introduced plasmid, or whether some
of the increase in signal is due to an increase in Pax6+5a expression from the
endogenous genomic locus.
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Figure 4.10: western blot analysis of Pax6 overexpression in
transiently transfected Neuro2A cells. L, molecular weight ladder.
+ve, in vitro synthesised control Pax6+5a and Pax6-5a.
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4.6: Results: Stable over-expression of Pax6+5a, Pax6-5a and 5'-
truncated Pax6 in Neuro2A and NIH3T3 cells
Although the introduction of Pax6 expression vectors leads to a more complicated
Pax6 expression pattern than had been anticipated, it is clear from the above results
that the plasmid vectors pJP 13.1 and pJP 14.1 are capable of causing over-expression
of Pax6, in both Neuro2A and NIH3T3 cells. For this reason, stable cell lines were
made with both plasmids, in both cell lines.
In addition, the plasmid pJP15.12 was introduced into the Neuro2A cell line. The
only protein product that could be made from the pJP 15.12 plasmid was an N-
terminally truncated Pax6, thought to be responsible for the 32kDa band observed in
western blot analysis of Sey/Sey mouse brain (see Chapter 3 for more details). If a
phenotype was seen in this cell line, it was indicative that N-terminally truncated
Pax6 could be contributing to the phenotype of Sey/Sey mice.
The plasmid pEGFPNl was also introduced into both cell lines, and stable clones
were obtained. This was done for two reasons. During the creation of stable cell lines,
it allowed a measure of transfection efficiency in live cells, by microscopic
visualisation of EGFP signal. After the creation of cell lines, the pEGFPNl positive
lines were used as experimental controls. They were proof that any phenotype seen in
stable Pax6 over-expressing cell lines was indeed due to the presence of extra copies
of Pax6, rather than the process of creating a stable, G-418 resistant cell line.
A number of cell lines were created from the insertion of each vector into each
parental cell line. Up to 30 clones were screened from each, and the two clones that
displayed the highest levels of Pax6 over-expression as assayed by a number of
techniques (see below), were chosen for further study.
These cell lines were:
NIH3T3 + pJP13.1 (Pax6+5a) clones L and O
NIH3T3 + pJP14.1 (Pax6-5a) clones O and Q
NIH3T3 + pEGFPNl clones A and B
Neuro2A + pJP 13.1 clones H and Q
Neuro2A + pJP14.1 clones G and AD
Neuro2A + pJP15.12 (5'-truncated Pax6) clones A and E
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Neuro2A + pEGFPNl clones C and E
4.6.1: Confirmation of Pax6 over-expression in stable cell lines by
Q-PCR
Q-PCR was used to confirm over-expression of mRNA from the introduced cDNA in
each cell line.
Adding Pax6+5a to the Neuro2A cell line leads to lip-regulation between
approximately 3- and 13-fold untransfected levels (Figure 4.11 B). The addition of
Pax6-5a, however, has less of an effect on Pax6-5a mRNA levels, although they rise
1.3- and 1.4-fold in the two cell lines chosen (Figure 4.11 A).
There is no endogenous Pax6 expression in the N1H3T3 cell line, but levels were
normalised to the level of transcript in the cell line with the lowest level of Pax6
expression, to create a reference point. NIH3T3 cells stably transfected with both
Pax6-5a and Pax6+5a express the mRNA at between 2- and 9.5-fold untransfected
Neuro2A levels (Figure 4.11 A, B). Expression levels vary between cell lines,
probably due to position effects of vector integration into the host genome.
4.6.2: Confirmation of Pax6 over-expression in stable cell lines by
western blot
In order to confirm that the increased levels of Pax6 mRNA were accompanied by an
increase in Pax6 protein levels, western blot analysis was performed on cell extracts
from each cell line.
Pax6 protein over-expression is clear in the Neuro2A cell lines (Figure 4.12).
Introduction of a Pax6+5a expression vector leads to between 20-and 40-fold over-
expression of Pax6+5a. The addition of a Pax6-5a expression vector leads to much
higher over-expression of Pax6-5a, from approximately 50- to 100-fold. The two cell
lines transfected with the Pax6-5a vector did not show a great increase in Pax6-5a
mRNA (Figure 4.11), but show a large increase in Pax6-5a protein (Figure 4.12).
This is an indication that the level of Pax6-5a transcript is being tightly regulated in
these cells, and that translation may be occurring with a higher efficiency from the
ectopic transcript than from the endogenous genomic locus.
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A) Pax6-5a mRNA in stable cell lines containing a Pax6-5a
expression construct
Cell line Pax6-5a mRNA
Neuro2A negative 1.00
NIH3T3 + Pax6-5a clone L 3.55
NIH3T3 + Pax6-5a clone 0 1.00
Neuro2A + Pax6-5a clone G 1.43
Neuro2A + Pax6-5a clone AD 1.29
B) Pax6+5a mRNA in stable cell lines containing a Pax6+5a
expression construct
Cell line Pax6+5a mRNA
Neuro2A negative 1.00
NIH3T3 + Pax6+5a clone 0 1.73
NIH3T3 + Pax6+5a clone Q 1.00
Neuro2A + Pax6+5a clone H 13.1
Neuro2A + Pax6+5a clone Q 2.70
Figure 4.11: Overexpression of introduced Pax6 in stable cell
lines, as determined by Q-PCR. All Neuro2A values are presented
as a proportion of Pax6 levels in untransfected Neuro2A cells,
assigned an arbitrary value of 1. All NIH3T3 values are presented
as a proportion of Pax6 levels in the cell line with lowest
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Figure 4.12 Expression of introduced Pax6 in stable Neuro2A cell
lines, as determined by western blot. Values are expressed as a
proportion of Pax6 levels in untransfected Neuro2A cells.
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As the NIH3T3 cell line does not express Pax6, and was analysed in separate western
blots to the Neuro2A cell line, there is no reference level of Pax6 with which to
normalise data from this cell line. Values were therefore expressed as optical density
of the appropriate band on photographic film (OD). Although this is an arbitrary
measure, all four NIH3T3 cell lines containing Pax6 expression vectors do produce
Pax6 protein (Figure 4.13), and at varying levels, as was seen by Q-PCR.
4.6.3: The effect of Pax6 over-expression on the endogenous Pax6
locus
Although the Pax6 expression vectors contain human Pax6, and were introduced into
murine cell lines, it is not possible to distinguish the two isoforms from the
introduced Pax6 mRNA or protein from that which originated from the endogenous
locus. At the protein level, the two sequences are identical. There are differences at
the mRNA level, but the primers used for Q-PCR are not in a position that can
distinguish between the murine and human forms. This is because the 3'end of each
primer must span an exon boundary, therefore they are restricted in position to a
sequence that is conserved across the two species (see Appendix 2 Figure A2.1 for a
detailed description of Q-PCR primers).
The autoregulation of Pax6 is well documented (Okladnova et al., 1998; Plaza et al.,
1993; Plaza et al., 1995). This is likely to affect the Pax6 content of a cell transfected
with a Pax6 expression vector, and regulatory mechanisms have been hinted at by the
previous mRNA and protein data (sections 4.5.1 and 4.5.2). Therefore, similar
experiments were performed to assess the levels of the Pax6 splice form that had not
been introduced into cell lines, i.e. the levels of Pax6-5a were determined in cell lines
which had been stably transfected with Pax6+5a, and vice versa. Any mRNA or
protein measured in these experiments must have been produced from the
endogenous genomic locus, and is evidence for Pax6 autoregulation.
Q-PCR demonstrates that the introduction of one isoform of Pax6 into the NIH3T3
cell line does indeed lead to the up-regulation of mRNA corresponding to the other
isoform (Figure 4.14 A). Although Pax6-5a levels are near to or below 1 in NIH3T3
cell lines with a Pax6+5a expression construct, these data are normalised to Pax6
expression in the cell line with the lowest expression level. The NIH3T3 cell line has
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Pax6+5a in stable NIH3T3 cell lines
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Figure 4.13 Expression of introduced Pax6 in stable NIH3T3 cell
lines, as determined by western blot. Values cannot be normalised to
untransfected cells, as these do not express endogenous Pax6.
Instead, values are expressed as optical density (OD X 103), an
arbitrary measure of the signal strength of a band.
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A) Pax6+5a mRNA in stable cell lines containing a Pax6-5a
expression construct
Cell line Pax6+5a mRNA
Neuro2A negative 1.00
NIH3T3 + Pax6-5a clone L 2.05
NIH3T3 + Pax6-5a clone 0 1.00
Neuro2A + Pax6-5a clone G 1.44
Neuro2A + Pax6-5a clone AD 1.39
B) Pax6-5a mRNA in stable cell lines containing a Pax6+5a
expression construct
Cell line Pax6-5a mRNA
Neuro2A negative 1.00
NIH3T3 + Pax6+5a clone O 2.01
NIH3T3 + Pax6+5a clone Q 1.00
Neuro2A + Pax6+5a clone H 17.3
Neuro2A + Pax6+5a clone Q 1.39
Figure 4.14: Overexpression of endogenous Pax6 in stable cell lines,
as determined by Q-PCR. All values are presented as a proportion of
Pax6 levels in untransfected Neuro2A cells, assigned an arbitrary
value of 1. All NIH3T3 values are presented as a proportion of Pax6
levels in the cell line with lowest expression, given an arbitrary value of
1 (all values expressed to 3 s.f.).
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no endogenous Pax6 mRNA, thus any mRNA indicates up-regulation from the
endogenous locus.
In the Neuro2A cell line, the results are slightly more complicated (Figure 4.14 A,
B). Pax6 mRNA levels from the endogenous locus are all above 1, but only Neuro2A
+ Pax6+5a clone H shows a large increase in levels when compared to untransfected
cells (approximately 17-fold). However, this result is largely consistent with that
described in section 4.5.1; often the Pax6 mRNA levels are not raised, despite an
increase in protein levels.
Western blot analysis was performed to detect any protein expression from these
transcripts. These data clearly indicate that in both cell lines, there was a large
increase in Pax6 protein levels from the endogenous locus (Figures 4.15 and 4.16).
4.6.4: Total Pax6 protein levels in stable cell lines
Figure 4.17 shows the combined western blot data from each cell line, giving an
indication of the total Pax6 content of each line. All transfected NIH3T3 and
Neuro2A cell lines express much more Pax6 protein than untransfected cells.
Variations in levels of expression between clones are probably due to position effects
and variation in the number of copies of plasmid that were integrated into the
genome. NIH3T3 + pJP13.1 clone Q expresses the highest amount of Pax6, and
NIH3T3 + pJPM.l clone O expresses the lowest amount. For the Neuro2A cell line,
Neuro2A + pJP13.1 clone H expresses the highest amount of Pax6, whilst Neuro2A +
pjP13.1 clone Q expresses the lowest amount, although this is still in great excess
when compared to untransfected cells.
The introduction of a Pax6 expression construct into Neuro2A cell lines also leads to
the up-regulation of a shorter Pax6 isoform, the 32/33kDa band described in Chapter
3.
The ratio of Pax6-5a : Pax6+5a varies between cell lines (Figure 4.18 ), from 1.5:1 to
4:1 in NIH3T3 lines, and from 1:1 to 6:1 in Neuro2a cell lines. This is within the
range of ratios described in vivo (see Figure 3.22).
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Pax6-5a in stable NIH3T3 cell lines
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Figure 4.15 Expression of endogenous Pax6 in stable Neuro2A cell
lines, as determined by western blot. Values cannot be normalised to
untransfected cells, as these do not express endogenous Pax6.
Instead, values are expressed as optical density (OD), an arbitrary
measure of the signal strength of a band.
173
Pax6+5a in stable Neuro2A cell lines
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Figure 4.16 Expression of endogenous Pax6 in stable Neuro2A cell
lines, as determined by western blot. Values are expressed as a
proportion of Pax6 levels in untransfected Neuro2A cells.
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Figure 4.17: Combined Pax6 protein levels in A, NIH3T3 (n=1) and
B, Neuro2A (n=2, except 15.12, where n=1) cell lines after stable
transfection with pJP13.1 (Pax6+5a), pJP14.1 (Pax6-5a) and
pJP15.12 (5'-truncated Pax6). Error bars represent SEM. 5'-tr.
Pax6 = 5'-truncated Pax6 NB All values in B are normalised to
levels of Pax6-5a in untransfected cells. This value is only 0.15 for
Pax6+5a protein in untransfected cells, therefore the values for
Pax6+5a in other cell lines do not represent fold over-expression of

















































































□ Pax6+5a 24.55 17.34 12.52 19.63 7.33 35.36 0.15
□ Pax6-5a 148.46 18.20 53.76 116.50 45.95 145.93 1.00
□ Pax6 33KDa 5.81 0.31 3.94 3.53 2.64 0.00 0.00
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Figure 4.18: Pax6-5a : Pax6+5a ratio in A, NIH3T3 (n=1) and B,
Neuro2A (n=2, except 15.12, where n=1) cell lines after stable
transfection with pJP13.1 (Pax6+5a), pJP14.1 (Pax6-5a) and
pJP15.12 (5'-truncated Pax6). Neg, untransfected Neuro2A. Error
bars represent SEM.
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Confirming the result seen by immunocytochemistry on transiently transfected cells
(Figure 4.9), the addition of 5'-truncated Pax6 leads to the up-regulation of both
isoforms of full-length Pax6 (Figure 4.17 B, Figure 4.18B). This may have
implications for the function of the 32kDa band observed by western blot in El2.5
mouse brain and eye, which will be discussed further in Section 4.8.4.
4.6.5: Confirmation of Pax6 over-expression in stable cell lines by
immunocytochemistry and flow cytometry
Cell lines were also analysed by immunocytochemistry on dissociated cells using the
anti-Pax6 PD antibody, to confirm Pax6 over-expression, and to ascertain whether
levels were raised in a few cells, or all cells.
For the NIH3T3 cell lines, clear differences were seen between untransfected and
transfected cell lines (Figure 4.19). A histogram showing FL1 fluorescence value
against cell number was plotted for each genotype. A gate was drawn on the
untransfected histogram, gating the 1% of cells with the highest fluorescence values.
An increase in Pax6 signal is indicated by either an increase in the percentage of
gated cells (more cells expressing high levels of Pax6), or by a shift in the mean FL1
value of the histogram (each cell expressing slightly more Pax6). Measured either
way, the increase in Pax6 immunofluorescence is greatest in cell lines containing the
Pax6-5a over-expressing construct, pJP 14.1.
Flow cytometry proved a less reliable technique for the analysis of Pax6 over-
expression in the Neuro2A cell line. Results seem to indicate that no Neuro2A cell
lines had been created which over-expressed Pax6 (Figures 4.20 and 4.21). Analysis
by western blot had proved this to be untrue (see sections 4.5.2 and 4.5.3), but
immunocytochemistry was unable to detect Pax6 over-expression in stable Neuro2A
cell lines.
One possible explanation for the observed discrepancy in results between
immunocytochemistry and western blot lies in practical differences between the two
techniques. Immunocytochemistry is a non-denaturing protocol, detecting proteins in
their native form within the cell. Western blot, on the other hand, is a denaturing
protocol; proteins were denatured to allow their resolution by SDS-PAGE. As the
untransfected Neuro2A cell line normally expresses Pax6, other proteins with which
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Figure 4.19 Flow cytometric immunocytochemical analysis of
Pax6 expression in stable NIH3T3 cell lines. A, untransfected
cells. B, no primary control reaction performed on untransfected
cells. C, Stably transfected with pJP13.1 (Pax6+5a), clone O. D,
Stably transfected with pJP14.1 (Pax6-5a), clone L. E, Stably
transfected with pJP13.1, clone Q. F, Stably transfected with
pJP14.1, clone O. Pax6 signal was detected in the FL1 channel,
mean FL1 value is indicated below each histogram.
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Figure 4.20 Flow cytometric immunocytochemical analysis of Pax6
expression in stable Neuro2A cell lines. A, untransfected cells. B,
Stably transfected with pJP13.1 (Pax6+5a), clone H. C, no primary
control reaction performed on untransfected cells. D, Stably
transfected with pJP13.1, clone Q. Pax6 signal was detected in the
FL1 channel, mean FL1 value is indicated below each histogram.
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A Neuro2A + pJP14.1 Clone G B Neuro2A + pJP15.12 Clone A
Mean FL1 value = 3.33 FL1 = 2.31
C Neuro2A + pJP14.1 Clone AD D Neuro2A + pJP15.12 Clone E
Figure 4.21 Flow cytometric immunocytochemical analysis of Pax6
expression in stable Neuro2A cell lines. A, Stable transfected with
pJP14.1 (Pax6-5a) Clone G B, Stably transfected with pJP15.12
(5'-truncated Pax6) Clone A. C, Stably transfected with pJP14.1
Clone AD. D, Stably transfected with pJP15.12, clone E. Pax6
signal was detected in the FL1 channel, mean FL1 value is
indicated below each histogram.
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Pax6 can interact may also be present. In its native state, Pax6 may be complexed
with these other proteins, and unrecognisable to the primary antibody. Denaturation
would break up these complexes, allowing the primary antibody to recognise its
epitope.
In accordance with this hypothesis, immunocytochemistry is capable of detecting
over-expressed Pax6 in NIH3T3 cells (Figure 4.19). NIH3T3 cells do not express
endogenous Pax6, and therefore might not be expected to express proteins which
interact with Pax6.
These results demonstrate that the introduction of both major Pax6 splice variants
into either cell line did not lead to the intended model system, the production of
clonal cell lines that expressed either one isoform or the other. However, it did result
in a number of cell lines with a spectrum of Pax6 expression levels, and a spectrum of
Pax6-5a : Pax6+5a ratios. Also, one set of cell lines demonstrates the effects of
introducing Pax6 into otherwise non-expressing cells, and the other set demonstrates
the effects of Pax6 over-expression.
This combination of factors makes the cell lines described above a useful model
system for studying the roles of Pax6 at the cellular level.
4.7: Results: The effect of Pax6 over-expression on the neuronal
differentiation of Neuro2A cells
When treated with 2'-0-dibutyryladenosine 3', 5'-cyclic monophosphate (dbcAMP),
Neuro2A cells have been shown to differentiate along the neuronal lineage (Prasad
and Hsie, 1971; Shea et al., 1988). They form axon-like, monopolar or bipolar
processes, spanning many cell diameters (Fischer et ah, 1986). Maximal
differentiation is seen 72 hours after dbcAMP addition (Shea and Beermann, 1994).
4.7.1: Total cell number in differentiated Neuro2A cell lines
Prior to the induction of neuronal differentiation by dbcAMP, cells of all genotypes
were seeded at the same density, 2.5Xl04cells.cm"2. Throughout these analyses, Pax6
over-expressing cells seemed to exist at a lower density after 72 hours than
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untransfected cells. This observation was made in both differentiated and
undifferentiated cell lines.
Comparative cell counts were made 72 hours after seeding, both with and without the
addition of dbcAMP after 24 hours (Figure 4.22), and at 96 hours with the addition
of dbcAMP. After 72 hours, there are a higher number of untransfected cells per field
of view than Pax6 over-expressing cells. This difference is statistically significant in
all over-expressing cell lines without the addition of dbcAMP, and all but one after
dbcAMP addition. By 96 hours, all dbcAMP treated Pax6 over-expressing cell lines
have reached significantly lower numbers than untransfected cells. Total cell number
increases between the two stages, indicating that cells are still proliferating in all
cases, but the rate of proliferation has dropped in Pax6 over-expressing cell lines.
EGFPN1 over-expressing cells behave as untransfected cells, indicating that the
decrease in cell numbers is due to Pax6 over-expression rather than the process of
transgene addition.
Undifferentiated Neuro2A cells have properties of neuronal precursor cells (Fischer
et al., 1986). After the addition of dbcAMP, cell number is lower in Pax6 over-
expressing cells than in WT cells. The decrease in proliferation is likely to be the
result of increased differentiation, as cells exit the cell cycle. In the experiments
described here, differentiation is induced either by Pax6 over-expression, by the
addition of dbcAMP, or both.
According to this hypothesis, the drop in the rate of proliferation after neuronal
differentiation is not due to a slowing of the cell cycle, but to an increased number of
cells exiting the cell cycle and becoming post-mitotic.
4.7.2: p-3-tubulin expression in undifferentiated and differentiated
Neuro2A cell lines
Anti-P-3-tubulin immunocytochemistry was used to visualise both undifferentiated
(Figure 4.23) and differentiated (Figure 4.24) cells. The majority of cells of all
genotypes are p-3-tubulin positive, both before and after the addition of dbcAMP; this
indicates that even untreated Neuro2A cells are partially differentiated along the
neuronal lineage. As anti-P-3-tubulin antibody labels both cell bodies and processes,
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Figure 4.22: Cells per field of view after seeding 5X104 cells.well"1
onto 4-well dishes, A, 72hrs, untreated and treated with 1mM dbcAMP
after 24 hours. B, 96hrs, all dbcAMP treated. Error bars represent
SEM.Below bars, f-test vs. untransfected cells * P<0.05, ** P<0.01, ***
P<0.001. ns, not significant. Above bars, f-test without vs. with
dbcAMP treatment.
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Figure 4.23 p-3-Tubulin expression in untransfected and
Pax6-overexpressing cells before treatment with dbcAMP. A,
untransfected cells. B, Neuro2A + pJP13.1 (Pax6+5a) clone
H, note the increased number of dendrites. C, Neuro2A +
pJP14.1 (Pax6-5a) clone G. D, Neuro2A + pEGFPNI. E,





















Figure 4.24 p-3-Tubulin expression in untransfected and Pax6-
overexpressing cells after treatment with dbcAMP. A,
untransfected cells. B, Neuro2A + pJP13.1 (Pax6+5a) clone H,
note the high frequency of larger cell types with increased
dendritogenesis (arrowhead) and smaller cells with long, axon-like
processes (arrow). C, Neuro2A + pJP14.1 (Pax6-5a) clone G. D,
Neuro2A + pEGFPNI. E, Neuro2A + pJP13.1 clone Q. F,










A comparison between untransfected cells before and after dbcAMP treatment
(compare Figure 4.23 A with Figure 4.24 A) shows an increase in the number of
larger cell types, and axon-like processes after dbcAMP treatment, as described by
Fischer et al. (1986). This increase is most profound in Neuro2A + Pax6+5a clone H,
the cell line with highest overall levels of Pax6 expression, and whilst most obvious
in treated cells (Figure 4.24 B), it is also apparent without addition of dbcAMP
(Figure 4.23 B). All Pax6 over-expressing cell lines exhibit this phenotype, whilst
EGFP over-expressing cells behave more like untransfected cells.
Pax6 over-expressing cells from the cell line Neuro2A + Pax6+5a clone H show two
obvious phenotypes. Many differentiated cells behave in a similar way to the
untransfected population, growing bi-polar processes that resemble the "axon-like"
phenotype described by Fischer et al., (1996) (arrow in Figure 4.24 B). In addition to
this, cells are often seen with a large number of processes (arrowhead in Figure 4.24
B), more closely resembling the "dendrite-iike" cells seen in the same study after
retinoic acid-mediated differentiation. Other Pax6 over-expressing cell lines also
appear to grow more processes than untransfected cells, although the effect is less
profound. Control cells which over-express EGFP, and untransfected cells also
change in morphology after dbcAMP treatment, most notably more large cells are
seen, but the increase in the number of processes is less dramatic than in Pax6 over-
expressing cells (Figure 4.24 D). In this respect, there appears to be a correlation
between Pax6 expression levels, and the number of cells exhibiting altered
morphology after dbcAMP treatment.
Although the majority of cells of all genotypes express P-3-tubulin, some cells (2 to
18%) do not (see Figure 4.25). This is characteristic of a heterogeneous cell
population, in which cells are at various stages of neuronal differentiation. The least
differentiated cells do not express P-3-tubulin. If Pax6 over-expression does indeed
promote neuronal differentiation, as indicated by the altered morphology of Pax6
over-expressing cells, a higher percentage of the Pax6 over-expressing cell
populations would be expected to express P-3-tubulin.
To test this hypothesis, the number of P-3-tubulin positive cells, expressed as a
percentage of total cell number, was compared across genotypes (Figure 4.25).
Before dbcAMP treatment, all Pax6 over-expressing cell lines have significantly
more P-3-tubulin positive cells than the untransfected cell line, whilst the EGFPN1
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Figure 4.25: Percentage of p-3-tubulin positive cells A, before and B,
after dbcAMP treatment of untransfected and Pax6 over-expressing
Neuro2A cell lines. Error bars represent SEM. Mest vs. untransfected
cells * P<0.05, ** P<0.01, *** P<0.001
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pronounced; only two cell lines show significantly more P-3-tubulin positive cells.
These are the cell lines with the highest, and the third highest level of Pax6
expression, implying that the more Pax6 protein is present in the cell line, the more p-
3-tubulin positive cells are produced.
According to this analysis, Pax6 over-expression in the Neuro2A cell line leads to
neuronal differentiation. The difference is most pronounced in untreated cells, and the
addition of dbcAMP seems to mask the effect. dbcAMP treated, untransfected cells
behave more like transfected cells.
4.7.3: MAP2 and Neurofilament expression in differentiated
Neuro2A cell lines
As the processes observed in untransfected cells appeared to be largely "axon-like" in
morphology, whilst those in Pax6 over-expressing cells appeared more "dendrite-
1 ike" (Fischer et al., 1986), dbcAMP treated cells were stained with antibodies against
MAP2 and Neurofilament. The anti-neurofilament cocktail of primary antibodies
should label all processes. MAP2, on the other hand, is specific to dendrites and
should not label axons (Fischer et al., 1986).
This experiment was performed on untransfected cells and the cell line Neuro2A +
pJP 13.1 clone H, as the difference in morphology was most obvious between these
two lines. As seen in Figure 4.26, both neurofilament and MAP2 are seen in all
processes, in both genotypes. This is evidence for dbcAMP treatment promoting
neuronal differentiation down the same pathway in all cells. The addition of extra
Pax6 leads to a further increase in the number of differentiated cells, but does not
appear to change their fate.
4.8: Discussion
Chapters 2 and 3 describe the Pax6 mRNA and protein content during development
of the murine central nervous system. The next step in understanding the role of Pax6
in embryonic development is to gain an understanding of what role Pax6 may be
playing in these tissues, and how alterations in the levels of various Pax6 isoforms
can affect this role.
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Figure 4.26 MAP2 and Neurofilament expression in untransfected
and Pax6-overexpressing cells after treatment with dbcAMP. A-C,
untransfected cells. D-F, Neuro2A + pJP13.1 clone H. Anti-MAP2
signal is red (A, D). Anti-neurofilament signal is green (B, E).
When overlaid (C, F), the two protwins are seen to co-localise in
all processes, whether dendrite-like, or axon-like.
 
4.8.1: Plasmid constructs can induce Pax6 over-expression in
NIH3T3 and Neuro2A cell lines
The results described above demonstrate that constructs containing Pax6-5a,
Pax6+5a and 5'-truncated Pax6 can all induce Pax6 over-expression in the NIH3T3
and Neuro2A cell lines. In both cell lines, the addition of one splice variant leads to
the up-regulation of both full-length Pax6-5a and Pax6+5a, from the endogenous
genomic locus.
Stable over-expression of Pax6 has an autoregulatory phenotype in both cell lines. In
the Neuro2A cell line, its role in neuronal differentiation can also be studied.
4.8.2: Limitations of this analysis
A cell culture system is an easily manipulable way of assessing the in vivo role of
Pax6 in cell lines derived from a number of different tissues, in particular the effects
of Pax6 over-expression, or of varying the levels of Pax6 isoforms.
One of the major limitations of this system is that immortalised cell lines represent an
artificial system, which is at best an approximation of the environment in which the
Pax6 gene usually acts.
However, by comparing untransfected to Pax6 over-expressing cells, we can be
confident that any difference in phenotype is due to the presence of the transgene.
Use of EGFPN1 over-expressing cell lines rules out effects of the addition of a non¬
specific transgene. Creating a number of Pax6 over-expressing stable cell lines rules
out position effects, due to transgene insertion interrupting genes whose function is
necessary to maintain the normal cellular phenotype.
The use of only two cell lines is a further limitation of this study. Although the two
cell lines were carefully chosen (see Section 4.4), they do not represent all the
environments in which Pax6 can act. For example, it would have been interesting to
assess the activity of Pax6 in a glial-derived cell line, and ascertain whether there
were any phenotypic differences between this and the Neuro2A cell line in particular.
It would also have been useful to use two different neuroblastoma cell lines, to see if
the phenotype of Pax6 over-expression was the same in each, which would lend
190
credence to the results described above. However, it was not practical to extend this
study to more cell lines, although this could be done in the future.
The aim behind using both Pax6-5a and Pax6+5a expression constructs was to assess
the different activities of each isoform. The ability to perform this assessment was
hampered by the fact that introduction of one full-length Pax6 isoform led to the up-
regulation of the other full-length Pax6 isoform, as did the introduction of a 5'-
truncated transcript. Although this initially seemed to be a significant limitation to
this technique, it is actually more representative of the in vivo activity of Pax6. As
shown in Chapters 2 and 3, the two Pax6 isoforms are invariably co-expressed. What
varies is their ratio to one another.
The cell culture system described here allows the analysis of cellular phenotype
across a number of Pax6-5a : Pax6+5a ratios, all of which are within the range
described in Chapter 2. The present study highlights the importance of the analysis of
protein content even in transiently transfected cells. A number of studies have been
conducted in which one Pax6 isoform is introduced into cells, their phenotype is
assessed, and conclusions are drawn as to the differential activity of the two isoforms
(e.g. Chauhan et al., 2004b). The results described above demonstrate that these
conclusions are invalid without an evaluation of the protein content of these cells
after transfection.
4.8.3: Pax6 and autoregulation
Introduction of any isoform of Pax6 into both Neuro2A and NIH3T3 cell lines leads
to up-regulation of other Pax6 isoforms, from the endogenous genomic locus.
Although the precise mechanism behind this up-regulation is unclear, it appears to
vary between transient and stable transfections, and between stable cell lines. The
variations between cell lines are likely to be due to position effects, as the
chromosomal location into which the Pax6 expression construct is inserted will have
an effect on its regulation.
Despite the variation between cell lines, what is clear is that autoregulation is a
strong, consistently observed phenomenon. In all cell lines, the introduction of a full-
length Pax6 isoform leads to some degree of up-regulation of the other full-length
isoform, from the endogenous genomic locus.
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The autoregulation of Pax6 was first documented by Plaza et al., (1993, 1995), who
demonstrated that quail Pax6, PAX-QNR, could bind to both of its known promoters,
PO and PI, and could activate transcription from each. The data presented here show
that the over-expression of either Pax6-5a or Pax6+5a leads to the up-regulation of
the other major Pax6 isoform from the endogenous Pax6 locus. In quail neuroretina
cells, however, only Pax6-5a can transactivate the PO and PI promoters; Pax6+5a
cannot (Plaza et al., 1993; Plaza et al., 1995). Similarly, Pax6-5a but not Pax6+5a can
activate Pax6 transcription via PO in the presence of head surface ectoderm-specific
enhancer sequences (Aota et al., 2003).
The discrepancy between the ability of Pax6+5a to up-regulate Pax6 transcription in
the cell culture system described here, but not in other systems, may be due in part to
species-specific differences in the autoregulation of Pax6. Human PAX6, for
example, can only activate PAX6 transcription from the PB promoter (equivalent to
PI), and not from the PA promoter (equivalent to PO) (Okladnova et al., 1998). A
second explanation for the discrepancies in observed results is that the autoregulation
of Pax6 may be tissue-specific, perhaps dependent on the expression of co-factors.
PAX6 activates transcription from promoter PB in one cell line, whilst it represses
transcription from the same promoter in a different cell line (Okladnova et al., 1998).
In the Neuro2A cell line, the over-expression of 5'-truncated Pax6 also leads to up-
regulation of both Pax6-5a and Pax6+5a. The activity of a "paired-less" Pax6 protein
has been studied in the quail neuroretina model system, and it was unable to
transactivate either the PO or PI promoters (Plaza et al., 1993; Plaza et al., 1995). The
data described here are the first evidence that "paired-less" Pax6 act to autoregulate
full-length Pax6.
It is also worth noting that the 32kDa isoform of Pax6, thought to result from internal
translation initiation (see Chapter 3) is also up-regulated in all Pax6 over-expressing
Neuro2A cell lines, although this was not seen in NIH3T3 cell lines. The up-
regulation of this protein could be due to an increase in full-length transcript, from
which internal translation may initiate. Alternatively, it could be due to an increase in
the levels of 5'-truncated transcripts. A murine "paired-less" transcript is initiated
from within intron 7, a region which contains a number of Pax6 regulatory elements,
some of which are known to be bound by Pax6 protein (Kleinjan et al., 2004).
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The existence of Pax6 autoregulatory mechanisms in vivo was first proposed by
Grindley et al. (1997), who observed reduced areas of Pax6 mRNA expression in the
caudal Sey/Sey diencephalon, implying that Pax6 protein was required for the
maintenance of Pax6 protein expression. In situ hybridisation analysis of the Pcix6
mRNA content of Pax6 <-» Pax6~' chimaeric mice shows that Pax6 transcript levels
are raised in Pax6" cells in the retina and in the dorsal telencephalon (Collinson et
al., 2003; J.C. Quinn, pers. comm.). These two findings appear to be contradictory,
the first indicating that Pax6 can activate its own transcription, the second indicating
that Pax6 represses its own transcription in WT cells. Pax6-5a over-expression in the
mouse lens leads to increased transcription of both Pcix6-5ci and Pax6+5a, consistent
with Pax6 acting to up-regulate its own transcription (Chauhan et al., 2002a). The
data presented in Chapter 3, however, indicate that Pax6 has a largely negative
autoregulatory effect in the brain as a whole, and no discernable autoregulatory effect
in the eye. Again, the mechanisms governing Pax6 autoregulation may vary in a
tissue-specific manner, dependent on the expression of co-factors.
One way in which the expression of co-factors is known to influence Pax6
transcription is by acting upon different cfv-regulatory elements. For example,
transactivation of the mouse P0 promoter in a cell culture system is stronger in the
presence of a 5' enhancer sequence, and strongest when co-transfected with Sox2 or
Sox3 (Aota et al., 2003). Transcription factors can bind to a number of regulatory
elements both 5' and 3' of the Pax6 gene, and can direct transcription in different
tissues from different promoters (Anderson et al., 2002; Kammandel et al., 1999).
Recapitulation of the complete Pax6 expression pattern requires the presence of up to
420kb of flanking sequence (Fantes et al., 1995; Schedl et al., 1996) and Pax6 is
likely to exert different autoregulatory effects at different c/.v-regulatory elements.
In general, the data presented here add weight to the hypothesis that Pax6 protein can
regulate Pax6 transcription. The precise nature of this interaction varies between
experimental systems and between tissues in the developing mouse, and this variation
is likely to be due to the differential expression of co-factors.
4.8.4: Pax6 over-expression induces neuronal differentiation in
the Neuro2A cell line
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The Neuro2A neuroblastoma cell line spontaneously differentiates along what is
thought to be a neuronal pathway in culture (Fischer et al., 1986). This effect is
enhanced by Pax6 over- expression and treatment with dbcAMP. Both manipulations
appear to drive differentiation along the same pathway. This conclusion is supported
by the fact that the effects of Pax6 over-expression are less profound in dbcAMP-
treated cells than in their untreated counterparts.
After both types of treatment, cells grow an increased number of MAP2- and
neurofilament-expressing processes, which are thought to be axonal rather than
dendritic (Fischer et al., 1986).
The growth of more axonal-like projections in Pax6 over-expressing Neuro2A cells
after dbcAMP-induced differentiation is consistent with the observation that Sey/Sey
cerebellar cells do not form neuronal processes in culture, unlike their wild type
counterparts (Engelkamp et al., 1999). A similar effect is also seen in the rat
rSey/rSey hindbrain, where axon growth is stunted (Osumi et al., 1997).
Two observations can be made from the Pax6 over-expressing cell populations in this
study, based on cellular morphology. Firstly, more cells become differentiated, as
described above. Secondly, of the differentiated cells, cells with more than two
processes are more common in the Pax6 over-expressing lines. Another study of
cultured cerebellar cells, from the rat rSey2/rSey2 (rat small eye) mutant, supports this
finding. These mutant cells showed disordered neural morphology; in particular fewer
long bipolar neurites were formed (Yamasaki et al., 2001).
It is worth noting that the changes in cellular morphology described here were not
observed in Pax6 over-expressing NIH3T3 cells, although this was not confirmed at a
molecular level. These cells do not express endogenous Pax6 and, unlike Neuro2A
cells, do not spontaneously differentiate in culture. From these observations it can be
concluded that Pax6 over-expression can enhance the differentiation of neuronal
precursor cells, but is not sufficient to cause transdifferentiation in a non-neuronal
cell type.
Pax6 is known to be important in the switch from proliferation to differentiation in
neuronal precursor cells. This is perhaps best demonstrated in D. melanogaster,
where the eyegone gene, paralogous to Pax6+5a, promotes cellular proliferation,
whilst the eyeless gene, paralogous to Pax6-5a, promotes differentiation (reviewed in
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Rodrigues and Moses, 2004). The two genes are expressed in a sequential manner in
Drosophila eye development, and the switch in expression is coincident with a switch
from proliferation to differentiation (Dominguez et al., 2004).
In the murine pancreas, Pax6 is required for the differentiation of islet cells
(Dohrmann et al., 2000; St-Onge et al., 1997), and in the eye it is involved in fate
restriction of retinal progenitor cells (Marquardt et al., 2001).
Previous studies have suggested that Pax6 promotes neuronal differentiation. It is
known to be a direct regulator of the proneural genes Nenrogenin2 (Scardigli et al.,
2003), Math5 and Mashl (Marquardt et al., 2001), which are crucial for specifying a
neuronal cell fate (reviewed in Bertrand et al., 2002). Pax6 is required for the normal
differentiation of glia (Gotz et al., 1998), and Pax6 over-expression in radial glial
cells leads to the generation of neurons (Heins et al., 2002). The increased level of
neuronal differentiation in Pax6 over-expressing Neuro2A cells described here is
consistent with Pax6 acting to promote neuronal differentiation.
Some evidence from the developing Sey/Sey cortex, however, indicates that Pax6 may
inhibit neuronal differentiation. An abnormally high proportion of Sey/Sey cortical
cells undergo asymmetrical division between E12.5 and E15.5 (Estivill-Torrus et al.,
2002), suggesting that Pax6 is required to maintain proliferation in these cells.
SeyNe"/SeyNe" cortical plate neurons cease differentiation earlier than those in the WT
(Schmahl et al., 1993), which also suggests that Pax6 is crucial for inhibiting
neuronal differentiation in early cortical development.
One hypothesis that might reconcile these seemingly disparate results is that Pax6
may have a role in controlling both proliferation and differentiation of neural
progenitor cells. Early in neurogenesis, Pax6 may act to promote symmetrical cell
division within the cortex, thereby maintaining a proliferative precursor cell pool.
Later in neurogenesis, the role of Pax6 may switch to promoting neuronal
differentiation by activating proneural genes.
The temporal and spatial differences in the role played by Pax6 may vary dependent
on the expression of co-factors, such as other HD-containing genes. Pax genes can
dimerise via their HDs and bind to target DNA (Wilson et al., 1993), and a number of
other Pax genes (Pax2, Pax3, PaxS, Pax7 and Pax8) are co-expressed with Pax6 in
some regions of the developing murine brain (Stoykova and Gruss, 1994), (see
195
Figure 1.1). The two Pax6 DNA-binding domains can also interact with one other,
either within a Pax6 molecule or between co-expressed Pax6 molecules (Mikkola et
ah, 2001; Mishra et ah, 2002; Singh et ah, 2000). As suggested in Chapter 2,
developmentally-regulated changes in the ratio of Pax6-5a : Pax6+5a might also play
a part in changing the action of Pax6. Although the cell lines described here express
Pax6-5a and Pax6+5a in a variety of ratios, and all display a similar increase in the
rate of differentiation, the role of the Pax6-5a : Pax6+5a ratio in regulating neuronal
differentiation may also be dependent on the expression of other genes.
4.8.5: A possible role for N-terminally truncated Pax6 in WT,
Sey/Sey and Pax6LacZJLacZ mice
Transient transfections in both cell lines and stable transfections in the Neuro2A cell
line indicate that 5'-truncated Pax6 is capable of up-regulating full-length Pax6
protein. As the "paired-less" Pax6 protein synthesised from the 5'-truncated construct
is shown to have transactivational properties (Figure 4.9, Figure 4.17), it could
potentially affect the transcription of other Pax6 target genes. This has implications
for the Sey/Sey and Pax6'"LZ,McZ mutant mice. Both of these mice have mutations in
the 5' portion of the Pax6 gene. Internal translation initiation from within the Pax6
gene could theoretically lead to the production of an N-terminally truncated Pax6
protein in either mouse mutant. In the Pax6 ac at mouse, there are four in-frame
ATG residues 3' of the inserted LacZ gene. In the Sey/Sey mouse, the mutation is
further on in the gene, and translation of a wild type Pax6 protein could only initiate
from the most 3' of these ATG residues.
The plasmid pJP15.12, containing 5'-truncated Pax6 cDNA, forces translation
initiation from this 3' ATG residue. The resultant protein would still contain an intact
DNA binding domain (HD) and TAD (Tang et al., 1998; Walther and Gruss, 1991),
thereby fulfilling the basic requirements of a transcription factor. The presence of
short, 32/33kDa Pax6 isoforms in mouse brain and eye (see Chapter 3), which are
thought to be the result of just such an internal translation initiation mechanism
(Carriere et ah, 1993), is compelling evidence that these Pax6 variants have an
important role in vivo. More work is needed to define this role, but it seems
increasingly likely that the Sey/Sey and Pax6lacZLacZ mice express some functional
Pax6, and therefore can no longer be considered Pax6-null.
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These protein isoforms are expressed at similar levels in Sey/Sey and WT mice,
suggesting that any functional role may be maintained across the two genotypes. Part
of the mutant phenotype in Sey/Sey, and by implication Pax6LacZ LacZ mice may indeed
be due to the presence of short Pax6 forms, rather than the absence of full-length
Pax6, as was previously assumed.
The role of N-terminally truncated Pax6 has yet to be established, either in a WT or a
Pax6 mutant context, but a number of studies have addressed the possible
transactivational abilities of Pax6 proteins lacking the PD. The homeodomain of a
"pairedless" Pax6 protein can bind to canonical homeodomain binding sites, but in
doing so does not activate transcription (Mishra et al., 2002). However, this Pax6
isoform can interact with full-length Pax6, and promote transcriptional activation via
consensus Pax6 binding sites (Mikkola et al., 2001). The results described here
demonstrate that short Pax6 isoforms can have a transcriptional effect not only on
consensus binding sequences, but also on a known target gene, as they are able to
upregulate full-length Pax6.
As seen in Chapter 3, the Sey/Sey mouse brain contains some short Pax6 isoforms,
thought to be lacking a paired domain as a result of internal translation initiation.
Whilst the up-regulation of full-length Pax6 protein by this "pairedless" form would
not be possible in these mice, it is likely to affect other transcriptional targets. The
data described above lend weight to the idea that short forms of Pax6 have a
functional role in the Sey/Sey mouse.
4.8.6: Future work
The phenotypic analysis of Pax6 over-expressing cells described here is preliminary.
Whilst it demonstrates that Pax6 over-expression has an effect on Pax6 autoregulation
and neuronal differentiation of cultured cells, further studies are needed to define
these effects, and the molecular mechanisms which underpin them.
After dbcAMP-induced differentiation, there is a clear difference in phenotype
between untransfected and Pax6 over-expressing cells. Pax6 over-expressing cells
produce more dendrite-like processes, whilst untransfected cells produce mainly
axon-like processes. On the other hand, the markers of neuronal cell type used in this
study failed to distinguish between the two phenotypes; they indicated that
differentiation was proceeding down the same pathway in both genotypes. A PCR-
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based screen of a larger number of cell type markers would enable a distinction to be
drawn between these two scenarios.
Pax6 over-expression can also be predicted to have an effect on cellular proliferation
(Estivill-Torrus et al., 2002; Maulbecker and Gruss, 1993; Mikkola et ah, 2001;
Warren et ah, 1999; Warren and Price, 1997). Analysis of the cell cycle in
untransfected and Pax6 over-expressing cells could be performed using the thymidine
analogue, bromodeoxyuridine (BrdU).
Another important role of Pax6, which was not addressed here, is in the control of
cellular adhesion. Cell adhesion defects have been demonstrated in the Sey/Sey mouse
(Stoykova et ah, 1997; Tyas et ah, 2003). Pax6 is known to be a direct transcriptional
regulator of cell adhesion molecules such as LI (Meech et ah, 1999) and NCAM
(Edelman and Jones, 1995), and is also thought to interact with R-cadherin (Andrews
and Mastick, 2003). These genes and a number of other regulators of cell adhesion
could be included in a PCR-based screen of untransfected and Pax6 over-expressing
cell lines.
The major drawback of the Pax6 over-expression system described in this chapter is
that it did not lead to the creation of cell lines over-expressing either just Pax6-5a or
just Pax6+5a. Whilst Pax6 autoregulation is an interesting phenotype in itself, and
worthy of further study, it sheds no light on the differential activity of the two best
know Pax6 splice variants. One way to address this problem would be to introduce
the constructs pJP 13.1 and pJP 14.1 into a Sey/Sey embryonic stem (ES) cell line.
Although this study has shown that Sey/Sey mice are capable of expressing some
short Pax6 forms, the up-regulation of both full-length splice forms could not occur in
Sey/Sey ES cells. Any phenotype could only be caused by the introduced construct, as
the endogenous locus is mutated, therefore cannot respond by producing full-length
Pax6. The Sey/Sey ES cell line would also be a useful tool in assessing the role of N-
terminally truncated Pax6.
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Chapter 5 : Conclusions
5.1: Chapter 2: The Pax6-5a : Pax6+5a ratio in embryonic
development
RNase protection assay was used to determine the Pax6-5a : Pcix6+5a mRNA ratio in
the telencephalon, diencephalon, eye, spinal cord and hindbrain from El2.5 to El8.5,
and in the olfactory bulb and cerebellum from E14.5 to El 8.5.
In all tissues studied, Pax6-5a is expressed at a higher level than Pax6+5a. The ratio
between the two splice variants is regulated in a tissue-specific and developmental
stage-specific manner. The telencephalon, diencephalon, spinal cord and hindbrain
appear to be regulated in a similar way; the ratio is generally high but variable at
E12.5, ranging from 2:1 to 18: l. It then falls to around 2:1 by E16.5, then rises
slightly to approximately 4:1 at El8.5. The fact that the ratio follows a similar trend
in these four tissues implies that Pax6 is playing a similar role in each. The fall in
ratio may lead to a change in Pax6 target genes, and is coincident with a change in
Pax6 activity, from a role in cellular proliferation to a role in neuronal differentiation.
In the olfactory bulb, the Pax6-5a : Pax6+5a ratio is around 2:1 from E14.5 to El 8.5,
and may rise slightly at El6.5. In the eye, the ratio is consistently higher than that in
other tissues studied; 7:1 at E12.5, falling to around 3:1 at El8.5. In the cerebellum,
the ratio remains largely constant, at around 4:1.
At El2.5, transcripts lacking exon 6 (Pax6A6) could not be detected in any tissue,
suggesting that this transcript may not be as common as previously thought.
The tissue-specific differences in Pax6-5a : Pax6+5ci ratio described here suggest
that Pax6 activity varies, and differential Pax6 isoform expression is developmentally
regulated, between tissues.
5.2: Chapter 3: Analysing the Pax6 protein expression pattern in
mice with various Pax6 alleles
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The Pax6 protein content of El2.5 whole brain and whole eye from, PAX77+",
PAX77+/+ WT, Sey/+ and Sey/Sey mice was analysed by western blot using an
antibody that detects all known Pax6 isoforms.
The various Pax6 isoforms are differentially expressed between genotypes. Most
isoforms are up-regulated in the brain of both PAX77 genotypes. Pax6 protein
expression level is not directly proportional to PAX6 copy number, and varies
between isoforms, suggesting autoregulation of the Pax6 product in order to minimise
the effects of over-expression. This conclusion is further supported by the observation
that no isoform is seen at higher levels in the PAX77+/+ brain than in the PAX77+/"
brain, despite there being six extra copies of the PAX6 transgene.
All Pax6 isoforms also appear to be up-regulated in the eye of PAX77+" and
PAX774 mice at E12.5. In the eye, Pax6 expression is more representative of PAX6
copy number than in the brain, suggesting that autoregulation does not occur in this
tissue. This may be one reason why the eye is more sensitive than the brain to PAX6
gene dosage. The Pax6-5a : Pax6+5a ratio is lower in the PAX77+/~ and PAX77+/+
brains than in the WT brain, but unaffected in the PAX77+/~ and PAX77+/+ eyes.
Again, Pax6 autoregulation is occurring in the brain but not in the eye.
Pax6+5a is up-regulated in the Sey/+ brain at El2.5, when compared to WT. Four
other isoforms, Pax6-5a, 43kDa Pax6, 32.5kDa Pax6 and 32kDa Pax6, are expressed
at the same level in Sey/+ and WT brains. This is evidence that autoregulation also
occurs to control the Pax6 protein level when the Pax6 copy number is reduced, and
that this effect varies between isoforms. As was observed with the PAX77 eye, the
Sey/+ eye does not seem to have a Pax6 autoregulatory mechanism, as all isoforms
appear to be down-regulated when compared to WT. This could explain why the
Sey/+ eye phenotype is stronger than the Sey/+ brain phenotype.
Although previously believed to be functionally null for Pax6, the Sey/Sey mouse
does express some Pax6 isoforms in the brain; 43kDa Pax6 and 32kDa Pax6. These
two isoforms are expressed at the same levels in the Sey/Sey and the WT brain, and it
is possible that they are contributing to its phenotype. Neither isoform was seen in the
Sey/Sey eye.
The Pax6 protein content of two further Pax6 mutant mice, SeyNc"/Sey and
Pax6,acZLacZ was also analysed by western blot. Both were found to express 32kDa
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Pax6 in the brain at El2.5, therefore this isoform may be contributing to the
phenotype of all three Pax6 null mice. Neither Se^eu/Se^eu, nor Pax6LacZLacZ mice
express 43kDa Pax6 in the brain at E12.5, therefore any differences between the
phenotype of these two mutant mice and that of Sey/Sey mice may be due to the
presence of 43kDa Pax6 in the developing Sey/Sey brain. The 43kDa Pax6 band was
previously thought to be the result of alternative splicing of exon 6, but this would not
explain the presence of a band in the Sey/Sey mutant, therefore an alternative
explanation must be sought. One possibility is that it is due to alternative splicing of
exon 8, which would remove the Sey STOP mutation.
5.3: Chapter 4: Analysing the effects of Pax6-5a and Pax6+5a
over-expression in immortalised cell lines
Expression constructs were made containing Pax6-5a, Pax6+5a, and 5'-truncated
Pax6 under the control of the strong viral CMV promoter. Transient and stable
transfections were carried out to introduce all three constructs into the Neuro2A
murine neuroblastoma cell line, and Pax6-5a and Pax6+5a into the NIH3T3 murine
fibroblast cell line.
Transient transfection of both Pax6 isoforms into both cell lines leads to the up-
regulation of the introduced transcript. In the Neuro2A cell line, transient introduction
of Pax6-5a leads to an increase in the level of Pax6-5a protein, and a decrease in the
level of Pax6+5a protein, suggesting that complex Pax6 autoregulation of the type
observed in Chapter 3 can occur in a cell culture system. Transient introduction of
Pax6+5a into the Neuro2A cell line leads to an increase in the level of both Pax6-5a
and Pax6+5a protein.
Stable transfection of all three Pax6 expression constructs into the Neuro2A cell line
causes a rise in the levels of the introduced protein. There is also a rise in the protein
levels of the other full-length Pax6 isoform(s), indicating autoregulation of Pax6 from
the endogenous locus, after the introduction of either Pax6-5a, Pax6+5a, or 5'-
truncated Pax6.
5'-truncated Pax6 is capable of regulating the expression of Pax6, and may therefore
be able to act on other Pax6 target genes. As the Sey/Sey and Pax6LacZ LacZ mutant
mice contain mutations in the 5' portion of the Pax6 gene, they are theoretically
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capable of producing "paired-less" Pax6 from the same transcript as that used in the
present study. As suggested by the results of Chapter 3, it is possible that short
isoforms of Pax6 may be contributing to the phenotype of these mice, and that of the
Sefeu/Sefeu mouse, and that they are not entirely null for Pax6, as was previously
thought.
Pax6-5a and Pax6+5a were also introduced into the NIH3T3 cell line, which does
not express endogenous Pax6, by stable transfection. As with the Neuro2A cell line,
both Pax6-5a and Pax6+5a proteins are up-regulated, indicating that Pax6
autoregulation can occur in a system in which Pax6 is not normally expressed.
Pax6 over-expression promotes neuronal differentiation in the Neuro2A cell line. The
low level of spontaneous neuronal differentiation seen in this cell line is known to be
increased by the addition of dbcAMP. This study shows that Pax6 over-expression
promotes an exit from the cell cycle, and a concomitant increase in the level of
neuronal differentiation, along the same pathway as that mediated by dbcAMP
treatment.
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Appendix 1 - Reagents and Protocols
Cell culture reagents
Minimal Essential Medium (MEM; forNeuro2A)
MEM {Gibco)
l% Non-essentail amino acids {Gibco)
1% Penicillin-streptomycin-L-glutamine {Gibco)
10% Foetal bovine serum {Gibco)
Minimal Essential Medium (DMEM; for NIH3T3, H36CE2 and
DMEM-F12 {Gibco)
1% Penicillin-streptomycin-L-glutamine {Gibco)
10% Foetal bovine serum {Gibco)
Transfection medium
RPMI 1640 {Gibco)




Foetal Bovine Serum {Gibco)
1% DMSO
Lipofectamine 2000 transfection reagent (Invitrogen)
G-418 stock
Geneticin (G-418 sulfate) {Gibco) to 200pg.pl"1
ImM HEPES buffer {Gibco) in IX PBS
Filter sterilised at 0.2pm to ensure there are no undissolved particles
Reagents for cAMP-Induced differentiation ofNeuro2A cells




dissolve in 250pl ddH20
Use at ImM, i.e. 509.4pg.ml"1
i.e. 5.094pl.mf1
cAMP-lnduced differentiation of Neuro2A cells
1) Seed cells 24 hours before induction of differentiation at 5X105 cells.welf1 in 6-
well plates on sterile glass coverslips
2) Incubate at 37°C, 5% C02 overnight
3) After 24 hours, change medium. Replace with 1.5ml medium
4) Add 7.64pl of 1 OOmg.ml 1 dbcAMP stock solution per well










add one Complete Mini protease inhibitor cocktail tablet {Roche) per 10ml buffer,
store aliquots at -20°C
BSA Stock
BSA Fraction V lOmg.ml"1 in TENT buffer
Make serial dilutions 10-lOOOpg.mf' in PBS
BCA Protein Assay Reagents (Pierce)
Protein Isolation
From Tissue Culture Cells
1) Wash cells 2X in ice-cold PBS
2) Bathe in 1ml ice-cold PBS
3) Scrape cells off dish using a sterile, disposable cell-scraper
4) Decant into a 1.5ml microfuge tube
5) Pellet by centrifugation at l,000g for 10 minutes at 4°C
6) Discard supernatant, and resuspend cells in 20-1 OOprl TENT buffer with protease
inhibitors
7) Homogenise using a motorised homogeniser and a disposable mini-pestle
8) Allow lysis to occur for 20 minutes at 4°C
9) Pellet out cell debris by centrifugation at 10,000g for 10 minutes at 4°C
10) Remove supernatant and store at -70°C for up to 6 months
From Embryonic Tissue
Dissections should be carried out in ice-cold, sterile PBS, within 90 minutes of
harvesting embryos.
Freeze tissue dry in cryovials, by immersion in liquid nitrogen. Tissue can then be
stored at -70°C until protein extraction.
1) Defrost tissue on ice
2) Add 50-200pl TENT buffer with protease inhibitor, triturate
3) Continue as protein isolation from tissue culture cells, from step 7).
Reagents for in vitro Protein Synthesis
pJP8.6 (Pax6-5a), pJP9.3 (Pax6+5a) ans pJP17.x (5'-truncated Pax6) at lpg.pl"1
TNT Quick Coupled Transcription / Translation System (Promega)
in vitro Protein Synthesis
1) Prepare the following mastermix:





2) Incubate at 30°C for 90 minutes
3) Store at -70°C for 12 months
Protein Quantitation
Perform all quantitations in 96-well plates
1) Dilute BSA stock solution to a range of concentrations from lOpg.ml"1 to
lOOOpg.mf1 in TENT buffer
2) Aliquot 25pl of each standard into a separate well, alongside a blank well with just
25pl TENT buffer
3) Aliquot lpl and 2.5pl of each protein sample into separate wells, and make up to
25pl with TENT buffer
4) Make BCA working reagent; 200pl per well n wells +1; by combining reagents A
and B in a 50:1 ratio
5) Add 200pl working reagent to each well, incubate at 37°C for 30 minutes
6) Allow to cool to room temperature, and measure absorbance at 565nm on a
microplate reader
7) Using values from BSA standards, plot a regression in Excel of pg BSA against
OD at 565nm
8) If the R2 value of the regression is >0.95, use the equation generated to calculate
the absolute amount of protein present in each sample
9) If only one value for a sample falls within the standard curve, discount the second
value. If both values for a sample fall within the standard curve, average the two
values
Protein Denaturinu Polyacrylamide Gel Electrophoresis (SDS-PAGE) Reagents
Novex 12% Tris-Glycine Gel, 1.0mm thick, 12 well (Invitrogen)








5% (v/v) (3-Mercaptoethanol (Add fresh, store for up to 6 weeks at
room temperature)
0.005% (w/v) Bromphenol Blue
MagicMark Western Protein Size Standard (Invitrogen)
Protein Denaturing Polvacrvlamide Gel Electrophoresis (SDS-PAGE)
1) For each lane, prepare 50pg protein, make up to 15pl with TENT buffer, and add
5pl 4X SDS loading buffer





3) For Pax6 positive control lane use lpl 1:10 in vitro synthesised Pax6+5a and Pax6-
5a with 13pl TENT buffer and 5pl 4X SDS loading buffer; heat at 65°C for 3
minutes, and load immediately
4) For MagicMark protein molecular weight ladder, use 4pl 1:10 MagicMark with
1 lpl TENT buffer and 5pl 4X SDS loading buffer. Do not heat prior to gel loading
5) Prepare the Novex gel:
Remove outer packaging
Rinse in ddH20 to remove storage buffer
Remove protective strip from bottom of gel
Remove comb and wash wells repeatedly in IX SDS running buffer
Place gel in tank alongside buffer dam, and tighten
Fill upper chamber with IX SDS running buffer
6) Load 20pl sample per well, fill lower chamber with IX SDS running buffer and
run at 150V for 1 hour 40 minutes
Protein Transfer and Western Blottina Reagents





1 OOmM Tris base (pH=7.5)
150mM NaCl
0.1% (v/v) Tween 20




Immuno-Blot PVDF membrane, 0.2 pm (BioRcut)
Nitrocellulose Membrane, 0.2 pm {BioRail)
Ponceau's solution {Sigma)
ECL Plus (Amersham Pharmacia Biotech)
18X24cm Photographic Film {Sigma)
Protein Transfer and Western Blotting
For detection with DSFIB anti-Pax6 or Chemicon anti-Pax6 primary antibody,
proteins were transferred to PVDF membranes. For detection with serum 13 anti-
Pax6, proteins were transferred to nitrocellulose membranes.
Prepare transfer buffer fresh on day of transfer
1) Pre-soak 2X sponges and 4X fdter papers per gel in transfer buffer
2) Pre-soak nitrocellulose membranes in transfer buffer; permeabilise PVDF
membranes in 100% methanol for 5 minutes before pre-soaking in transfer buffer
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3) Remove gel from plastic casing, and prepare the transfer cell in the following
order:
-ve; IX sponge; 2X filter papers; gel; membrane; 2X filter papers; IX sponge; +ve
4) Smoothe out bubbles, close the cassette tightly and place in the transfer tank
5) Fill tank with transfer buffer and transfer overnight at 50mA, 4°C
6) Stain the membrane with Ponceau's solution, and de-stain with 2X ddH20 washes
to check transfer efficiency
7) Membranes can be wrapped in saran wrap and scanned in using the GS-710
densitometer to record transfer efficiency and protein loading accuracy
8) Block membranes in blocking buffer for 1 hour at room temperature, with shaking
9) Prepare primary antibody solutions by centrifuging antibodies at 13000rpm for 5
minutes, and dilute to the required concentration in 600pl - 1 ml blocking buffer
10) Incubate membranes with primary antibody solutions in sealed plastic bags at 4°C
overnight
11) Wash 3X 10 minutes in TBS-tween
12) Prepare secondary antibody solutions by centrifuging antibodies at 13000rpm for
5 minutes, and dilute to the required concentration in 10ml blocking buffer
13) Incubate membranes with secondary antibody solutions for 1 hour at room
temperature with shaking
14) Wash 3X 10 minutes in TBS-tween
15) Prepare ECL+ solution by mixing lml solution A and 25pl solution B per
membrane
16) Bathe the membrane in ECL+ solution for 5 minutes
17) Dab off excess ECL+ solution onto a tissue, wrap the membrane in saran wrap,
and expose to photographic film to visualise
18) If P-actin detection is required to allow relative quantitation of proteins, wash 3X
10 minutes in TBS-tween and repeat from step 9)
Reagents for Innunocytochemistrv on Tissue Culture Cells





Passed through 0.22pm fdterto remove undissolved BSA crystals
Serum should be from the species in which the secondary antibody was raised
100% Methanol pre-cooled to -20°C
TOPR03 (Molecular Probes) diluted 1:5000 in PBS, with 1:1000 RNaseA (Sigma)
Boil RNaseA for 30 minutes before use to remove DNase activity
Vectashiled (Vector Laboratories) diluted 1:10 in PBS
Confocal Immunocytochemistry on Tissue Culture Cells
For stably transfected cells: Seed at 5X10' cells.welf1 on glass coverslips in 6-well
plates. Fix after 48 hours
For transiently transfected cells: Seed at 1X10' cells.well"' on glass coverslips in 6-
well plates. Transfect after 24 hours, fix a further 48 hours after transfection
1) On ice, remove media and wash in ice cold PBS X2
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2) Remove PBS and cover in 4% PFA in PBS, take off ice
3) Incubate at room temperature for 30 minutes
4) Remove fix by washing in PBS
5) Remove PBS, permeabilise the cells by incubating in pre-cooled 100%
Methanol at -20°C for 10 minutes
6) Wash 2X with PBS
7) Incubate cells in blocking solution for 30 minutes at room temperature
8) Microfuge primary antibody at 13000rpm for 15 minutes at 4°C. Prepare correct
dilutions (usually 1:75, 90pl is adequate to cover one coverslip, prepare lOOpl each)
of primary antibodies in blocking solution
9) Apply 90pl of the primary antibody and incubate in a sealed, humid, container at
4°C overnight - can put PBS-soaked tissue paper in the gaps between wells, put the
lid on, and leave in fridge
10) Wash 2X with PBS
11) Dilute the secondary antibody 1:200 in blocking solution (again, 90pl per
coverslip, make 100pl each) NB may help if direct light is avoided from this stage
onwards, although alexa-conjugated antibodies are less sensitive to photo-degradation
than some fluorescent conjugates
12) Apply 90pl diluted secondary antibody to the cells and incubate in a sealed,
humid, dark container at room temperature for 1 hour (as above, but covered to keep
light out)
13) Wash the cells 2X in ddHLO (can use PBS, but this leaves crystals)
14) Aspirate PBS, cover in TOPR03/RNaseA mix in PBS, incubate at room
temperature for 30 minutes
15) Wash 2X in ddFLO
16) Mount on a microscope slide using 10% Vectashield, visualise within 48 hours
Flow Cytometric Immunocytochemistrv on Tissue Culture Cells
Cells should be seeded as for confocal immunocytochemistry
Before fixation, trypsinise cells and resuspend in 1ml PBS
Pellet cells by centrifugation at 5000rpm for 4 minutes at 4°C
All wash and incubation steps should be carried out in lOOpl solution, followed by
pelleting cells and removing supernatant
Immunocytochemistry is performed as for confocal microscopy, but without the
addition of T0PR03 nuclear counterstain
Cells are then run through an Epics-Coulter-XL flow cytometer. Voltages are kept
constant for each set of samples to allow comparison between cell populations
Alexa-488-conjugated secondary antibody can be detected in the FL1 channel
Reagents for RNA Extraction from Tissue Culture Cells
RNeasy mini kit (Qiagen)
Buffer RWL supplemented with 1% (3-mercaptoethanol (fresh)
RNA Extraction from Tissue Culture Cells
All RNA work must be performed in RNase-free conditions. Scrub benches with 70%
ethanol before starting. Where possible, all solutions should be treated with DEPC,
and fdter tips should be used throughout
1) Seed cells at 1X106 cells per 25cm2 flask
2) Collect after 48 hours by trypsinisation
3) Pellet cells by centrifugation at 1000 rpm for 5 minutes, discard medium
4) Wash in PBS, repeat centrifugation, and discard PBS
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5) Resuspend pellet in 700pl RWL buffer with p-mercaptoethanol
6) Carry out RNA extraction as per manufacturer's protocol
7) Elute sample in 50pl RNase-free H20
8) Samples can be stored at -70°C for up to 6 months
Reagents for RNA Extraction from Embryonic Tissue
RNagents Total RNA Isolation System (Promega)
75% Ethanol, 25% DEPC-treated H20, ice-cold
RNA Extraction from Embryonic Tissue
Dissections should be carried out in ice-cold, sterile PBS, within 90 minutes of
harvesting embryos
Freeze tissue dry in cryovials, by immersion in liquid nitrogen. Tissue can then be
stored at -70°C until RNA extraction
1) Resuspend tissue in the appropriate volume of denaturing solution:
Olfactory bulb (pool as many as possible)
120pl
Telencephalon (pool 2-4 telencephalic vesicles, depending on age)
300pl
Diencephalon (pool as many as possible at E12.5, decreasing to 2-3 by El8.5)
120pl
Eye (pool as many as possible)
120pl
Spinal cord (pool as many as possible at E12.5, decreasing to 2-3 by E18.5)
120pl
Hindbrain (pool 2-3, exclude cerebellum from El6.5)
300j.il
Cerebellum (pool 2-3, only E16.5 and E18.5)
300j.il
Hindfoot (pool as many as possible)
3 00j.il
Where very small amounts of tissue are present in a sample, 60pl of denaturing buffer
can be used, but RNA yield will be low, as RNA may be lost during successive
precipitations
2) Homogenise using a motorised homogeniser and a disposable mini-pestle
3) Proceed with RNA extraction as per manufacturer's protocol
4) Resuspend RNA pellet in RNase free H20. Generally, where 300pl denaturing
solution was used, resuspend in 150pl; where 120pl denaturing solution was used,
resuspend in 50pl.
5) RNA can be stored at -70°C for up to 12 months
Reagents for RNA Quantitation
RiboGreen RNA quantitation kit {Molecular Probes)
PicoFuor bench-top fluorimiter {Turner Designs)
RNA Quantitation
N.B. RiboGreen is photosensitive, keep lights dimmed at all times
1) Dilute appropriate amount of RiboGreen 1:1000 in IX TE
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80|nl per sample if trying 2 different dilutions + 40pl per standard (usually
X8)
2) Dilute rRNA standard to lOOng.mf1 in IX TE
3) Prepare the following rRNA standards:
Total ng RNA pi of 100ng.ml"1stock rRNA pi TE Final cone (ng.ml"1)
4 40 0 50
2.4 24 16 30
2 20 20 25
1.6 16 24 20
1.2 12 28 15
0.8 8 32 10
0.4 4 36 5
0 0 40 0
4) Dilute sample RNA in IX TE (usually use 0.2pl and 0.02pl, to ensure than one is
within the range of the assay) to 40pl
5) Add 40pil sample/standard RNA (in IX TE) to 40pl 1:1000 RiboGreen. Mix well,
incubate at room temperature for 5 minutes
6) Calibrate PicoFluor using the 4ng standard and the blank (Ong)
- Switch ON
- Check it's set to blue, not UV
- Set "STANDARD" value to 400 (arbitrary, but in this case, 400 = 4ng RNA)
- Press "CAL", Calibrate according to the instructions it gives you (use 4ng as
calibration standard, Ong as blank)
- After calibration, insert sample and press "READ"
7) Take readings first for all standards, then for all sample RNAs
8) In Excel, use standards to plot a regression, and use the equation of the regression
to calculate total RNA in each sample
Reagents for Riboprobe Synthesis
Maxiscript SP6 Kit (Ambion)
Linearised template DNA at 0.5pg.pl"1
,2P UTP at 800Ci/mmol, lOmCi/ml (Signui)
MicroSpin G-25 columns (Amersham Pharmacia Biotech)
Acrylamide / bis-acrylamide 40% solution (Sigma)
RepelcoteVS (BDH)
Ammonium persulphate 10% (Make fresh)
Dissolve lg in 10ml ddH20, mix thoroughly
TEMED (N,N,N',N'-Tetramethyl-l,2-diaminomethane) (Sigma)
6% acrylamide, 8M Urea solution
Make up 100 ml acrylamide:
10ml 10XTBE
15ml Acrylamide/Bis-acrylamide (40% mix)
46.Og Urea
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Make up to 100ml with water (not very much)
Mix until dissolved
Filter to remove any undissolved urea
Keep in the dark @4°C for 14 days, after which crystals of acrylamide start to
form
Riboprobe Synthesis
Preparation of a 6% polyacrylamide, 8M urea denaturing gel:
1) Clean 2 glass plates with water and 70% ethanol
2) Coat front plate with repelcote, marking the outer surface, rub in with a tissue, and
wash off with 100% ethanol X2
3) Assemble the gel, washing alignment card with ethanol first. Check for a seal
against the gasket at the bottom of the gel
3) Make fresh 10% APS
4) To polymerise 100ml of 6% acrylamide, 8M urea solution (need ~60ml per gel, if
it doesn't leak) add:
lOOpl TEMED
lml APS
5) Pour immediately, avoiding bubbles and leakage, insert comb before gel sets
6) Once the gel has set, soak 2X Whatman strips in 1X TBE and lay over either end
of gel
7) Wrap in Saran wrap and place in fridge for 30 minutes, to harden the wells. Can be
left overnight.
Transcription Reaction







For GAPDH probe: 1 mM UTP
2) In radioactivity room, add:
32P UTP 4.0pl
RNA polymerase
3)Mix well and incubate at 37°C for 10 minutes
4) Add 1 pi DNasel to remove template and incubate at 37°C for 15 minutes
5) Add 1 pi 0.5M EDTA (pH8.0) to stop the reaction
G25 sepharose column purification of probe:
1) Vortex G25 column briefly to resuspend resin
2) Loosen cap % and snap off bottom
3) Place in a clean 1.5ml eppendorf, spin at 3000rpm (785g in benchtop microfuge in
room 350) for 1 min
4) Place in a clean 1.5ml eppendorf, spin at 3000rpm for 2 minutes
5) Collect eluate, store at -20°C for 48 hours. After this time, radiolysis begins to
occur
Verification of probe integrity:
1) Aliquot lpl into a fresh microfuge tube with 5pl Gel Loading Buffer
2) Heat to 95°C for 5 minutes
3) Load onto a 6% Polyacrylamide, 8M Urea gel (usually 1.5mm thick with 1cm
wells), and run at 400V for~l hour












This was achieved by cerenkov counting
1) Aliquot lpl and 2pl of each probe into 2ml ddH20 in scintillation vials. Also
include a blank, with just 2ml ddH20.
2) Measure fluorescence at 420nm
3) Compensate for the inefficiency of cerenkov counting by multiplying all cpm
values by 3.33
Reagents for RNase Protection Assay (RPA)
Purified and quantitated target RNA (see above for methods of purification and
quantification of RNA)
Radiolabeled, Quantitated Antisense RNA Probe (see above)
HybSpeed RPA Kit (Ambion)
Gel fixation buffer
5% Glacial acetic acid
15% Methanol
to 1 litre in ddlPO
RNase Protection Assay (RPA)
Hybridisation of Probe and target RNA:
1) Aliquot 80,000cpm (Pax6) or 40,000cpm (GAPDH) of probe into a 2ml, snap-cap,
RNase-free eppendorf.
2) Add a known amount of target RNA, lpg for E12.5 and E14.5 RNAs, 4pg for
E16.5 and El8.5
3) Make up to 5Opig with yeast tRNA
4) For each probe, prepare a no target positive control reaction, with 50pg yeast
tRNA
5) For each RPA, also prepare a no target negative control reaction with one probe
and 50pg yeast tRNA
6) Precipitate the probe - target mix by adding 1/10 volume of 5M ammonium
acetate and 2.5 volumes of 100% ethanol
7) Place on dry ice >20 minutes
8) Microfuge at 13000rpm at4°C for 15 minutes
9) Turn on 95°C hotblock, defrost HybSpeed Hybridisation Buffer, and pre-heat to
~90°C (at 95°C it can be difficult to aliquot)
10) Using gel-loading tips, remove all ethanol, being careful not to disturb the
precipitate
11) Add lOpl pre-heated Hybridisation buffer, immediately place the tube in the 95°C
hotblock. Do not let the samples drop below 65°C after the addition of Hybridisation
buffer
12) Vortex each sample for 15 seconds, then return to the hotblock to regain heat.
Repeat 3 times.
13) Incubate samples for 2-3 minutes at 95°C after vortexing the final sample.
14) In the hotblock, quickly transport 5 or 6 tubes at a time to the 68°C oven.
15) Incubate overnight (>10 hours, or signal will be lower than anticipated) at 68°C
RNase Digestion
1) Make up RNase digestion mastermix (n total number of tubes - positive controls +
1)
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100j.il HybSpeed RNase Digestion Buffer
2pl RNase cocktail / RNase A/Tl mix
2) Centrifuge samples briefly
3) Add lOOpl mastermix to each sample except positive controls, vortex
4) Add lOOpl RNase digestion buffer to each positive control sample, vortex
5) Incubate at 37°C for 30 mins, vortex after 15 minutes
6) Add 150pl HybSpeed Inactivation/Precipitation Mix to each tube, vortex
7) Place on dry ice >20minutes
8) Microfuge at 13000rpm at 4°C for 15 minutes
Detection on a Denaturing Polyacrylamide Gel:
1) Pre-run a 6% polyaciydamide, 8M urea gel at 400V for >15 minutes, washing the
wells with 1XTBE to remove accumulated urea and polyacrylamide
2) Turn on 95°C hotblock, defrost Gel loading buffer and radio-labelled dsDNA
ladder (see below)
3) Using gel-loading tips, very carefully remove supernatant, a second brief
microfuge step is usually necessary to ensure all traces of ethanol are removed
4) Resuspend the pellet in 4pl gel loading buffer
5) Vortex each sample for 60 seconds to ensure the pellet is fully resuspended
6) In a separate eppendorf, aliquot 4pl loading buffer, and add 2pl DIG-labelled DNA
ladder
7) Heat tubes to 95°C for 3-4 minutes to solubilise and denature the RNA
8) During this denaturation step, wash each well of the gel a second time with
1XTBE
9) Using a Hamiltonian syringe and custom-made 0.43mm thick loading tips,
carefully load the gel, rinsing the loading tip after each well
10) Run at 450V for 2'A hours, using a cooling jacket filled with running cold water
to stop the glass plates cracking through over-heating
11) Peel off the smaller, front glass plate
12) Keeping the gel attached to the back plate for support, immerse in gel fixation
buffer for 1 hour
13) Transfer from glass plate onto filter paper, cover in saran wrap and dry overnight
using a vacuum drier
14) Expose to photographic film at -70°C using an intensifying screen for 14 days
Reagents for Synthesis of Radiolabeled dsDNA Ladder
,2P[dCTP] 3000 Ci/mmol, lOmCi/ml {Sigma)
pUC 19/Hpa II Digested dsDNA Markers {Ambion)
Klenow DNA Polymerase (5u.pl1) (Promega)
lOOmM dATP, dGTP, dTTP and dCTP {Roche)
MicroSpin G-50 columns {Amersham Pharmacia Biotech)
Synthesis of Radiolabeled dsDNA Ladder
1) Prepare the following in a 500pl microfuge tube:
pUC19////?aII Digested dsDNA markers










3000 Ci/mmol, lOmCi/ml 32P[dCTP] l.Opl
ddH20 11.9f.il
Klenow DNA Polymerase 1.0/j.l
2) Mix well and incubate at 37°C for 15 minutes
3) Prepare a G-50 column: Shake well
Snap off bottom, place in an empty microfuge tube
Microfuge at 3000rpm for 1 minute
Place in a fresh microfuge tube
4) Aliquot the reaction product (20pl) into the column, microfuge at 3000rpm for 1
minute
5) Store at -20°C for up to 2 weeks
Reagents for cDNA Synthesis
First Strand cDNA Synthesis Kit (Invitrogen)
cDNA Synthesis
Use 5pl total RNA per cDNA synthesis reaction
Use lpl oligo d(T) primer (0.5pg.pl"1) per reaction, to specifically amplify poly(A)
mRNA
Carry out cDNA synthesis according to the manufacturer's instructions
Reagents for Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR)
Expand DNA Polymerase (Roche)
Taq DNA Polymerase (Promega)
10X DNA polymerase buffer with 15mM MgCl2 (Promega)
1 OmM dNTP solution - 1 Opl dATP (1 OOnrM, Roche)
lOpl dCTP(100mM, Roche)
lOpl dGTP (lOOmM, Roche)
lOpl dTTP (1 OOmM, Roche)
60pl ddFbO
1 OpM each primer (MWG)
Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR)
Expand PCR
1) Prepare 25pl Mastermix 1 for each sample
IX
0.75pl forward primer (lOpM)
0.75pl reverse primer (lOpM)
2.00pl dNTP (1 OmM)
1.00pl template DNA
20.50pl ddFTO
2) Prepare 25pl Mastermix 2 for each sample, make enough for ;?+l samples
IX
5.00pl 10X Expand reaction buffer
0.75jliI Expand DNA polymerase
19.25pil ddPFO
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3) Combine each 25pl Mastermix 1 with 25pl of Mastermix 2
4) Perform PCR using the following programme:
2 minutes at 94°C
15 seconds at 94°C
30 seconds at annealing temperature
3 minutes at 68°C
15 seconds at 94°C
30 seconds at annealing temperature
3 minutes and 5 seconds at 68°C|
Plus 5 seconds per cycle at 68°C|
5 minutes at 72°C
4°C for ever
5) Store PCR product at 4°C, and use within 24 hours
Genotyping PCR
1) Prepare 19pl mastermix per sample, make enough for/z+l samples
IX
0.5pl forward primer (lOpM)
0.5pl reverse primer (lOpM)
0.4pl dNTP (lOmM)
2.0pl 10X reaction buffer (inch 15mM MgCL)
0.1 pi Taq DNA polymerase
1 .Opl template DNA
15.5pl ddHiO
2) Perform PCR using the following programme:
5 minutes at 96°C
1 minute at 96°C |
30 seconds at annealing temperature | X35 cycles
45 seconds at 72°C
Colony PCR
1) Prepare 20pl mastermix per sample, make enough for n+\ samples
2) Using a sterile pipette tip, touch the bacterial colony, then dip the tip into the PCR
mix
3) Leave for 5 minutes, then expel any liquid within the tip and discard
4) Perform PCR using the following programme:
5 minutes at 96°C
1 minute at 96°C |
30 seconds at annealing temperature | X35 cycles
45 seconds at 72°C
XI0 cycles
X20 cycles
Reagents for Agarose Gel Electrophoresis
10X Gel loading buffer
20% Ficoll 400
0.1M disodium EDTA, pH8
1% sodium diodecyl sulphate
0.25% bromphenol blue
0.25% xylene cyanol





20mM disodium EDTA, pH8
Autoclave before use, dilute to IX with ddH20
Agarose (Sigma)
Molecular weight ladders
DNA molecular weight marker XIV (Roche): for fragments <600bp
DNA molecular weight marker XVII (Roche): for fragments >600bp
DNA molecular weight marker X (Roche): for fragments of mixed sizes
Working dilutions:
5pl DNA molecular weight marker
6pl 10X gel loading buffer
49pl ddl-EO
Agarose Gel Electrophoresis
1) Prepare an agarose solution
0.8% agarose (for DNA fragments >600bp): 40g agarose in 50ml IX TBE
1.5% agarose (for DNA fragments <600bp): 75g agarose in 50ml IX TBE
2) Microwave on full power for 1 minute
3) Add 1 pi ethidium bromide, mix gently
4) Pour into a gel casting tray, immediately insert comb
5) Allow to set for 30 minutes
6) Prepare sample DNA by adding 2pl 10X loading buffer per 20pl PCR reaction
7) Load lOpl sample per well
8) Load 5pl DNA molecular weight marker in one well per gel
9) Run gels at 50V for ~45 minutes, or until bands have resolved
10) Visualise by exposure to UV light
Reagents for DNA Extraction from Agarose Gels
Gel extraction mini kit (Qiagen)
DNA Extraction from Agarose Gels
Visualise gels with minimum exposure to UV light, to avoid DNA damage
Cut out bands with a sterile scalpel blade
Carry out gel extraction according to manufacturer's protocol
Elute in 50pl ddLLO
Reagents for Quantitative RT-PCR
QuantiTect SYBR Green PCR kit (Qiagen):
A complete reaction mix containing reaction buffer, dNTPs, SYBR Green and DNA




1) For each set of primers, set up a template DNA dilution series to act as a standard
curve. Ideally, these should be serial dilutions of the most highly concentrated
template DNA:
O.OOlpl (1 jliI 1:1000)




For each other template DNA, make a 1:10 dilution and use lpl per reaction (O.lpl
template)
2) Make the template DNA solution up to 9.5pl with ddLLO
3) Prepare 14pl mastermix per sample, make enough for n+1 samples
1.5pl Forward primer (20pM)
12.5pl 2X SYBR Green mix
4) Add 14pl mastermix to each diluted DNA template
5) Add 1.5pl Reverse primer (20pM) to each reaction
6) Perform PCR using the following programme:
15 minutes at 95°C
16 seconds at 94°C |
30 seconds at annealing temperature | X35 cycles
30 seconds at 72°C
Plate read
Melting curve analysis
Reagents forTOPO Cloning of PCR Products
PCR product
Zero Blunt TOPO PCR Cloning Kit (Invitrogen)
Top-10 Chemically Competent E.coli (Invitrogen)
LB Agar plates
3.5g LB Agar per 100ml
Autoclave before use
Pour plates at <50°C
Add antibiotic to cooled agar before cooling
Kanamycin (Sigma)
Stock solution at 50mg.mf'
Use at 1:1000, final concentration 50pg.mf'
TOPQ Cloning of PCR Products
Perform PCR using Expand DNA polymerase.
Use 4pl fresh PCR product per TOPO cloning reaction
Carry out TOPO cloning according to the manufacturer's instructions
Transform into chemically competent TOP-10 E.coli according to the manufacturer's
instructions
Spread 1 Oju.1, 50pl and lOOpl transformed E.coli onto LB agar-kanamycin plates,
allow to grow at 37°C overnight
Transformed bacteria on LB agar plates can be stored at 4°C for up to 14 days
Reagents for DNA Ligation
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T4 DNA ligase (Promega)
T4 DNA ligase buffer (Promega)
Quantitated, linearised vector and insert DNA
DNA Ligation
Use 1 molecule vector per 10 molecules insert
1) Set up the following reaction:
Vector DNA wp 1
Insert DNA /?pl(100ng)
T4 DNA ligase l.Opl
T4 DNA ligase buffer 2.5pl
ddH,0 to 25.0pl
2) Incubate at 4°C overnight
3) Transform into chemically competent TOP-10 E.co/i as described above
Reagents for Glycerol Bacterial Strain Storage












Stock solution at lOOmg.mf1 in 50% ethanol
Use at 1:1000, final concentration lOOpg.mf'
Glycerol Bacterial Strain Storage
1) Seed 1ml LB broth containing the appropriate selective antibiotic with the bacterial
clone
2) Grow at 37°C overnight with shaking
3) Add 1ml glycerol strain storage mix
4) Store at -70°C for up to 18 months
Reagents for Plasmid Minipreps and Midipreps
LB broth (see above)
Kanamycin (see above)
Ampicillin (see above)
QIAprep Spin Miniprep Kit (Qiagen)
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HiSpeed Plasmid Midi Kit (Qiagen)
Plasmid Minipreps and Midipreps
1) Seed 2ml (miniprep) or 150ml (midiprep) LB broth containing the appropriate
selective antibiotic with the bacterial clone
2) Grow at 37°C overnight with shaking
3) Pellet cells by centrifugation at lCfOOOg for 1 minute (miniprep), or 6000g for 15
minutes at 4°C (midiprep)
4) Remove LB broth, and resuspend the pellet in the appropriate amount of buffer PI
5) Carry out plasmid prep according to the manufacturer's instructions
Antibodies
Primary Antibodies
Anti-Pax6 PD (Developmental Studies Hybridoma Bank)
Monoclonal antibody, raised in mouse and directed against the paired
domain (amino acids 1-122) of chick Pax6. Will detect both human and
murine Pax6, as peptide sequence is identical across the three species.
Use in immunocytochemistry at 1:75, detect with direct fluorescence
Anti-Pax6 HD, Serum 13 (Carriere et al., 1992)
Antipeptide serum raised against the homeodomain of quail Pax6
(Pax QNR)
Use in Western Blotting at 1:200 in blocking buffer
Each aliquot can be re-used up to 3 times
Anti-Pax6 C-terminus (Chemicon)
Antipeptide serum raised against a C-terminal portion of mouse Pax6
Use in western blotting at 1:500 in blocking buffer
Use in immunocytochemistry at 1:500
Each aliquot can be re-used up to 2 times
Anti P-Actin (Sigma)
Monoclonal antibody, raised in mouse and directed against the N-
terminal portion of P-actin
Use in western blotting at 1:1000 in TBS-Tween
Anti p-Tubulin Isotype 111 (Sigma)
Monoclonal antibody, raised in mouse and directed against the C-
terminal portion of human P-III-tubulin
Use in immunocytochemistry at 1:1000 in blocking buffer
Anti-MAP2 (Sigma)
Monoclonal antibody, raised in mouse and directed against all mouse
MAP2 forms. Does not cross react with tubulin from other microtubule
associated proteins
Use in immunocytochemistry at 1:200
Anti-Taul (Chemicon)
Monoclonal antibody, raised in mouse and directed against bovine
Tau-1. Recognises both mouse and human Tau-1
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Use in immunocytochemistry at 1:200
Secondary Antibodies: Immunocytochemistry
AlexaFluor 448- conjugated anti-mouse IgGl (Molecular Probes)
secondary antibody, raised in goat
Use in Immunocytochemistry at 1:200
Alexa-Fluor 568-conjugated anti-mouse IgGl {Molecular Probes)
Secondary antibody, raised in rabbit
Use in immunocytochemistry at 1:200
R-PE- conjugated anti-mouse IgGl {Molecular Probes)
secondary antibody, raised in goat
Use in Immunocytochemistry at 1:75
Biotin-Anti-Mouse
Biotin-conjugated anti-mouse IgG secondary antibody, raised in goat
Use in Immunocytochemistry at 1:500
Streptavidin AlexaFluor 488 conjugate {Molecular Probes)
AlexaFluor 488- conjugated streptavidin
Use in immunocytochemistry at 1:1000
Secondary Antibodies: Western Blotting
HRP-Anti-mouse {SAPU)
Horseradish Peroxidase- conjugated anti-mouse IgG secondary
antibody, raised in sheep
Use in Western blotting at 1:1000 in blocking buffer
HRP-Anti-Rabbit {Sigma)
Horseradish Peroxidase- conjugated anti-rabbit IgG secondary
antibody, raised in donkey
Use in Western blotting at 1:10000 in blocking buffer
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Appendix 2 - Primer sequences and optimal annealing
temperatures for PCR
PCR primers
Human Pax6 Full 5' Xbal
5' AAT CTA GAA TGC AGA ACA GTC ACA GC 3' Anneal: 63°C
Human Pax6 Full 3' Xbal
5' AAT CTA GAT TAC TGT AAT CTT GGC CA 3' Anneal: 59°C
Product size:1327bp/1285bp (Full-length Pax6+5a/ Full-length Pax6-5a)
These primers were designed by Dr T. I. Simpson to amplify full-length Pax6 from
the U373-MG cell line. These primers were specific to sequence within the 5' and 3'
UTRs of the human Pax6 gene. The 5' end of each primer contained an Xbal
recognition site. As primer specificity is conferred by 3' sequence, the presence of
this 5' restriction endonuclease recognition site did not adversely affect primer-cDNA
binding. However, cDNA clones obtained this way could then be cut with the
restriction endonuclease Xbal, and cloned into sites with compatible cohesive DNA
ends.
Pax6 Exon 5 F
5' GTC ACA GCG GAG TGA ATC AG 3' Anneal: 58.5°C
Pax6 Exon 7 R
5' CTA GCC AGG TTG CGA AGA AC 3' Anneal: 58.5°C
Product size: 385/427bp (-5a /+5a) 169/21 lbp (-5aA6 /+5aA6)
These primers were designed by Dr. T. I. Simpson to amplify a region between exons
5 and 7 of the Pax6 cDNA. Due to the high degree of sequence conservation at the
Pax6 locus between mouse and human, these primers were 100% complementary to
cDNA from both species. This PCR spans two intron-exon boundaries, thus
eliminating the risk of amplifying any contaminating genomic DNA and obtaining
false positive results. It also spans the alternatively spliced exons 5a and 6, giving
four PCR products corresponding to Pax6+5a, Pax6-5a, Pax6+5aA6, and Pax6-5aA6,
with product sizes from 169bp to 427bp, which are easily resolved by agarose gel
electrophoresis.
Pax6 exon 9 F
5' CAT CCT TTA CCC AAG AGC AA 3' Anneal: 58°C
Pax6 BR
5' GTA TGA GGA GGT CTG GCT GG 3' Anneal: 61°C
These primers were used to amplify the 5'-truncated Pax6 form in pJP 15.12. "Pax6
exon 9 F" anneals within exon 9 of the human Pax6 gene, after the internal ATG
putative translation start site. "Pax6 BR" anneals within exon 12. They allowed




5' GGG TGG AGC CAA ACG GGT C 3' Anneal: 58.5°C
GAPDH R
5' GGAGTTGCTGTTGAAGTCGCA 3' Anneal: 58.5°C
Product size: 532bp
These primers were designed to allow amplification of the murine glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) cDNA. This is a housekeeping gene expressed
in all mammalian cells, and was used to confirm the presence of cDNA in samples
which were being tested for Pax6, in order to confirm that negative results were due
to the absence of Pax6 expression rather than cDNA degradation or problems with
cDNA synthesis.
GAPDH F Light
5' GGG TGT GAA CCA CGA GAA AT 3' Anneal: 58°C
GAPDH R Light
5' CCT TCC ATG CCA AAG TT 3' Anneal: 56°C
Product size: 120bp
These primers were designed to allow amplification of the murine GAPDH cDNA for
quantitative real-time PCR. This was used to confirm the presence of cDNA in
samples which were being tested for Pax6, in order to confirm that negative results
were due to the absence of Pax6 expression rather than cDNA degradation or
problems with cDNA synthesis. Levels of GAPDH cDNA as determined by this
primer set were also used to create quantitative standards, to allow the exact
quantitation of Pax6 in cDNA samples.
Pax6 Exon 5F light
5' GCT TGG TGG TGT CTT TGT CA 3' Anneal: 55°C
Pax6 Exon 56R light
5' TCA CAC AAC CGT TGG ATA CC 3' Anneal: 55°C
Pax6 Exon 55aR light
5' TTT GCA TCT GCA TGG GTC T 3' Anneal: 55°C
Product size Exon 5F light / Exon 56R light: 131 bp
Exon 5F light / Exon 55aR light: 129bp
These primers (see Figure A2.1) were designed to allow amplification of the Pax6
gene between exons 5 and 6. Exon 5F light binds within exon 5 of the Pax6 cDNA,
and should bind all Pax6 cDNA present in a sample. Exon 56R light takes advantage
of the fact that primer binding specificity is conferred by 3' sequence, to allow
selective amplification of the Pax6-5a splice form. 19bp of this primer corresponds to
sequence in the 5' end of exon 6. The most 3' residue, however, binds to the G
residue at the 3' end of exon 5. Thus, this primer can only bind target cDNA when
exon 5 is spliced directly onto exon 6, and exon 5a is absent. In a similar manner, the
Exon 55aR light primer spans the junction between exons 5 and 5a, and can only bind
















































































































































Pax6 MMu Exon 3F
5' AAG TGG ACG TAT ATC CCA GTT CTC 3' Anneal: 49°C
Pax6 MMu Exon 5AR
5' AGC ACC TGG ACT TTT GCA TC 3' Anneal: 49°C
Product size: 247bp
These primers were designed to amplify murine Pax6 between exon 3, in the 5'UTR
of the gene, and exon 5a. Products created in this way were subsequently cloned and
used as templates for riboprobe synthesis.
Pax6 MMu Exon6F
5' GAG ACT GGC TCC ATC AGA CC 3' Anneal: 65°C
Pax6 MMu Exon7R
5' CTT GCG TGG GTT GCC CTG GT 3' Anneal: 65°C
Product size: 340bp
These primers were designed to amplify murine Pax6 between exon 6 and exon 7.
Products created in this way were subsequently cloned and used as templates for
riboprobe synthesis.
Pax6 MMu RiboF
5' AGG GCA ACC CAC GCA AGA 3' Anneal: 63°C
Pax6 MMu ExonllR
5" TGG TGA GGG CGG TGT CTG TTC 3' Anneal: 63°C
Product size: 464bp
These primers were designed to amplify murine Pax6 between exon 7 and exon 11.




5' TTT GCC CGA GAA AGA CTA GC 3' Anneal: 61°C
Pax6 AR
5' AAC TCTTTC TCC AGG GCC TC 3' Anneal: 61°C
Pax6 BF
5' CCA GCC AGA CCTACCTACAT AC 3' Anneal: 61°C
Pax6 BR
5' GTA TGA GGA GGT CTG GCT GG 3' Anneal: 61°C
These primers were designed to anneal at intervals within the Pax6 coding sequence.
In combination with M13 primers either side of the multiple cloning site into which




5' GTA AAA CGA CGG CCA G 3' Anneal: 52°C
M13R
5' CAG GAA ACA GCT ATG AC 3' Anneal: 52°C
These primers were used to sequence all Pax6 over-expression constructs and
riboprobe template constructs in both directions.
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